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ABSTRACT 
 
 
The biosynthesis of medically relevant bisindole natural products rebeccamycin, 
staurosporine, and violacein from the common starting material L-tryptophan involves 
shared enzymatic transformations.  However, the pathways diverge at two steps, each 
involving a reactive, bisindole intermediate.  We have taken a structural approach to 
characterize the biosynthetic enzymes responsible for these divergence points in each 
pathway.   
 
One major difference between rebeccamycin and staurosporine is the oxidative state of 
the C-7 carbon.  The enzymes RebC and StaC (65% sequence identity) control the 
oxidative outcome at the C-7 position.  Our work on the rebeccamycin biosynthetic 
enzyme RebC has enabled us to crystallographically ‘trap’ its putative substrate and to 
identify a likely enzymatic function for RebC in controlling the outcome of this key step 
in rebeccamycin biosynthesis.  We have also used the structure of RebC with reduced 
flavin to probe the likely reaction cycle of a single round of flavin-based hydroxylation 
chemistry in RebC.  Finally, the structure of RebC has allowed us to use a structure-based 
mutagenesis approach to install a higher affinity binding site for FAD in the RebC 
homologue StaC, which normally binds FAD weakly.  The resulting protein possesses 
RebC-like properties.   
 
Another divergence point between these biosynthetic pathways is the presence or absence 
of the VioE enzyme, which diverts a reactive intermediate toward violacein precursor.  
Our structural studies on VioE have shown that this enzyme shares a fold with lipoprotein 
carrier proteins.  A series of site-directed mutagenesis experiments on residues around a 
PEG molecule bound in the VioE structure have revealed the likely location of the active 
site in VioE.    
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Collectively, our work has uncovered a key theme in bisindole enzymology: RebC, StaC, 
and VioE function by intercepting reactive substrate molecules, stabilizing these 
molecules in their active sites, and promoting their conversion to on-pathway products.  
In the absence of these enzymes, the reactive substrate molecules decompose to shunt 
products.  RebC, StaC, and VioE therefore function in part simply as ‘stabilizing’ 
enzymes, providing enough chemical energy to prevent the production of spontaneously 
derived shunt products. 
  
Thesis Supervisor:  Catherine L. Drennan 
Title:  Professor of Chemistry and Biology and HHMI Investigator 
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Overview 
 
 This thesis discusses structural studies on enzymes that control divergence points 
in the biosynthesis of bisindole natural product molecules.  Bisindole natural products 
include rebeccamycin (a human DNA-topoisomerase I inhibitor), staurosporine (a kinase 
inhibitor) and violacein (a less-studied purple pigment), which are the focus of this work.  
Chapter I introduces the reader to bisindole natural products, with a specific focus on the 
proposed mechanisms of enzymatic construction for this class of molecules.   
 Chapter II describes structural studies of RebC, an enzyme involved in the 
divergence point between rebeccamycin and staurosporine biosynthesis.  RebC propels 
molecules towards rebeccamycin through a largely unknown mechanism.  The structural 
studies described have resulted in the elucidation of a putative function for RebC as a 
flavin-dependent hydroxylase and have identified a putative small molecule substrate for 
RebC.  Further studies on RebC are described in Chapter III with the presentation of the 
FADH2-RebC structure.  Surprisingly, RebC crystals incubated with sodium dithionite 
result in major conformational changes in the RebC protein.  Particularly, the flavin 
cofactor changes conformation, and a helix closing off the active site becomes ordered.  
Together with kinetic data on the rate of reduction in the absence of substrate, this 
structural work suggests that reduction of the flavin cofactor is likely to occur after 
substrate binding, in a manner analogous to other well-studied flavin hydroxylases, such 
as para-hydroxybenzoate hydroxylase.   
 In Chapter IV the RebC homologue StaC is introduced.  StaC, also involved in the 
divergence point between rebeccamycin and staurosporine biosynthesis, propels 
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molecules toward the product staurosporine.  Using a combination of isothermal titration 
calorimetry, structure-based mutagenesis, and activity assays, the role of the cofactor 
FAD in the chemistry catalyzed by StaC is explored. 
 Violacein is introduced in Chapter V with a discussion of VioE, which controls 
the divergence point between rebeccamycin and staurosporine on one hand, and violacein 
on the other.  Our structure of VioE, which reveals that VioE is a cofactorless protein 
sharing structural homology with lipoprotein transporter proteins, suggests that the 
divergence of molecules towards violacein is controlled solely by orientation effects in 
the VioE ‘active’ site.   
 Finally, Chapter VI briefly describes overall conclusions and future directions of 
work on the structural biology of bisindole biosynthesis.   
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Chapter I: 
Divergent pathways in the biosynthesis of bisindole natural products 
 
I.A.  Summary 
 Two molecules of the amino acid L-tryptophan are the biosynthetic precursors to 
a class of natural products named the ‘bisindoles.’  Hundreds of these bisindole 
molecules have been isolated from natural sources, and many of these molecules have 
potent medicinal properties.  Recent studies have clarified the biosynthetic construction 
of six bisindole molecules, revealing novel enzymatic mechanisms and leading to 
combinatorial synthesis of new bisindole compounds.  Collectively, these results provide 
a vantage point for understanding how much of the diversity of the bisindole class is 
generated from a small number diverging pathways from L-tryptophan, as well as 
enabling identification of bisindoles that are likely derived via completely distinct 
biosynthetic pathways.   
 
Note:  This chapter is formatted to include ‘Box’ sections, which are intended to explain concepts 
necessary for understanding the main material or to provide information tangential to the central themes.   
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I.B.  Introduction 
 
 The rich chemical ecology that is exhibited by sessile organisms such as 
microbes, fungi, and plants is due in large part to secondary metabolism.1  This secondary 
branch of biochemistry stands in stark contrast to the primary biochemical processes that 
enable organisms to convert organic molecules into chemical energy and to build up 
carbohydrates, lipids, nucleotides, and amino acids from simpler precursors.2  Secondary 
metabolism instead entails making molecules for defense and communication, often in 
response to changing environmental conditions.  Secondary metabolites are 
characteristically diverse, with a cornucopia of new molecules isolated each year from 
natural sources.  Further, while primary metabolites are often found ubiquitously in the 
various kingdoms, constituting largely conserved biochemical processes, secondary 
metabolites can be highly restricted in their distribution, and are thought to play roles in 
enabling organisms to thrive in niche environments.1  Humans have used these secondary 
metabolites since pre-historical times for their own purposes, from mining organisms for 
medicines to gathering dye molecules and poisons.   
 One major class of secondary metabolites, or natural products, are the alkaloids, 
which are nitrogen-containing molecules derived from amino acids or purines.3  
Particularly infamous among the alkaloids are those derived from L-tryptophan 
molecules, with notable examples including the psychoactive LSD, ergot (St. Anthony’s 
fire), and the active ingredients of ‘magic mushrooms.’  A newer class of L-tryptophan 
derived alkaloids consists of the ‘bisindoles’ (Fig. I.1A).  These molecules, generated by 
the fusion of two molecules of L-tryptophan, contain two indole rings in their structures 
(structure of indole 35 in Box 1A).  The first reported ‘observation’ of a bisindole 
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molecule was of violacein 15, noticed as a colored material contaminating flour in the 
1880’s;4 the violacein molecule was purified5 and synthesized by 1958.6  Subsequent 
mining of microbial organisms for anti-cancer natural products led to the discovery of 
staurosporine 9,7 a kinase inhibitor,8 and, later, rebeccamycin 12,9 analogues of which are 
DNA-topoisomerase I inhibitors.10  More recently, terrequinone A 19, structurally related 
to antitumor, antiviral, and antidiabetic compounds,11 was isolated from a fungus 
dwelling in the rhizosphere of an Arizona desert plant,12 and molecules AT2433-A1 3313 
and K252a 3414 and have been reported (Table I.1).   These six molecules represent the 
only bisindoles for which biosynthetic information is now available.  They share the 
presence of two indole rings, but differ in how these indole rings are connected and in the 
types of chemical ornamentation, for instance prenylation, chlorination, and 
hydroxylation, that decorates their skeletons (Table I.1).   
 Beyond these six molecules, hundreds of bisindole molecules have been isolated 
and characterized,15 but the mechanisms of their biosyntheses are largely unexplored.  
Bisindoles have been isolated from tunicates, sponges, plant leaves, roots, bark, and 
flowers, algae, fungi, and myxomycetes,15 and are most commonly isolated from 
actinomycetes,15 a class of bacteria known for its proliferative production of secondary 
metabolites.16  Although there are many reports on bisindole molecules, the focus of most 
research is clear:  most scientists are interested in how bisindoles can be used as drug 
molecules.  They work to synthesize derivatives, test medical properties, and isolate new 
molecules from natural sources.15,17  Hence, despite the large interest in bisindoles, there 
is a paucity of studies on why organisms make bisindoles at all, which will represent a 
rich area for study in the next years.   
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 However, in the last decade, studies on the biosynthetic pathways that lead to 
bisindoles have emerged on six different bisindole molecules (Table I.1).  This work has 
revealed the enzymatic players involved in construction of complex bisindole natural 
products.  A key finding from the biochemical studies seems to be the role of reactive 
intermediates.  Enzymes in these pathways appear to have evolved both to carry out 
‘standard’ enzymatic chemistry (making and breaking chemical bonds) as well as to 
stabilize intermediate molecules that when left in solution spontaneously decompose to 
undesired side products.   
 In this Review, we discuss the known, diverging pathways that lead from L-
tryptophan molecules to bisindoles (Fig. I.1A).  We begin by describing the biosynthetic 
pathways which are now well understood, starting with a discussion of a major class of 
bisindoles, the indolo[2,3-a]pyrrolo[3,4-c]carbazoles (Fig. I.1B, Box 1D), and then 
turning to a discussion of violacein (Fig. I.1C) and terrequinone A biosynthesis (Fig. 
I.1D), which represent diverging pathways to construct alternate bisindole skeletons from 
two molecules of L-tryptophan.  Our focus in these sections is on the enzymology of the 
biochemical construction and the biosynthetic logic used in making bisindoles.  Using the 
principles discovered from the investigation of indolo[2,3-a]pyrrolo[3,4-c]carbazoles, 
violacein, and terrequinone, we then discuss some of the hundreds of bisindoles whose 
biosynthesis is still unexplored, and postulate routes for the construction of some of the 
yet unexplored molecules.  Finally, we reflect on major questions that still remain from 
the indolo[2,3-a]pyrrolo[3,4-c]carbazole, violacein, and terrequinone A biosynthetic 
pathways, and future directions of research for biochemists and microbiologists.   
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I.C.  Indolo[2,3-a]pyrrolo[3,4-c]carbazoles  
 The most frequently isolated bisindole molecules are the indolocarbazoles 
(structure of carbazole 36 in Box 1B), and, among indolocarbazoles, the most common 
are the indolo[2,3-a]carbazoles 37 (Box 1C).  Among this subgroup, the most widespread 
are the indolo[2,3-a]pyrrolo[3,4-c]carbazoles 38 (Box 1D).  Dimerization of the L-
tryptophan molecules via their Cβ carbons gives rise to a connectivity that favors 
formation of this core indolo[2,3-a]pyrrolo[3,4-c]carbazole structure, which may explain 
its prevalence (Box 1G and H).  Recently, gene clusters encoding the proteins needed to 
biosynthesize four indolo[2,3-a]pyrrolo[3,4-c]carbazoles – rebeccamycin 12, AT2433-A1 
33, staurosporine 9, and K252a 34 – have been isolated and characterized (Table I.1).  
Rebeccamycin and AT2433-A1, on one hand, and staurosporine and K252a, on the other, 
represent the two major classes of indolo[2,3-a]pyrrolo[3,4-c]carbazoles.  Rebeccamycin 
and AT2433-A1 are chlorinated, contain a fully oxidized C-7 carbon (numbering, Box 
1D), and bear a β-glycosidic bond to only one indole nitrogen.  Staurosporine and K252a, 
by contrast, are not halogenated, contain a fully reduced C-7 carbon, and contain a sugar 
attached to both indole nitrogens.  Three parts of the biosynthesis are thus distinct 
between the two groups: (1) halogenation, (2) oxidation of the C-7 carbon, and (3) 
glycosylation.  Because rebeccamycin and staurosporine are the best studied pathways, 
only details for these pathways will be reviewed here, although initial information about 
the molecular details of AT2433-A1 and K252a construction are now available.18,19 
 Chlorination is the first step in rebeccamycin biosynthesis, however, the presence 
of a chlorine atom is apparently not essential to substrate recognition in the later steps in 
rebeccamycin biosynthesis, as des-chloro substrates are utilized by all of the downstream 
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rebeccamycin biosynthetic enzymes (Fig. I.1B).20  Additionally, many of the subsequent 
enzymes in the pathway are also able to accept alternately chlorinated substrates (5-
chloro- and 6-chloro-L-tryptophan), as well as 7-bromo-L-tryptophan, however, the 
yields are lower with such modifications.20  As is true for several natural products, the 
presence of chlorine in rebeccamycin does alter its biochemical properties,10,21 prompting 
intensive investigation of enzymatic mechanisms of chlorination.22,23  In rebeccamycin 
biosynthesis, chlorination occurs via the FADH2-dependent (Box 2A) halogenase RebH, 
with the FADH2 generated by the partner flavin reductase, RebF (Fig. I.1B).  Co-
incubation of RebF and RebH with L-tryptophan,  O2, FAD, and NADH in a Na36Cl-
containing buffer enables production of 7-36Cl-L-tryptophan.24  Amazingly, the reaction 
can also be carried out in two parts, with incubation of RebH with FADH2, Cl-, and O2 in 
a first reaction leading to production of FAD, all of which can be removed on a desalting 
column.  A second reaction, where the substrate L-tryptophan is added to RebH, results 
in production of the product.  This experiment suggests that a stable intermediate, which 
has a half-life of 28 h at room temperature,25 is generated in RebH in the first reaction, 
and the intermediate is still available for reaction with L-tryptophan in the second 
reaction.  The crystal structure reveals that there are also two active sites in RebH:  one, 
where FADH2, Cl-, and O2 will bind, and ~11 Å away, a second site where L-tryptophan 
binds.  Occluding the tunnel between the active sites is the conserved amino acid lysine-
79 (Fig. I.2A).25  Based on the stability of the intermediate in the protein but the rapid 
decomposition of HOCl in solution, it has been suggested that RebH may use lysine-79 
as a transferring agent, generating a chloramine intermediate on its terminal ε-NH2 to 
bring the HOCl generated from FADH2 in the first reaction to the L-tryptophan bound at 
 23
a distant site in the protein.25  RebH, thought to enable stabilization of the reactive HOCl 
using a lysine side chain, is an example of a bisindole biosynthetic enzyme that stabilizes 
an intermediate that would otherwise decompose in solution.     
 RebO, the next enzyme in the pathway, is an L-amino acid oxidase, which use the 
cofactor FAD to oxidize L-amino acids to their corresponding imines (Fig. I.1B).  RebO’s 
favored substrate is 7-chloro-L-tryptophan, with a 57-fold greater kcat/Km than for L-
tryptophan itself.26  Identification of 7-chloro-L-tryptophan as the preferred substrate 
suggests that chlorination precedes generation of the imine (Fig. I.1B), and that the 
rebeccamycin biosynthetic enzyme RebO provides a control point between primary and 
secondary metabolism by utilizing a non-proteogenic amino acid as a substrate.26  StaO, 
the corresponding enzyme from the staurosporine pathway,27 is likely to carry out an 
identical reaction, but its physiological substrate is deschlorinated L-tryptophan, and 
StaO is not likely to provide such a control point between primary and secondary 
metabolism. 
 The indole-3-pyruvate imine 3 generated by RebO, which is not stable in solution, 
is thought to be channeled to the next enzyme RebD, which is a ~113 kDa protein and 
putative dimer that contains three equivalents of iron (2 as heme iron).28  To determine if 
the product of the upstream enzyme, RebO, is the substrate for RebD, a series of isotopic 
labeling experiments were carried out.  These experiments demonstrated that the product 
of RebO, indole-3-pyruvate imine, rather than its decomposition product, indole-3-
pyruvic acid, is indeed the preferred substrates for RebD.28  RebD’s use of the reactive 
substrate indole-3-pyruvate imine is another example of a bisindole biosynthetic enzyme 
that stabilizes and channels a reactive intermediate to a desired product.  It is thought that 
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RebD, as well as its functional homologues, StaD (from the staurosporine pathway) and 
VioB (from the violacein pathway), acts to install a carbon-carbon bond between the two 
Cβ carbons of two molecules of indole-pyruvate imine (Fig. I.1B), with spontaneous 
chemistry resulting in the production of chromopyrrolic acid 5, the final product and 
substrate for subsequent enzymes.28,29   
 Both StaP and RebP, enzymes with 54% identity from the staurosporine and 
rebeccamycin biosynthetic pathways, respectively, are functionally equivalent 
cytochrome P450 enzymes (Box 2B) that react with chromopyrrolic acid 5.20  Only one 
of the two enzymes, StaP, has been studied extensively, and all results are thought to 
extend to its homologue, RebP.  The crystal structure of StaP (Fig. I.2B) shows the bound 
substrate chromopyrrolic acid in the active site of StaP with its indole rings turned away 
from one another,30 consistent with minimization calculations describing the preferred 
orientation for chromopyrrolic acid.31  The orientation of chromopyrrolic acid 5, which 
appears to be ‘locked’ into place by extensive interactions with the StaP active site, 
strongly suggests that reaction occurs between the C10 carbon of chromopyrrolic acid 
and the heme iron.  These atoms are 4.7 Å apart, a distance that is within range of 
substrate-iron distances in other cytochrome P450 enzymes.32,33  By contrast, the 
carboxylates are > 8Å from the heme iron, which is too far for interaction.30  A proposed 
reaction scheme involves generation of two indole cation radicals, with subsequent steps 
enabling aryl-aryl coupling to occur between the two C2 carbons of the indole rings of 
chromopyrrolic acid (Fig. I.1B).30   
 StaP, however, is best considered collectively with the downstream enzymes 
RebC (from the rebeccamycin pathway) and StaC (from the staurosporine pathway).  Co-
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incubation of StaP with StaC results in exclusive formation of the 4-electron oxidation 
product, the staurosporine aglycone 6, and co-incubation of StaP with RebC results in 
exclusive formation of the 8-electron oxidation product, the rebeccamycin aglycone 10 
(Fig. I.1B).34  While both enzymes RebC and StaC contain sequence homology to flavin-
dependent oxygenases (Box 2A), only RebC is co-purified with the cofactor FAD.34  The 
crystal structure of RebC, solved with a decomposition product of aryl-aryl coupled 
chromopyrrolic acid trapped in the active site, shows flavin in an appropriate position to 
carry out flavin-based chemistry on the C7 carbon (Fig. I.2C).  The structure suggests 
that RebC acts to carry out oxidative chemistry at the C7 carbon on a intermediate 
produced by the upstream enzyme, thus promoting production of a single product.31  The 
intermediate trapped in the RebC active site decomposes within 30 min in solution,35 yet 
a RebC crystal is able to stabilize the same molecule over a week-long time span, 
suggesting that one of RebC’s roles is to stabilize a reactive intermediate.31  StaC, which 
is purified without FAD,34 may be an enzyme that acts without flavin-based 
hydroxylation chemistry and primarily acts in stabilizing reactive intermediates.  In any 
case, the stabilization of reactive intermediates is likely a key function of both enzymes.   
 After formation of the rebeccamycin or staurosporine aglycones, further 
modification occurs via glycosylation and methylation.  In the rebeccamycin pathway, a 
β-glycosidic bond is installed between one indole nitrogen and a molecule of glucose by 
the enzyme RebG (Fig. I.1B).36  Subsequently, the glucose is methylated by RebM (Fig. 
I.1B, Box 2C).36  RebG exhibits flexibility in the indoles it can glycosylate, and RebM 
exhibits flexibility in the sugars it can methylate.36  In the staurosporine pathway, glucose 
is converted via the action of enzymes StaA, StaB, StaE, StaJ, StaI, and StaK to NTP-L-
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ristoamine.27,37  L-ristoamine is then installed on the staurosporine aglycone at one indole 
nitrogen by the action of StaG; re-orientation of the sugar into the unfavored 1C4 
conformation is followed by attachment to the second indole nitrogen by the action of 
StaN (Fig. I.1B).37  Both StaG and StaN are able to use alternate sugars as substrates, 
suggesting flexibility in substrate specificity.37  Following attachment, O-methylation at 
the 4'-amine of L-ristoamine and N-methylation at the 3'-hydroxyl of L-ritosamine occurs 
by the action of StaMA and StaMB, respectively (Fig. I.1B, Box 2C).37  With the 
exception of RebM, glycosylases and methylases from the rebeccamycin and 
staurosporine pathways have only been characterized in vivo.   
 
I.D.  Violacein 
 Although the violacein biosynthetic operon was annotated as a four-gene cluster 
(VioABCD) in a number of separate studies,38-40 when work on the biosynthesis of 
violacein began in two independent laboratories in 2006, it was discovered that the four 
genes were insufficient for production of violacein in a heterologous system, and that an 
additional gene, VioE, was necessary for pigment production.29,41  Once the five gene 
operon (VioABCDE) was identified as necessary and sufficient for violacein production, 
it was possible to begin investigations of the biochemical steps necessary for production 
of the pigment violacein (Table I.1, Box 3).   
 Recent studies have shown that VioA is the first enzyme in the violacein 
biosynthetic pathway.29,41  VioA, which has been shown to be functionally equivalent to 
RebO and StaO from the rebeccamycin and staurosporine biosynthetic pathways,41 is a 
flavin-dependent L-amino acid oxidase, converting L-tryptophan to indole-3-pyruvate 
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imine 3 (Fig. I.1C).29   VioB, the second enzyme in the violacein biosynthetic pathway, is 
a close homologue of RebD, StaD, and InkD,29 as well as AtmD,42 suggesting a 
relationship, as for VioA, with the indolo[2,3-a]pyrrolo[3,4-c]carbazole biosynthetic 
pathways.  Multiple studies have established that this sequence homology translates to 
functional equivalence,29,41 and the combination of VioA and VioB results in the same 
product (chromopyrrolic acid 5) as the combination of RebO and RebD.41  Additionally, 
incubation of RebO, RebD, and later enzymes of the violacein pathway – VioCDE – 
results in violacein production,41 further demonstrating the equivalence of VioAB with 
RebOD.  However, the production of chromopyrrolic acid 5 by VioAB is not on pathway.  
Chromopyrrolic acid 5 is a shunt product and not a precursor to violacein.29,41  A 
filtration-HPLC assay established that VioE, the next enzyme in the pathway acts on a 
yet-uncharacterized intermediate produced by VioB to generate prodeoxyviolacein 13.29  
Based on the ability of VioE to produce prodeoxyviolacein 13 from the VioB product, a 
likely reaction for both VioB and RebD to catalyze is the dimerization of two molecules 
of indole-3-pyruvate imine to give the Cβ-Cβ benzylically coupled iminophenylpyruvate 
dimer 4, a molecule which can spontaneously decompose to chromopyrrolic acid in the 
absence of VioE (Fig. I.1B).  If the coupled iminophenylpyruvate dimer is indeed the 
substrate of VioE, then VioE is required to mediate a 1,2 shift of an indole ring, closure 
of the pyrrolo ring, two decarboxylations, and additional oxidative chemistry (Fig. I.1C).  
Despite carrying out these many reactions, VioE, a protein with few sequence 
homologues, lacks any detectable cofactors or metals, as judged by biochemical29 as well 
as subsequent crystallographic analysis.42,43  The crystal structures of VioE reveal a 
dimeric, 11-stranded antiparallel β sheet and show that the active site resides are located 
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in the concave surface of the VioE β-sheet.  Two sets of site-directed mutagenesis 
experiments demonstrate six residues in the active site that are important (but not 
essential) to catalysis (Fig. I.2D).  From crystallographic analysis, it appears that VioE 
functions by orienting a substrate in the cleft of its surface, promoting the production of 
prodeoxyviolacein and suppressing formation of the shunt product chromopyrrolic acid 
5.42,43  
 The product of VioE-mediated catalysis, prodeoxyviolacein 13, is in turn the 
substrate for VioD, a flavin-dependent enzyme (Box 2A).  VioD hydroxylates 
prodeoxyviolacein in the presence of NAD(P)H, generating proviolacein 14 (Fig. I.1C).29  
VioC, another flavin-dependent enzyme that requires NAD(P)H for activity,  is then 
responsible for the oxygenation in the oxindole ring (Fig. I.1C).  Although VioC is able 
to react with either prodeoxyviolacein 13 (the VioE product) or proviolacein 14 (the 
VioD) product, VioD is only able to react with prodeoxyviolacein 13 (the VioE product), 
suggesting that VioD acts before VioC in the biosynthetic pathway (Fig. I.1C).29  This 
pathway order is also consistent with in vivo results.41   
 
I.E.  Terrequinone A 
 Terrequinone A (Table I.1) was first isolated from the fungus Aspergillus terreus 
residing in the rhizosphere of canyon ragweed (Ambrosia ambrosioides) from the Tucson 
Mountains of Arizona.12  Previously, it was anticipated that genes encoding biosynthetic 
enzymes for secondary metabolites would be dispersed across fungal genomes; however, 
surprisingly, studies have revealed that genes for fungal secondary metabolites are in fact 
clustered.44  The identification of the terrequinone biosynthetic gene cluster relied on the 
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identification of LaeA as a nuclear protein that regulates secondary metabolite gene 
clusters in the related fungus Aspergillus nidulans.45  Transcriptionally active clusters in 
LaeA deletion fungal mutants versus in LaeA overexpression fungal mutants were 
identified via microarray analysis.46  One cluster of five genes was identified, and found 
to encode five enzymes, TdiABCDE, which were shown to biosynthesize terrequinone 
A.46 
   The principles of terrequinone A biosynthesis may extend directly to other 
bisindolylquinones as each is thought to be made through a common intermediate, 
didemethylasterriquinone D 17 prior to further modification.11  Further, the unique 
prenylation (Box 2D) of terrequinone A 19 – with one prenyl group attached to the C5 
carbon (but not the C2) of the quinone core, and the other prenyl group attached to one 
(but not both) of the C2 indole rings (numbering in Box 1E) – suggest that further 
investigation of terrequinone A biosynthesis may unravel unique modes of 
prenyltransferase specificity or regulation.  Finally, initial steps in dimerization to 
generate the bisindole core also stand in contrast to the steps used in indolocarbazole or 
violacein biosynthesis, using a completely different set of chemistries to generate a 
distinct core bisindole compound.47 
 The first step in terrequinone A construction is the pyridoxal-5’-phosphate (PLP)-
dependent (Box 2E) reaction of TdiD with L-tryptophan, generating indole pyruvic acid 
16 (Fig. I.1D)11,47 using an unknown co-substrate,47 which may be phenylpyruvic acid.11  
This step immediately separates terrequinone A biosynthesis from indolocarbazole and 
violacein biosynthesis, as these pathways use indole-3-pyruvate imine 3 as a precursor, 
rather than indole-3-pyruvic acid 16 (Fig. I.1A).  One key chemical issue in the 
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production of indole pyruvic acid is its instability.  However, TdiA, the next enzyme in 
the terrequinone A pathway reacts with indole-3-pyruvic acid with a KM of 1.2 ± 0.3 μM, 
suggesting that the instability of the indole-3-pyruvic acid produced by TdiD is countered 
by the high affinity for this molecule by TdiA.47  
 TdiA represents a novel enzyme.  Bioinformatic analysis suggests that TdiA is a 
non-ribosomal peptide synthetase (NRPS) (Box 2F), however, it has many unusual 
features.  It is a rare single domain NRPS, it lacks the canonical condensation (or 
replacement cyclization) domain, and it may use a new mechanism of release from the 
thioesterase domain.  A new mechanism of release from the thioesterase domain is 
needed because terrequinone A lacks an acid, amide, or ester group that would be 
generated by a hydrolysis or cyclization reaction on the thioesterase (Box 2F).47  
Additionally, its putative substrate is not, as usual, an amino acid, but instead is an α-keto 
acid.  Structural studies of the adenylation domain of another NRPS, PheA, together with 
bioinformatic analysis have resulted in a ‘code’ describing the specificity of adenylation 
domains for specific amino acids.48,49  These amino acid adenylation domains contain a 
conserved aspartate (Asp235 in PheA numbering), which normally stabilizes the amino 
group of the amino acid substrate.50  TdiA, by contrast, has been reported by one group to 
contain an alanine at this position,47 and by another group to contain a valine at this 
position.11  Collectively, this bioinformatic analysis suggests that TdiA may have 
conferred specificity for indole pyruvic acid, rather than L-tryptophan, through 
substitution of an aspartate with a hydrophobic amino acid at this key site.  Loading of an 
indole pyruvic acid, rather than L-tryptophan, is in fact key to the construction of the 
bisindolylquinone.  Loading of an amino acid, rather than an α-keto acid, would not 
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enable generation of a core quinone.  The amino acid, more reduced that an α-keto acid, 
is insufficiently activated to react without a condensation domain; further, the presence of 
the amino acid nitrogens would result in a heterocyclic ring, rather than a core quinone.  
Additionally, loading of an imine such as indole-3-pyruvate imine, rather than an α-keto 
acid, would instead result in a diaminobenzoquinone core, i.e. a molecule containing 
amine nitrogens in place of the hydroxyls. 47 
   Because TdiA is a putative NRPS, it likely employs a phosphopantetheinyl 
transferase to prime its thiolase domain serine with a phosophopantetheinyl arm (Box 
2F).  Although the physiological phosphopantetheinyl transferase for TdiA is unknown, 
either Ppant transferase Svp11,51 or the Ppant transferase Sfp47,52 enable activation of TdiA 
to the holo-enzyme and production of the bisindole product, didemethylasterriquinone D 
3, from two molecules of indole-3-pyruvic acid.  Mutagenesis of a conserved serine in the 
thioesterase domain to an alanine abolishes this activity.47  The need for both a 
phosphopantetheinyl arm (on the T domain) as well as the active site serine (on the TE 
domain) for product formation suggests that both domains are necessary to dimerize two 
molecules of indole pyruvate to didemethylasterriquinone D. 
 Accounting for the known final product, as well as chemical logic associated with 
NRPS enzymes, a plausible reaction scheme involves reaction between one indole 
pyruvate tethered at the TE domain, via an ester linkage, and the other indole pyruvate 
tethered at the T domain, via a thioester linkage.  Two Claisen-like condensations could 
occur to give rise to the final product (Fig. I.1D).  This is a yet-unknown chemistry for 
NRPS domains and represents the first reported NRPS that can catalyze carbon-carbon 
bond formation.47  The ability of the NRPS domain to dimerize two indole pyruvate 
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molecules by tethering them on adjacent T and TE domains of a single NRPS explains 
both the need for only one NRPS module, as well as the lack of amide, ester, or acid 
linkages connecting the two indole pyruvate molecules in the final product 
didemethylasterriquinone D 17.   
 Subsequent enzymes in the biosynthetic pathway have been shown to be even 
more unusual than TdiA.  Sequence analysis of TdiB suggests that the enzyme is a 
prenyltransferase (Box 2D).46   However, the role of TdiB is peculiar.  Although there are 
two prenylations in the final terrequinone A product, they occur at two sites with 
different connectivities,47 and the prenylation is non-symmetric.  That is, although 
prenylation occurs at the C2 carbon of one indole ring, it does not occur at the C2 carbon 
of the other indole ring.  Additionally, prenylation occurs at the C5 carbon of the quinone 
core but not at the C2 carbon of the quinone core (numbering, Box 1E).  How a single 
prenyltransferase could specifically catalyze a prenylation on two unique sites of the 
same molecule, and avoid prenylation on near-equivalent sites, is still unknown.   
 Two groups came to distinct conclusions regarding the role of TdiB in the 
biosynthesis of terrequinone A.  One group was able to demonstrate a single-enzyme 
mediated prenylation of didemethylasterriquinone D 17 to asterriquinone C-1, involving 
a prenylation at the C2 of one indole carbon,53 but the other group showed that TdiB was 
unable to react with didemethylasterriquinone D directly but could carry out the same 
prenylation reaction on the monoprenylated derivative, ochrindole D 18, generating the 
bisindole terrequinone A 19.47  This second group also demonstrated that 
didemethylasterriquinone D 17 was a substrate for the three enzyme system – TdiB, 
TdiC, and TdiE – which collectively generated terrequinone A.47  TdiB and TdiC alone 
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resulted in low levels of terrequinone product formation from didemethylasterriquinone 
D (Fig. I.1D).47  Many of the different conclusions of the two groups can be attributed to 
differing reaction conditions or the particular constructs used in purifying TdiB.  
However, despite the differences in observed activity, it is clear that only one prenylation 
(on the C2 of one indole ring) occurs by the action of TdiB alone,47,53 and the presence of 
TdiB, TdiC, and TdiE does allow the prenylation at the C5 of the quinone core to occur.47  
These results suggest a complicated and yet-unelucidated relationship between TdiB, 
TdiC, and TdiE.  
 
I.F.  Other bisindole molecules 
 The studies described in this Review have revealed the biosynthetic steps that lead 
to the construction of the indolo[2,3-a]pyrrolo[3,4-c]carbazole core, the violacein 
skeleton, and the terrequinone A skeleton.  A number of related molecules may be 
biosynthesized through similar pathways, and it is worthwhile to consider the similarities 
and differences that are likely to exist between the biosynthesis of rebeccamycin 12, 
AT2433-A1 33, staurosporine 9, K252a 34, violacein 15, and terrequinone A 19 and 
other, related molecules.  Based on the variety of bisindole molecules isolated from 
nature, however, it is also clear that some bisindole molecules cannot be understood in 
terms of indolocarbazole, violacein, or bisindolylquinone biosynthesis, and these 
molecules are likely to be formed by unique pathways.  The study of bisindole 
biosynthesis, therefore, will be a rich area of investigation for many more years.    
 One example of a variation on rebeccamycin is the molecule indocarbazostatin B 
20 (Fig. I.3A), which contains a similar aglycone core to rebeccamycin, but differs in the 
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glycosylation, with glycosylation partially resembling that of K252a 34.  
Indocarbazostatin B is also hydroxylated at the C5 position of one indole ring and 
aminated at the C4 position of the same ring.  Therefore, it is reasonable to anticipate that 
the bacteria encoding the biosynthetic cluster for indocarbazostatin B will contain 
homologues to RebO, RebD, RebP, and RebC but will differ from the rebeccamycin gene 
cluster in the presence of a distinct set of enzymes devoted to hydroxylation and 
amination reactions of the phenyl ring.  Additionally, glycosylation enzymes in this 
pathway may largely resemble those from the K252a pathway, with some modifications.  
More dramatically distinct from rebeccamycin and staurosporine is a molecule such as 
arcyriacyanin A 21 (Fig. I.3B), but it is possible that the unusual linkage in its core 
structure results from an alternate aryl-aryl coupling by a StaP substitute (Fig. I.3B).  The 
biosynthesis of granulatimide 22 (Fig. I.3C), may also be similar to the indolo[2,3-
a]pyrrolo[3,4-c]carbazole biosynthetic pathways but would use one molecule of L-
tryptophan and one molecule of L-histidine as biosynthetic precursors.  Molecules related 
to terrequinone A include semicochliodinol A 23 (Fig. I.3D), whose biosynthesis should 
be identical to terrequinone A biosynthesis through the intermediate 
didemethylasterriquinone D 17.  However, its biosynthetic pathway will differ in the type 
of prenyltransferase, as it is prenylated at a distinct site from either prenylation site in 
terrequinone A.  Further, the molecule fellutanine A 24 (Fig. I.3E) may also, like 
terrequinone A, be constructed using NRPS chemistry, but would use two modules 
specific for L-tryptophan, with formation of an amide bond to release the product. 
 While the studies presented in this Review do clarify the biosynthetic construction 
of some bisindole natural products, a number of unusual bisindole molecules are unlikely 
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to be constructed via the same types biosynthetic pathways.  For instance, although the 
molecule nortopsentin A 25 (Fig. I.3F) appears to have a similar core skeleton to that of 
violacein, nortopsentin A must be generated through an alternate process: unlike 
violacein, whose biosynthesis involves loss of one amide nitrogen, nortopsentin A 
contains two nitrogens in its central ring.  Other molecules (Fig. I.4), including iheyamine 
B 26, rhopaladin A 27, tjipanazole I 28, fascaplysin 29, malasseziazole A 30, pityriarubin 
A 31, and ancorinazole 32, while clearly derived from L-tryptophan, are unlikely to be 
generated by processes that generate indolo[2,3-a]pyrrolo[3,4-c]carbazole cores, the 
violacein skeleton, or the terrequinone A skeleton.  Future studies on the biosynthetic 
clusters for such molecules will be a valuable addition to the current studies on the 
construction of bisindole molecules.   
 
I.G.  Future directions in bisindole biosynthesis 
 Although studies have clarified the role of many of the enzymes involved in the 
construction of the three types of bisindole molecules presented in this Review, a large 
number of questions remain about the details of these enzymatic reactions.  In 
rebeccamycin biosynthesis, the spectroscopic elucidation of the proposed Lys-79-
chloramine intermediate in RebH is still elusive, as is an understanding of how FADH2 
produced by the partner reductase RebF is transferred to RebH.  The structure of RebD, 
which is not yet available, would represent a largely uncharacterized enzyme.  It also 
might shed light on how RebD (with 3 equivalents of iron)28 can be functionally identical 
to VioB (with less than 1 equivalent of iron),29 as well as provide details about potential 
routes for the proposed channeling of indole-3-pyruvate imine from RebO to RebD.  For 
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the two enzyme RebP-RebC system, although a series of studies suggest that an unstable 
intermediate is produced by RebP and is the substrate of RebC,31,34,35 questions of 
intermediate channeling, the precise identity of the substrate of RebC, and the mechanism 
of flavin based hydroxylation chemistry are areas of active study.  Further, in the 
staurosporine pathway, questions remains about the role of StaC, which is a close 
homologue of RebC but is purified without bound FAD and carries out a distinct 
reaction.34  In the violacein pathway, a number of questions are also outstanding.  
Although an intermediate has been shown to be transferred from VioB to VioE, the 
identity of this intermediate has only been suggested.29  Further, while structural 
characterization now provides a model of VioE,42,43 the lack of an essential residue in 
VioE is puzzling, and the organic chemistry involved in converting the Cβ-Cβ 
benzylically coupled iminophenylpyruvate dimer 4 to prodeoxyviolacein 13 is largely 
unexplored.  Next, VioD, while apparently a ‘standard’ flavin hydroxylase, will 
hydroxylate prodeoxyviolacein but not the related molecule (oxyviolacein),29 suggesting 
either steric or electronic effects modulate its substrate specificity.  Finally, as mentioned 
earlier, questions remain about the structure and mechanism of VioB, as for its 
homologue RebD.  In the terrequinone A biosynthetic pathway, only TdiD is well-
understood.  For TdiA, various mechanisms are consistent with the available evidence, 
including an alternate proposal for formation of the quinone core.47  For TdiB, TdiC, and 
TdiE, the available data suggest a complicated relationship between the three enzymes,47 
and further studies will be needed to delineate how TdiE accelerates the TdiB-TdiC-
mediated production of terrequinone A 19 from didemethylasterriquinone D 17.  For 
many of the bisindole biosynthetic enzymes, whose roles include enzymatic reactions and 
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stabilization of reactive intermediates, standard biochemical approaches are often 
difficult, particularly when putative substrates decompose quickly in solution.   
 Major questions also remain about the roles of these molecules for their producing 
organisms.  For instance, staurosporine is often isolated as a natural product;54 why do so 
many actinomycete bacteria invest so much biochemical energy to produce a protein 
kinase inhibitor such as staurosporine?  Additionally, what is the physiological role of 
violacein; is it related to its various biochemical properties (for instance anti-bacterial and 
anti-viral properties),55 to its apparent regulation with quorum sensing pathways,56 or to 
its distinctive purple color?  Finally, why do plant associated fungi such as Aspergillus 
nidulans produce molecules such as terrequionone A, which has unknown properties?  Is 
there a yet unexplored role for terrequinone A that is relevant to its role in its ecological 
niche?  The next frontier in the basic science research of bisindole natural products will 
be a detailed investigation of the ecological interactions mediated by natural products 
such as rebeccamycin, staurosporine, violacein, and terrequinone A.   
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Table I.1.  Bisindole natural products with characterized biosynthetic clusters. 
 
Compound # Structure Source organism 
used to isolate 
biosynthetic 
genes 
Known medicinal 
properties 
Biosynthetic 
enzymes 
Rebeccamycin 12 HN
NN
H
OO
ClCl
O
OH
OCH3
HO
OH
 
Lechevaleria 
aerocolonigenes 
Anticancer; DNA-
topoisomerase I 
inhibitor 
RebF, RebH, RebO, 
RebD, RebP, RebC, 
RebG, RebM 
AT2433-A1  33 
OHN
HO
N
NN
H
OO
ClO
H3CO
OH
CH3
O
HO
 
Actinomadura 
melliaura 
Antitumor, 
antibacterial 
AtmH, AtmA, 
AtmO, Atm D, 
AtmP, AtmC, 
AtmG, AtmM, 
AtmM1, AtmG1; 
AtmS7, AtmS8, 
AtmS9, AtmS14, 
AtmS12, AtmS13, 
AtmS10 
Staurosporine 9 HN
NN
O
O
NHCH3
H3C
H3CO  
Streptomyces 
staurosporeus 
Protein kinase 
inhibitor 
StaO, StaD, StaP, 
StaC, StaG, StaN, 
StaMA, StaMB; 
StaA, StaB, StaE, 
StaJ, StaI, StaK 
K252a  34 
NN
H
N O
O
H3C
H3C
O OCH3  
Nonomuraea 
longicatena 
Protein kinase C 
inhibitor 
InkO, InkD, InkP, 
InkE, InkG, InkC, 
InkA, InkL, InkB, 
InkH, InkL, InkG, 
InkC, InkM 
Violacein 15 
N
H
H
N
HN
O
O
OH
 
Chromobacterium 
violaceum 
Antibacterial, 
antiviral, 
anticancer, 
antileishmanial, 
antiulcerogenic 
VioA, VioB, VioE, 
VioD, VioC 
Terrequinone 
A 
19 
O
H
N
O
HO
N
H  
Aspergillus 
nidulans 
Unknown TdiD, TdiA, TdiC, 
TdiB, TdiE 
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Figure I.1.  Divergent pathways in bisindole biosynthesis.  R=Cl for rebeccamycin 
precursors; R=H for staurosporine, violacein, and terrequinone A precursors.  
Compounds in boxes are characterized intermediates, whereas compounds that are not 
boxed are proposed but yet-uncharacterized intermediates.  Double boxes indicate final 
products or the L-tryptophan starting material.  1, L-tryptophan; 2, 7-chloro-L-
tryptophan; 3, indole-3-pyruvate imine; 4, Cβ-Cβ benzylically coupled 
iminophenylpyruvate dimer; 5, chromopyrrolic acid; 6, K252c (staurosporine aglycone); 
7, holyrine A; 8, O-demethyl-N-demethyl-staurosporine; 9, staurosporine; 10, dichloro-
arcyriaflavin A (rebeccamycin aglycone); 11, 4'-demethyl-rebeccamycin; 12, 
rebeccamycin; 13, prodeoxyviolacein; 14, proviolacein; 15, violacein; 16, indole-3-
pyruvate; 17, didemethylasterrequinone D; 18, ochrindole D; 19, terrequinone A.  A.  L-
tryptophan is thought to be the biosynthetic precursor for all bisindole molecules, and the 
diverging pathways from L-tryptophan to terrequinone A, staurosporine, rebeccamycin, 
and violacein are depicted.  B.  Biosynthesis of staurosporine and rebeccamycin, 
including proposed intermediates.  C.  Biosynthesis of violacein, including proposed 
intermediates.  D.  Biosynthesis of terrequinone A, including proposed intermediates.   
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Figure I.1B 
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Figure I.1D 
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Figure I.2.  Active sites of bisindole biosynthetic enzymes.  A. RebH, an FADH2-
dependent chlorinase, contains two active sites, separate by ~11 Å.   In the first active 
site, FADH2, O2, and Cl- are thought to bind; FAD (shown in green) has been co-
crystallized and is shown (PDB ID 2OAL).25  In the second active site, L-tryptophan 
(shown in orange) binds (PDB ID 2E4G).25  Situated between the two active sites is Lys-
79 (shown in magenta).  HOCl is thought to be generated from flavin-C4a-O-Cl.  The 
HOCl then reacts with Lys-79, becoming a chloramine intermediate and is then 
transferred to L-tryptophan.  Lys-79 has distance of 4 Å from its ε-NH2 to the C-7 of L-
tryptophan, and a distance of 9 Å from its ε-NH2 to the C4a of FAD.  B.  StaP (PDB ID 
2Z3U),30 a cytochrome P450 enzyme, binds chromopyrrolic acid (shown in yellow) with 
a distance of 4.7 Å from one C10 carbon to its heme iron (brown sphere), and is proposed 
to catalyze an aryl-aryl coupling between the two C2 carbon atoms of the chromopyrrolic 
acid indole rings.  C.  RebC (PDB ID 2R0G),31 a putative flavin hydroxylase, binds a 
tautomer of 7-carboxy-K252a (shown in pink) in its active site, in an appropriate position 
for flavin-based hydroxylation chemistry to occur at the C-7 carbon.  FAD is shown in 
blue, and two arginines (in gray) hydrogen bond to the out-of-plane carboxylate of the 7-
carboxy-K252c tautomer.  D.  VioE, an enzyme with no cofactors, metals, or single 
essential side-chain, binds a PEG molecule (in green, from PDB ID 3BMX42) or two 
molecules of phenylpyruvic acid (from PDB ID 2ZF443, not shown), molecules which 
partially mimic the putative substrate of VioE, in its active site.  Nearby are 6 residues (in 
gray) which play a role in the enzymatic acceleration of prodeoxyviolacein 
production.42,43  
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Figure I.3.  Underexplored bisindole products.  A. The biosynthesis of the aglycone core 
of indocarbazostatin B 20 likely resembles that of rebeccamycin biosynthesis, with 
addition of a hydroxylase and an aminase.  Its biosynthesis and attachment of the sugar 
moiety is likely to be similar to K252a, with some modifications.  B.  Arcyriacyanin A 21 
resembles the rebeccamycin aglycone but with a different connectivity.  It may be 
generated through a rebeccamycin-like pathway, with an aryl-aryl coupling between the 
C2 of one indole and the C4 of the other indole ring.  C. Granulatimide 22 may be 
biosynthesized through a rebeccamycin-like pathway, with one L-tryptophan and one L-
histidine molecule as alternate precursors.  D. Biosynthesis of semicochliodinol A 23 
should resemble that of terrequinone A except that the prenylation occurs at a distinct 
site.  E. The biosynthesis of molecules such as fellutanine A 24 may involve traditional 
non-ribosomal peptide synthetase chemistry, unlike the unusual NRPS-type chemistry 
used in terrequinone A biosynthesis.  F. Nortopsentin A 25 resembles violacein in its 
skeleton, however, it contains two nitrogens in its core ring, suggesting it is made by non-
violacein-like chemistry. 
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Figure I.4.  Unusual bisindole molecules.  A number of unusual molecules are unlikely 
to be constructed by processes that generate indolo[2,3-a]pyrrolo[3,4-c]carbazole cores, 
the violacein skeleton, or the terrequinone A skeleton.  Each bisindole molecule shown 
below, however, could be derived from two dimerized L-tryptophan molecules.  To 
emphasize this point, the molecules are drawn with atoms in blue (representing atoms 
from one L-tryptophan molecule) or red (representing atoms from a second L-tryptophan 
molecule) or green (for pityriarubin A, which may be derived from three L-tryptophan 
molecules).  Note, however, that labeling studies have not established the biosynthetic 
origins of any of these molecules.  Future studies on the biosynthetic clusters for such 
molecules will be a valuable addition to the current studies on the construction of 
bisindole molecules. 
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I.J.  Box 1:  L-tryptophan as a biosynthetic building block 
 Like other indole alkaloids,57 naturally occurring compounds containing two 
indole rings are generally thought to be derived from the amino acid L-tryptophan,54 and 
this assumption has indeed proven true for all characterized bisindole biosynthetic 
pathways.  L-tryptophan provides an excellent scaffold for dimerization and 
derivitization, and consequent production of bisindole molecules which, via distinct 
chemical properties, give rise to distinct biological properties.  A key feature of the L-
tryptophan molecule is the indole ring, shown with standard numbering (A).  Heterocyles 
related to indole include carbazole (B), indolo[2,3-a]carbazole (C), indolo[2,3-
a]pyrrolo[3,4-c]carbazole (shown with standard numbering in D; R=2H or O), and 
bisindolylbenzoquinone (shown with standard numbering in E).      
 The pathways described in this Review show how enzymes take advantage of the 
inherent reactivity of L-tryptophan to generate divergent natural products.  One feature of 
the indole ring of L-tryptophan is the potential reactivity of the C2, C4, C5, C6, and C7 
carbons in electrophillic aromatic substitution reactions (F).  In the indolo[2,3-
a]pyrrolo[3,4-c]carbazole pathways, the indole ring of L-tryptophan is subjected to 
derivatization at the phenyl ring via electrophillic aromatic substitution reactions, which 
give rise to hydroxylated and halogenated rings.  In the violacein pathway, oxidation of 
the C5 carbon of the indole by VioD takes advantage, again, of the inherent reactivity of 
this site in electrophillic aromatic substitution reactions.  In various bisindolylquinone 
biosynthetic pathways, prenylation occurs at the reactive carbons of the indole. 
 Conversion of L-tryptophan to either indole-3-pyruvate or to indole-3-pyruvate 
imine increases its reactivity.  In the indolo[2,3-a]pyrrolo[3,4-c]carbazole and violacein 
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pathways, conversion to indole-3-pyruvate imine generates a substrate suitable for an 
enzymatically catalyzed dimerization of two indole-3-pyruvate imine molecules at their  
Cβ carbons (G).  Once formed, the Cβ-Cβ benzylically coupled iminophenylpyruvate 
dimer contains reactive nitrogens, one of which can react as a nucleophile (H).  
Displacement of the imine nitrogen gives rise to a pyrrolo ring and generates 
chromopyrrolic acid.  The C2 carbon of one indole, whose reactivity was noted above, 
can then be subjected to an enzymatically catalyzed aryl-aryl coupling with the C-2 
carbon from the second indole ring (J).  The aryl-aryl coupling, however, generates a 
reactive molecule that undergoes spontaneous and/or enzymatically catalyzed 
(occasionally oxidative) decarboxylations (J).  Finally, the indole nitrogens can become 
glycosylated by additional biosynthetic enzymes (K).   
 Also utilizing the inherent reactivity of L-tryptophan derivatives, the violacein 
pathway demonstrates a reasonable divergence from the above pathway.  While 
formation of the same Cβ-Cβ benzylically coupled iminophenylpyruvate dimer from two 
molecules of indole-3-pyruvate imine proceeds identically as in the indolo[2,3-
a]pyrrolo[3,4-c]carbazole class, this intermediate can break down through an alternate 
route.  Instead of formation of a pyrrole-like ring, a cyclopropyl ring can form and 
collapse (I), with the process driven by a decarboxylation.  This alternate pathway leads 
to the migration of an indole ring, generating a violacein precursor.   
 Alternatively, additional opportunities for dimerization and cyclization emerge 
via formation of indole 3-pyruvate from L-tryptophan.  As exemplified by the 
terrequinone A biosynthetic cluster, tethering of the carboxylate of indole-3-pyruvate to a 
thioester carrying protein generates a strong electrophile at the carbonyl carbon, which 
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can be subjected to nucleophillic attack by another indole-3-pyruvate molecule (L).  
Hence, the rich chemistry of L-tryptophan provides a template for the production of a 
diversity of bisindole natural products.   
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I.K.  Box 2: Enzymatic mechanisms of natural product biosynthesis 
 Enzymes use of a vast array of mechanisms to biosynthesize natural products, 
however, a number of strategies are widely recurring.  Six strategies are described here.   
 
A.  Flavin-dependent oxygenases  The versatile, bright yellow cofactor FAD is used in a 
variety of reactions, but one common mode is via its reduced form, FADH2.  FADH2 can 
either be generated by a ‘partner’ enzyme (as in the case of RebH, whose ‘partner’ is 
RebF) or by reaction of the FAD cofactor with NAD(P)H in a separate site of the same 
enzyme.  Once formed FADH2 can react with oxygen to generate the flavin-C4a-
hydroperoxy intermediate, which can be subjected to attack by molecules such as 
electron rich aromatics or halides.   
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B.  Cytochrome P450 enzymes  Cytochrome P450s are heme containing enzymes with an 
axial cysteine coordinating the iron and with a characteristic absorbance at 450 nm upon 
reaction with carbon monoxide.  While P450s catalyze a variety of reactions, the most 
common reaction is hydroxylation of aliphatic molecules.  The overall reaction of P450-
catalyzed hydroxylation (top) is not disputed, but some details of a proposed reaction 
scheme (bottom) are still under investigation, or are thought to differ from enzyme to 
enzyme.58  How P450s might catalyze aryl-aryl couplings, as in the case of StaP or RebP, 
is being explored.30,58,59  
 
Overall reaction: 
NADPH + H+ + O2 + RH NADP+ + H2O + ROH  
 
Proposed reaction scheme:   
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C.  AdoMet-dependent methyltransferases S-adenosylmethionine (AdoMet) is Nature’s 
“methyl iodide” (a commonly used reagent in organic chemistry).  Transfer of a methyl 
group to a hydroxyl or an amine is driven by the loss of the positive charge at the sulfur 
of AdoMet.   
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D.  Prenyltransferases  Dimethylallyl transferases (prenyltransferases) catalyze the 
reaction of electron rich molecules (such as indole) with dimethylallyl diphosphate.  A 
divalent cation (such as Mg2+) is often a required cofactor.  ‘Regular’ prenyltransferases 
(bottom) displace the pyrophosphate directly.  ‘Reverse’ prenyltransferases (top) displace 
the pyrophosphate through attack at a conjugated carbon.  The mechanism of 
prenyltransferases may involve generation of a carbocation (via loss of the 
pyrophosphate) prior to nucleophillic attack. 
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E.  PLP Dependent Chemistry  Reaction of a lysine-bound pyridoxyl pyruvate (PLP) 
cofactor with an amino acid results in hydrolysis to generate an α-keto acid and 
pyridoxamine-5'-phosphate (PMP), as shown below.  The PLP cofactor must then be 
regenerated from PMP by a co-substrate. 
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F.  Non-ribosomal peptide synthetases (NRPS’s)  Peptide natural products are build up by 
the assembly line action of NRPSs.  NRPS modules are composed of four (or more) 
domains, the most common of which are adenylation (A) domains, peptidyl carrier 
proteins (PCP) (or alternately, thiolation (T) domains), condensation (C) domains, and 
thioesterase (TE) domains.  Adenylation domains act to activate specific amino acids, by 
generating adenylated (AMP-derivatized) amino acids.  These adenylated amino acids 
then react with the phosphopantetheinyl group on a PCP domain, which displace the 
AMP activating group.  Condensation domains catalyze amide bond formation between 
sequential modules, as shown below.  Long peptides can be generated by iterative rounds 
of amide bond formation, with each step catalyzed by a distinct module.  In a final stage, 
the elongated peptide is transferred to an active site serine on the TE domain.  Release of 
the peptide from the enzyme can occur by hydrolysis (giving rise to an acid) or 
cyclization (giving rise to either an ester or an amide linkage).   
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I.L.  Box 3: Violacein from the Ithaca soil.  Chromobacterium violaceum is the best-
studied violacein producer.  A.  Chromobacterium violaceum has been isolated from the 
Negro River in South America, and is normally considered a ‘tropical’ or ‘subtropical’ 
bacterium.60  B.  Interestingly, DNA isolated from soil samples in Ithaca, New York were 
used to generate cosmid libraries, which were screened for the presence of colored 
clones.39  Purple clones that were isolated from two samples contained genes for 
violacein biosynthesis that were homologous to the gene cluster isolated from 
Chromobacterium violaceum.39  This second discovery of violacein, from a yet 
unidentified bacteria, suggests that violacein may be a widespread natural product.   
A      B 
 
 
 
 
 
 
 
 
 
 
Negro River      Cornell University 
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Chapter II: 
Crystallographic trapping in the rebeccamycin biosynthetic enzyme RebC 
 
II.A.  Summary 
 The biosynthesis of rebeccamycin, an anti-tumor compound, involves the 
remarkable eight-electron oxidation of chlorinated chromopyrrolic acid.  While one 
rebeccamycin biosynthetic enzyme is capable of generating low levels of the eight-
electron oxidation product on its own, a second protein, RebC, is required to accelerate 
product formation and eliminate side reactions.  However, the mode of action of RebC 
was largely unknown.  Using crystallography, we have determined a likely function for 
RebC as a flavin hydroxylase, captured two snapshots of its dynamic catalytic cycle, and 
trapped a reactive molecule, a putative substrate, in its binding pocket.  These studies 
strongly suggest that the role of RebC is to sequester a reactive intermediate produced by 
its partner protein and to react with it enzymatically, preventing its conversion to a suite 
of degradation products that includes, at low levels, the desired product.    
 
Note:  This chapter was previously published as:  Ryan K.S., Howard-Jones A.R., Hamill M.J., Elliott S.J., 
Walsh C.T., Drennan C.L. Crystallographic trapping in the rebeccamycin biosynthetic enzyme RebC. Proc. 
Natl. Acad. Sci. U. S. A., 104: 15311-15316 (2007).1  Chromopyrrolic acid, K252c, and RebC protein were 
prepared and chromopyrrolic acid degradation products were analyzed by Dr. Annaleise R. Howard-Jones 
in the laboratory of Prof. Christopher T. Walsh at Harvard Medical School.  The RebC redox potential was 
measured by Michael J. Hamill in the laboratory of Prof. Sean J. Elliott at Boston University.  The redox 
potential methods and data have been removed and will be published later in the Ph.D. thesis of Michael J. 
Hamill.   
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II.B.  Introduction 
 Rebeccamycin 1 (Fig. II.1A) is a natural product isolated from Lechevalieria 
aerocolonigenes2 and is a prototype for a class of compounds that bind to DNA-
topoisomerase I complexes,3 preventing the replication of DNA and thereby acting as 
antitumor compounds.4  Rebeccamycin is synthesized by the action of eight enzymes, 
with the overall conversion of L-tryptophan, chloride, molecular oxygen, glucose, and a 
methyl group to the glycosylated indolocarbazole rebeccamycin 1.5-10  One step in this 
pathway is the conversion of chlorinated chromopyrrolic acid 2 to the rebeccamycin 
aglycone 3; this reaction involves an eight-electron oxidation, and it is carried out by the 
enzyme pair, RebP and RebC.11  The mechanism of this reaction is not established.9   
RebP is annotated as a cytochrome P450, and it is functionally equivalent to its 
homologue StaP from the staurosporine biosynthetic pathway,11 which has been used in 
place of RebP in initial biochemical investigations.  Additionally, all biochemical work 
on StaP and RebC has used nonchlorinated substrates since they are well tolerated by 
both enzymes.9  One of the most remarkable features of StaP is that when it is incubated 
alone with its nonchlorinated substrate, chromopyrrolic acid 4, as well as with an electron 
source (provided by ferredoxin, flavodoxin NADP+-reductase, and NAD(P)H), StaP is 
capable of generating a number of products, including arcyriaflavin A 5, 7-hydroxy-
K252c 6, and K252c 7 at a 1:7:1 ratio9 (Fig. II.1B).  Inclusion of RebC, an FAD-
containing protein, in the reaction mixture results in near-exclusive production of 
arcyriaflavin A 5 and acceleration of turnover.9  One possibility to account for this 
phenomenon is that RebC can direct the outcome of the reaction by mediating the 
catalytic activity of StaP through a protein-protein interaction rather than acting 
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catalytically itself.  Although no stable interaction was found between StaP and RebC 
through pull-down assays,9 a transient complex cannot be ruled out.  Another possibility 
is that RebC can affect product distribution by reacting enzymatically with an unstable 
compound produced by StaP.  In this latter case, when RebC is not present, the StaP 
product could react further with StaP or could spontaneously degrade, giving rise to a 
number of nonspecific products.  It is known that RebC does not react with 
chromopyrrolic acid 4, arcyriaflavin A 5, 7-hydroxy-K252c 6, K252c 7, or arcyriarubin A 
8,9 but these results do not rule out an enzymatic reaction with an unidentified product 
produced by StaP.     
To provide a framework for further biochemical investigations of RebC, we solved 
the structure of RebC alone as well as RebC soaked with chromopyrrolic acid 4 and 
K252c 7. These studies have allowed for an identification of a likely function for RebC as 
a flavin-dependent hydroxylase and have further resulted in the crystallographic isolation 
of a reactive molecule – a putative substrate – in the substrate binding pocket. 
 
II.C. Materials and Methods 
Crystallization and data processing   
 RebC was purified as described earlier.9  Crystals of RebC were grown using 
hanging-drop vapor diffusion by incubating 1.5 µL of RebC (9 mg/mL in 150 mM NaCl, 
10% glycerol, 25 mM HEPES pH 7.5) with 0.35 µL of 1.0 M guanidine-HCl for 30 s, 
followed by addition of 1.5 µL of precipitant solution (19% PEG-8000, 0.1 M HEPES pH 
7.4), without mixing, at room temperature.  Immediately after set up, crystal trays were 
placed on a gel shaker, and then, after 12 h, transferred to a storage space in vibration-
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isolation.  Small crystals appeared overnight and grew larger over time.  Before being 
flash frozen in liquid nitrogen, crystals were soaked for 5 s in cryogenic solution (19% 
PEG-8000, 0.1 M HEPES 7.4, 20% glycerol).  To prepare a heavy-atom derivative, a 
native crystal of RebC was incubated with 19% PEG-8000, 0.1 M HEPES pH 7.4, and 10 
mM samarium acetate for 12 h.  The crystal was then back-soaked for 5 s in the 
cryogenic solution and flash frozen in liquid nitrogen.  Compounds chromopyrrolic acid 
4 and K252c 7 were prepared as described earlier9 and dissolved in DMSO at 50 mM and 
10 mM, respectively.  A chromopyrrolic acid-soaked dataset was prepared by incubating 
a native crystal of RebC in 19% PEG-8000, 0.1 M HEPES pH 7.4, and 5 mM 
chromopyrrolic acid for one week; shorter soaks of up to three days did not result in 
convincing electron density for a bound molecule.  The crystal was then soaked for 5 s in 
a cryogenic solution containing 19% PEG-8000, 0.1 M HEPES pH 7.4, 20% glycerol, 
and 5 mM chromopyrrolic acid and then flash frozen in liquid nitrogen.  A K252c soaked 
dataset was prepared by incubating a native crystal of RebC in 19% PEG-8000, 0.1 M 
HEPES pH 7.4, and 1 mM K252c for 11 days.  The crystal was then soaked for 5 s in a 
cryogenic solution containing 19% PEG-8000, 0.1 M HEPES pH 7.4, 20% glycerol, and 
1 mM K252c and then flash frozen in liquid nitrogen. 
 Data for the native crystals were collected at beamline 9-2 at the Stanford 
Synchrotron Radiation Laboratory (Palo Alto, California), integrated in HKL2000, and 
scaled in SCALEPACK.12  Multiple wavelength anomalous dispersion (MAD) data from 
a samarium derivative were collected at beamline 9-2 of the Stanford Synchrotron 
Radiation Laboratory using an inverse beam with a data wedge of 30°.  Data were 
integrated in HKL2000 and scaled in SCALEPACK.  Data for the chromopyrrolic acid-
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soaked and K252c-soaked crystals were collected beamline NE-CAT 24ID-C at the 
Advanced Photon Source (Argonne, Illinois), integrated in DENZO,12 and scaled in 
SCALEPACK.  Data collection statistics are shown in Table II.1.   
 
Structure determination and refinement   
 Phases were determined using multiple wavelength anomalous dispersion (MAD) 
data from a samarium-derivative.  Four samarium sites were identified in SOLVE13 and 
located on anomalous difference Patterson maps.  Heavy atom positions were refined in 
SHARP14 with a figure of merit (acentric) of 0.596 for data to 3.2 Å.  Initial density 
modification on phases to 3.2 Å was carried out using SOLOMON,15 which generated 
maps suitable for placement of α-helices and β-sheets in COOT,16 with refinement carried 
out in CNS.17  Phase combination with a partial model was used to carry out two 
subsequent rounds of SHARP and SOLOMON, which extended phases to 2.8 Å and then 
2.3 Å, and allowed manual building of the rest of the model.  A final model was built 
using iterative rounds of building in COOT and refinement in CNS, without a sigma cut-
off.  Coordinates for the cofactor flavin adenine dinucleotide (FAD) were modified from 
the FAD in PDB code 1N4V,18 which was used to generate topology and parameter files 
in XPLO2D.19 The complete samarium derivative model was then used to carry out 
molecular replacement20 on the 1.8 Å resolution native data set, as the unit cells of the 
samarium and native data had sufficiently different dimensions that rigid body refinement 
was not satisfactory.  A native model was obtained from further rounds of building in 
COOT and refinement in CNS, without a sigma cut-off, using the same topology and 
parameter files for FAD.   
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 The K252c-soaked structure was refined using the final native model, including 
only protein atoms, for rigid body refinement.  After one round of refinement, density 
was revealed for the FAD in the OUT conformation and for residues 354-363 (which 
were missing from the native structure), and there was weak density for a K252c-like 
compound near the FAD.  In a next round of refinement, water molecules were placed, 
the FAD from the native structure was added, and the helix was built, and resulting maps 
showed slightly improved density for the compound, which was then built as K252c for a 
third round of refinement.  Coordinates and topology and parameter files for K252c were 
based on the staurosporine structure21 available in the Cambridge Structural Database.   
Native, samarium-soaked, and K252c-soaked crystals had one RebC molecule per 
asymmetric unit, however, chromopyrrolic acid-soaked crystals had two molecules per 
asymmetric unit, in a larger unit cell.  The two molecules of the asymmetric unit of the 
chromopyrrolic acid-soaked unit cell show a 169° rotation relative to one another, 
suggesting global changes in both the relative orientation and overall structure of two 
monomers that were previously related by a crystallographic 180° rotation.   
 The final native model, including only protein atoms, was used for molecular 
replacement20 into the different cell of the chromopyrrolic acid-soaked data set.  After 
one round of refinement of the molecular replacement model in CNS, maps were 
examined, which revealed positive density corresponding to a chromopyrrolic acid-like 
molecule, residues 354-363 (missing from the native structure), and a flavin molecule 
with a shifted isoalloxazine ring.  Coordinates for FAD were initially refined using the 
FAD from PDB code 1C0K.22  Coordinates and topology and parameter files for 
chromopyrrolic acid were manually built based on CNS library values for tryptophan and 
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aspartate and a related structure23 available from the Cambridge Structural Databank and 
adjusted to best account for the electron density.  Additionally, coordinates for 
chromopyrrolic acid were minimized in Gaussian24 to determine ideal conformations.  
Coordinates and topology and parameter files were also generated for the products and 
intermediates of chromopyrrolic acid degradation, which were based on available 
structures in the Cambridge Structural Database23,25 and additionally minimized in 
Gaussian.24  The chromopyrrolic acid-soaked structure was adjusted in COOT and 
refined in CNS, without a sigma cut-off.    
 All models were examined with omit, 2Fo-Fc, and Fo-Fc maps.  Refinement 
statistics for all models are shown in Table II.2. 
 
HPLC analysis   
 Analytical HPLC was performed on a Beckman System Gold (Beckman Coulter) 
system with a Higgins analytical C18 column (50 x 4.6 mm) at 3 mL/min using a gradient 
of 0-60% acetonitrile in 0.1% trifluoroacetic acid.  Elution profiles were monitored at 280 
nm.   
 
Alignment of homologous proteins   
 RebC was individually aligned using LSQMAN26 to structures of phenol 
hydroxylase (1PN0),27 para-hydroxybenzoate hydroxylase (1DOC and 1DOD),28 and 
meta-hydroxybenzoate hydroxylase (2DKH).29  Structures with the OUT conformation of 
FAD were aligned to the native conformation of RebC, and structures with the IN 
conformation of FAD were aligned to the chromopyrrolic acid-soaked structure of RebC.  
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A final alignment was generated when three guidelines were met: (1) distances between 
Cα carbons were within 3.5Å; (2) residues were in sequential groups of three or more; (3) 
residues were aligned near-equivalently using both chromopyrrolic acid-soaked and 
native crystals, with the exception of residues 354-363, which had no density in the 
native structure.    
 
Final protein models   
 Crystallized RebC contains 529 residues with an N-terminal 20-amino acid tag.  
In all structures, the 20 residues of the N-terminal tag are disordered.  In the native 
structure, residue 1, as well as residues 354-363 and residues 417-425, are missing from 
the density.  In this structure 91.0% of residues are in the most-favored region of a 
Ramachandran plot, with one residue in the disallowed region.  In the K252c-soaked 
structure, residues 222-224, 246-250, and 417-425, are missing from the density, and 
89.8% of residues are in the most-favored region of a Ramachandran plot, with no 
residues in the disallowed region. In the chromopyrrolic acid-soaked structure, residues 
246-250 and 419-421 were not included in the model.  In this structure 88.3% of residues 
are in the most-favored region of a Ramachandran plot, with one residue in the 
disallowed region.  Chloride ions were added to account for 9 sigma positive difference 
density peaks in the native and K252c-soaked structures. When modeled as water, 
positive difference density peaks greater than 4.5 sigma were present.  Because this 
density is near an arginine, chloride was selected, because it is the only negatively 
charged ion in crystallization buffers.   
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II.D.  Results 
Resemblance to flavin hydroxylases   
 RebC is a monomer with three distinct domains (Fig. II.2A-B, Fig. II.3).  Domain 
I (residues 1-72, 104-190, and 279-354, in red), which binds the cofactor flavin adenine 
dinucleotide (FAD), is intertwined through four loops and one helix with domain II 
(residues 73-103, 191-278, and 355-398, in blue), which forms the base of a substrate 
binding pocket.  Domain III (residues 399-529, in green) is connected via an extended 
loop (residues 399 - 423) to domain II.  Domain III, which is distant from the active site, 
exhibits a typical thioredoxin fold,30 but lacks conserved cysteines and is of unknown 
function.     
 RebC exhibits overall structural homology to three proteins: phenol hydroxylase27 
(RMSD of 1.52 Å for 281 Cα carbon pairs), meta-hydroxybenzoate hydroxylase29 
(RMSD of 1.50 Å for 264 Cα carbon pairs), and para-hydroxybenzoate hydroxylase28 
(RMSD of 1.72 Å for 248 Cα carbon pairs) (Fig. II.2C, Fig. II.4).  Structurally 
homologous residues are primarily located in domains I and III, with only 49 residues of 
domain II having structural homology to any Cα carbons of the three structural 
homologues.  Each of these three homologues catalyze flavin-mediated hydroxylations 
on the ortho position of electron-rich phenol derivatives (Fig. II.5).29,31,32 
Further, the reduction potential of RebC is –179 mV ± 3 mV, a value close to those 
reported for para-hydroxybenzoate hydroxylase (-163 mV)33 and phenol hydroxylase (-
213 mV).34  By contrast, the reduction potential reported for other well-studied non-
hydroxylase flavoproteins can differ significantly from this value:  for instance, 
lipoamide dehydrogenase (Escherichia coli) has a value of -317 mV, yeast glutathione 
 78
reductase has a value of -327 mV,35 and the flavin of plant-type assimilatory nitrate 
reductase has a value of -270 mV.36  The structural homology and the close similarity of 
the reduction potential of RebC to flavin hydroxylase enzymes suggests that RebC is also 
a catalyst, functioning to carry out a flavin-mediated hydroxylation reaction on an 
electron-rich substrate.   
 
Flavin shift upon substrate binding   
 To identify the substrate-binding site of RebC, we soaked crystals with 
chromopyrrolic acid 4, the substrate for the two-enzyme system, and a related molecule, 
K252c 7.  These molecules, which are not substrates of RebC, were chosen for soaking 
experiments because the substrate for RebC itself has not been identified through genetic 
or biochemical analysis.9  The high-resolution structures resulting from these soaks show 
electron density in the cleft between domains I and II of RebC, positioned above the β-
sheet of domain II (Fig. II.2B).  Careful inspection of the chromopyrrolic acid-soaked 
structure compared with the native structure reveals that the isoalloxazine ring of the 
flavin of RebC undergoes a major conformational change.   This so-called ‘mobile 
flavin,’ previously described for para-hydroxybenzoate hydroxylase28 and phenol 
hydroxylase37 (Fig. II.6A), is observed to shift from an OUT position in the RebC native 
structure, where the isoalloxazine ring is more accessible to solvent and can be reduced 
by NAD(P)H, to an IN position in the chromopyrrolic acid-soaked structure, where the 
flavin can form a protected C4a-hydroperoxide intermediate adjacent to a substrate 
molecule.38  Although the adenosyl-diphosphate moiety of the FAD remains immobile 
(Fig. II.7), the isoalloxazine ring moves on the pivot of the lowest phosphate, with the 
 79
C4a carbon moving 5 Å (Fig. II.6B), leading to drastic changes in its interactions with 
surrounding residues (Fig. II.6C-D).  Thus, not only does RebC have an overall structure, 
sequence motifs, and a redox potential resembling established flavin-dependent 
hydroxylases, it also appears to have a similar catalytic mechanism, involving a ‘mobile’ 
flavin, further suggesting that RebC is a true flavin-dependent hydroxylase.   
 
Melting helix of RebC   
 One major difference between RebC and its structurally homologous flavin-
dependent hydroxylases is the size of its putative substrates.  While para-
hydroxybenzoate hydroxylase is thought to use a third conformation of the flavin (the 
OPEN conformation) to allow substrate to enter,39 any putative substrates of RebC would 
be too large to enter the active site through this conformation.  Instead, our structural 
studies have revealed an alternative route for substrate entry. 
 Density for residues 354-363, at the domain I-domain II interface, is absent in the 
native structure of RebC (Fig. II.2A).  In both the chromopyrrolic acid 4- and K252c 7-
soaked structures, density for these residues appears as an extension into domain II of a 
helix that begins in domain I, closing off the substrate-binding pocket (Fig. II.2B).  We 
speculate that residues 354-363 may be a gateway for exchange of substrate and product: 
the exposure of the substrate-binding site to solvent in the native structure suggests that a 
substrate could easily enter the substrate binding pocket when residues 354-363 are a 
mobile loop.  Upon substrate binding, the helix could form, sealing the substrate from 
solvent and preventing its departure.  This ‘melting’ helix has not been observed in any 
 80
other structural homologues of RebC and may represent a unique adaptation of this flavin 
hydroxylase for reaction with larger substrates.   
 
Identification of compound bound   
 Although an authentic sample of chromopyrrolic acid 4 was used in our RebC 
crystal soaks, this compound is not a good fit to the experimental density (Fig. II.8A-D), 
suggesting that during the week-long soak at room temperature, the integrity of the 
chromopyrrolic acid sample may have been compromised.  In particular, while the 
experimental electron density is planar, modeling studies carried out using the program 
Gaussian24 show that the energetically favorable conformation of chromopyrrolic acid 
would be non-planar, with the indole rings turned out from one another to avoid steric 
clash.  To eliminate difference electron density peaks beyond ± 3.0 σ in RebC, the indole 
rings of chromopyrrolic acid must be refined as planar, with a distance of 2.2 Å or less 
between the two indole C-2 carbons.  Such a distance would imply an energetically 
destabilizing van der Waals clash between these two close carbon atoms, if this molecule 
were indeed chromopyrrolic acid.  Analysis of the substrate binding site of RebC reveals 
no mechanism for the stabilization of chromopyrrolic acid in such a high-energy 
conformation.  Further, refining a distance of 1.43 Å (a covalent bond) between these two 
carbons atoms gives an even better fit to the observed density. 
 While HPLC analysis of chromopyrrolic acid, as stored in a -20°C freezer, 
showed the presence of only one peak, corresponding to chromopyrrolic acid, similar 
analysis of a chromopyrrolic acid solution left at room temperature for one week, as 
occurs during the crystal soaking experiment, showed the presence of multiple species 
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including a major peak corresponding to chromopyrrolic acid and minor peaks 
corresponding to arcyriaflavin A 5, 7-hydroxy-K252c 6, and K252c 7 (Fig. II.9).  These 
results were confirmed by mass spectrometry and UV/visible spectroscopy (data not 
shown).  The minor peaks indicate that, at low levels, chromopyrrolic acid spontaneously 
degrades under aerobic conditions at room temperature.  This result suggests that the 
bound molecule in the RebC active site might be an intermediate or product of 
chromopyrrolic acid degradation rather than chromopyrrolic acid itself.  A molecule other 
than chromopyrrolic acid in the active site is consistent with observed planar density, as 
well as with the long soak times required to obtain electron density.    
   Knowing that chromopyrrolic acid underwent spontaneous degradation during the 
week-long soak, we tried a series of crystallographic refinements to identify whether the 
molecule bound was a final product of degradation (5, 6, or 7) or an intermediate such as 
9-11 (Fig. II.1A).  Aryl-aryl coupled chromopyrrolic acid 9, which differs from 
chromopyrrolic acid by having an additional carbon-carbon bond and being planar, is a 
better fit to the overall density.  Refinement of this compound, however, results in 
significant negative electron difference density at the C-5 carboxylate site, suggesting a 
substituent smaller than a carboxylate at the C-5 ring carbon.  Electron difference density, 
however, shows an acceptable fit for a carboxylate at the C-7 carbon, when it is 
positioned out-of-plane to the plane of the indolocarbazole (Fig. II.8E).  We then refined 
arcyriaflavin A, which has carbonyl oxygen atoms in place of both carboxylates.  The 
resulting Fo-Fc maps show no difference density at the carbonyl of the C-5 carbon but 
show significant positive difference electron density at the carbonyl of the C-7 carbon, 
suggesting a larger substituent, like a carboxylate, is attached to the C-7 carbon (Fig. 
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II.8F).  Refinement of a molecule with a carbonyl at the C-5 carbon and an out-of-plane 
carboxylate at the C-7 carbon yields no significant electron difference density at either 
position (Fig. II.8G).  In summary, the experimental density is consistent with a 
compound containing an aryl-aryl bond between the indole C-2 carbons, with a single 
oxygen atom as a substituent at the C-5 carbon and a substituent larger than a single 
oxygen atom – such as an out-of-plane carboxylate – at the C-7 carbon.  This density is 
most consistent with two tautomers (10 and 11) of 7-carboxy-K252c.  Allowing the 
molecule to refine against the experimental electron density gives a short C-C bond (1.3 
Å) from the C-7 carbon to the carboxylate, suggesting that tautomer 10 is bound, but also 
gives out-of-plane carboxylate density, suggesting that tautomer 11 is bound.  It is likely 
that RebC is able to bind both 10 and 11 forms of 7-carboxy-K252c in its active site, and 
that our final, refined 7-carboxy-K252c molecule reflects the presence of both tautomers.  
Given the observed degradation of chromopyrrolic acid to the products arcyriaflavin A, 
7-hydroxy-K252c, and K252c, we postulate that an intermediate such as 7-carboxy-
K252c must accumulate during the week-long crystal soak with chromopyrrolic acid and 
be ‘captured’ by the RebC crystal.   
 The binding pocket of RebC is ideally suited for a molecule such as 7-carboxy-
K252c.  There are a series of hydrophobic side-chains to stabilize a poorly water soluble 
molecule, and the three charged residues in the binding pocket interact with specific polar 
groups on the molecule:  Arg230 and Arg239 are positioned to hydrogen bond with a 
negatively charged carboxylate (Fig. II.10A, II.10D) and may partially stabilize an out-of-
plane carboxylate, and Glu396 is within hydrogen bonding distance to the two indole 
nitrogens (Fig. II.10A).  Interestingly, the side-chain of Glu396 is disordered in the native 
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structure of RebC (Fig. II.10C) and becomes ordered in the chromopyrrolic acid- and 
K252c-soaked structures (Fig. II.10A-B), suggesting that its role is to stabilize the indole 
nitrogens upon substrate binding.  The arrangement of side-chains in the active site may 
preclude the binding of chromopyrrolic acid itself, due to its extended and twisted 
conformation.  This idea is consistent with the previous observation that chromopyrrolic 
acid itself is not turned over by RebC,9 and it is also consistent with our finding that 
experimental density in the chromopyrrolic acid-soaked structure is not due to 
chromopyrrolic acid itself.        
Additional support for our assignment of a carboxylate-containing chromopyrrolic 
acid degradation intermediate, such as 7-carboxy-K252c, as the unknown compound 
bound in the chromopyrrolic acid-soaked crystal, comes from the structure of K252c-
soaked RebC (Fig. II.10B, Fig. II.11).  Although K252c was found to bind in the same 
binding pocket as the molecule bound in the chromopyrrolic acid-soaked structure (Fig. 
II.10B), the flavin does not shift into the IN conformation in the K252c-soaked structure.  
Instead, the flavin assumes the OUT conformation seen in the native crystal (Fig. II.10C).  
The flavin is locked into the OUT position through an interaction between the flavin N3 
nitrogen and the carbonyl oxygen of K252c (Fig. II.10B), as well as through interactions 
with Arg239.  Hence, the presence of a substrate carboxylate, which K252c lacks, appears 
key to the shift in the position of Arg230, Arg239, and the flavin.  Structural differences 
between the two soaked structures rule out the possibility that we have captured K252c 
itself in our chromopyrrolic acid-soaked structure and further predicts that the other two 
final products of chromopyrrolic acid decomposition – 7-hydroxy-K252c and 
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arcyriaflavin A, neither of which have carboxylates – will bind to RebC in a similar 
fashion as does K252c, with no shift of the flavin. 
 
Flavin-substrate interactions   
 The distance from the C4a carbon of the FAD, the usual site for the generation of 
a hydroperoxy intermediate, to 7-carboxy-K252c, refined in the chromopyrrolic acid-
soaked structure, is 5.1 Å (Fig. II.10D).  Similarly, in phenol hydroxylase, the distance of 
the C4a of flavin to the site of hydroxylation of substrate is 5.3 Å in the IN 
conformation;27 in para-hydroxybenzoate hydroxylase, the distance of the C4a of flavin 
to the site of hydroxylation of the substrate is 4.3 Å in the IN conformation.28  The 
similar distance found between the C4a of the flavin and the C-7 of 7-carboxy-K252c 
suggests that the C-7 carbon is indeed the likely site of flavin-mediated hydroxylation by 
RebC.  Furthermore, based on the arrangement of 7-carboxy-K252c relative to the flavin, 
hydroxylation is likely to occur on the exposed face of 7-carboxy-K252c (Fig. II.10D, 
Fig. II.12).   
The favored binding of a planar molecule in the active site at an appropriate 
distance for flavin-based hydroxylation to occur suggests that the real substrate of RebC 
may be a compound such as 7-carboxy-K252c; that is, that 7-carboxy-K252c would have 
been made by StaP (or RebP) and presented to RebC, as its substrate. Studies on 
synthetically isolated 7-carboxy-K252c have shown that the compound degrades within 
30 min in DMSO, resulting in the production of both arcyriaflavin A and 7-hydroxy-
K252c.40  Although this synthetic work further suggests that 7-carboxy-K252c is on the 
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pathway to the desired final product, the spontaneous decomposition of 7-carboxy-K252c 
has precluded direct testing of its ability to serve as a substrate of RebC.40  
 
II.D.  Discussion 
 Previous observations suggested that RebC might be a flavin hydroxylase:  RebC 
contained three sequence motifs found in flavin hydroxylases, RebC bound FAD, RebC 
was able to oxidize NADH in the presence of FAD, and the StaP/RebC tandem reaction 
showed FAD- and NADH-dependent effects.9  However, what role a flavin hydroxylase 
would play in the StaP/RebC mediated catalysis of chromopyrrolic acid 4 to the 
arcyriaflavin A 5 product was unknown.9  Furthermore, low levels of product 5 formation 
in a reaction mixture excluding RebC suggested that RebC might not need to have any 
enzymatic role at all.  Finally, if RebC was an enzyme, its substrate was elusive: RebC 
did not react with chromopyrrolic acid 4, arcyriaflavin A 5, 7-hydroxy-K252c 6, K252c 
7, or arcyriarubin A 8.9   
 Our work has provided strong evidence that RebC is indeed a flavin-dependent 
hydroxylase.  It is a structural homologue of three known flavin aromatic hydroxylases, 
has a redox potential close to that of two known flavin aromatic hydroxylases, has the 
characteristic mobile flavin, and binds a putative substrate at an appropriate distance from 
the flavin C4a carbon to be hydroxylated by a flavin C4a-hydroperoxide.  Together, these 
findings make a strong case for the role of RebC in using flavin-based redox chemistry to 
hydroxylate a substrate en route to the production of arcyriaflavin A.    
 Our study further sheds light on the elusive nature of the substrate for RebC.  
Soaking RebC with chromopyrrolic acid for over one week gave experimental electron 
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density that could not be accounted for by an energetically reasonable conformation of 
chromopyrrolic acid.  Therefore, based on electron-density arguments and HPLC studies, 
we have refined 7-carboxy-K252c in the active site.  The ability of RebC crystals to 
purify this molecule from the suite of chromopyrrolic acid degradation products and 
intermediates present after a week-long soak with chromopyrrolic acid suggests that 
RebC has a unique affinity for this molecule and that 7-carboxy-K252c is likely to be a 
substrate of RebC. 
 Finally, our crystallographic study helps to explain the puzzle of why nature uses 
a two-enzyme system when one enzyme alone, RebP, appears to produce a small amount 
of the correct product.  Our results suggest that RebP does not in fact produce the product 
arcyriaflavin A, but instead converts chromopyrrolic acid to a reactive intermediate.  This 
intermediate, without RebC present, spontaneously decomposes to a mixture of 
compounds, including a small quantity of product.40  With RebC present, the highly 
reactive intermediate is sequestered in the chiefly hydrophobic environment of its active 
site, where it is acted upon enzymatically, resulting in a single, correct product.  Thus, 
both enzymes catalyze one or more reactions, and RebC is particularly well-designed to 
stably bind a highly reactive intermediate, produced by RebP, on the pathway from 
chromopyrrolic acid to arcyriaflavin A.  Using RebC as a crystallographic trap to purify 
out what may be the true substrate from the mixture of chromopyrrolic acid degradation 
products, we have provided strong evidence that RebC is a flavin hydroxylase, whose 
role is to hydroxylate a reactive intermediate, 7-carboxy-K252c, en route to production of 
the rebeccamycin precursor, arcyriaflavin A.  
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II.G. Tables and Figures 
Table II.1. Data collection statistics for native, chromopyrrolic acid-soaked, K252c-
soaked, and samarium derivative RebC crystals.   
 Native Chromo-
pyrrolic 
acid soaked 
K252c-
soaked 
 Samarium 
derivativea 
 
Data collection     
Space group P21 P21 P21 P21 
Cell dimensions       
    a  (Å) 63.22 64.89 63.10 61 
    b  (Å) 77.56 78.44 77.51 78 
    c  (Å) 64.67 123.63 64.65 63 
    β  (°)   108.04 99.61 108.85 109.5 
    Peak Inflection Remote 
Wavelength (Å) 0.9798 0.9795 0.9795 1.8455 1.8447 0.9798 
Resolution (Å)b 50-1.80 
(1.86-1.80) 
50-2.37 
(2.45-2.37) 
50-2.10 
(2.18-2.10) 
50-2.30 
(2.38-2.30) 
50-2.60 
(2.69-2.60) 
50-2.90 
(3.0-2.90) 
Rsymb,c 0.090 
(0.458) 
0.054 
(0.274) 
0.053 
(0.291) 
0.089 
(0.219) 
0.095 (0.248) 0.116 
(0.248) 
Completeness (%)b 93.9 (67.2) 90.8 (61.9) 91.9 (53.8) 91.1 (90.0) 95.0 (93.3) 84.9 (84.1) 
I / σIb 25.4 (2.6) 28.9 (3.5) 33.7 (3.2) 8.8 (3.9) 8.7 (3.2) 7.1 (3.2) 
Redundancy 7.2 6.2 6.5 2.1 2.2 2.0 
 
a For this dataset, Bijovet pairs were not merged during data processing   
b Values in parentheses indicate highest resolution bin 
c Rsym = ( ∑i∑hkl ǀ Ii(hkl) - <I(hkl)> ǀ ) / ∑hkl <I(hkl)>, where Ii(hkl) is the intensity of the ith measured 
reflection, and <I(hkl)> is the mean intensity for the reflection with the miller index (hkl) 
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Table II.2.  X-ray refinement statistics for RebC structures 
 Native Chromopyrrolic 
acid-soaked 
K252c-soaked 
Resolution (Å) 50 - 1.80 50 - 2.37 50 - 2.10 
Rwork/Rfreea 21.5 / 24.4 20.8 / 25.6 21.9 / 25.5 
Protein molecules per asu 1 2 1 
Number of atoms    
 Protein 3898 7961 3909 
 FAD 53 106 53 
           7-carboxy-K252c - 54  
 K252c - - 24 
 Chloride 1 - 1 
 Water 426 354 181 
B-factors (Å2)    
 Protein 41.0 47.2 56.2 
 FAD 36.7 39.3 48.6 
 7-carboxy-K252 - 52.0 - 
 K252c - - 82.0 
 Chloride 56.0 - 75.8 
 Water 48.9 45.6 57.9 
R.m.s.d.b    
 Bond lengths (Å)  0.006 0.007 0.007 
 Bond angles (°) 1.28 1.31 1.26 
 
a Rcryst  = ( ∑hkl ǀǀFobs(hkl) ǀ - ǀFcalc(hkl) ǀǀ ) / ∑hkl ǀFobs(hkl)ǀ ; Rfree is calculated identically, using 5% of 
reflections omitted from refinement 
b r.m.s.d. = root mean squared deviation 
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Figure II.1. Structures of small molecules and overall reaction scheme.  A.  Structures of 
compounds discussed in the text are shown schematically.  B.  StaP (or RebP), incubated 
with an electron source, reacts with chromopyrrolic acid 4 to give three products, as 
shown.  Addition of RebC leads to near-exclusive formation of arcyriaflavin A 5. 
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Fig. II.2.  RebC structural comparisons.  A.  The structure of native RebC is shown with 
domain I (red), domain II (blue), domain III (green), and a flavin in the OUT 
conformation (green carbons).  Density for residues 354 to 363 are missing in this 
structure; two arrows indicate the residues bordering the missing density.  B.  The 
structure of chromopyrrolic acid-soaked RebC, also colored by domain, shows flavin in 
the IN conformation (green carbons), with Fo-Fc omit density for the molecule captured 
in the substrate binding pocket, contoured at +3 σ.  The ‘melting’ helix, which traverses 
from domain I to II, is visible in this structure, and two arrows indicate the residues 
bordering this helix.  C.  Chromopyrrolic acid-soaked RebC (gray) is shown with aligned 
portions of para-hydroxybenzoate hydroxylase (pale blue, 1DOC, 248 of 394 residues), 
phenol hydroxylase (pale pink, 1PN0C, 281 of 664 residues), and meta-hydroxybenzoate 
hydroxylase (pale yellow, 2DKH, 264 of 639 residues).  Aligned FAD molecules, which 
have been observed in the IN conformation, are shown in black (RebC), blue (para-
hydroxybenzoate hydroxylase), and red (phenol hydroxylase). 
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Figure II.2A 
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Figure II.2B 
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Figure II.2C 
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Figure II.3. Stereo image of chromopyrrolic acid-soaked RebC with flavin in the IN 
conformation.  Domain I (red) contains a β-sandwich, composed of a four-stranded mixed 
β sheet and a five-stranded parallel β sheet and is adjacent to seven α-helices.  This 
domain binds the cofactor flavin adenine dinucleotide (FAD).  Domain II (blue) is a 
seven-stranded mixed β-sheet surrounded by five α-helices.  This domain forms the base 
of a substrate binding pocket, below domain I.  Domains I and II are connected by four 
loops and one helix that each traverse between domains I and II.  Domain III (green) is 
connected via an extended loop (residues 399 - 423) to domain II.  Domain III exhibits a 
typical thioredoxin fold.  The modeled 7-carboxy-K252c and FAD are shown as sticks, 
with green carbons.   
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Figure II.3 
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Figure II.4. Structure-based sequence alignment of RebC to structural homologues meta-
hydroxybenzoate hydroxylase (MHBH, PDB code 2DKH), phenol hydroxylase (PHHY, 
PDB code 1PN0C), and para-hydroxybenzoate hydroxylase (PHBH, PDB code 1DOD).  
Complete conservation across the four proteins is indicated with yellow highlighting, and 
partial conservation is indicated with gray highlighting.  Pink highlighted residues are 
near the 7-carboxy-K252c in the chromopyrrolic acid-soaked structure of RebC.  The 
turquoise highlighted residue (Arg239) is involved in binding FAD in the native structure 
and binding the 7-carboxy-K252c in the chromopyrrolic acid-soaked structure of RebC.  
Consensus regions for flavin hydroxylases are listed below in green (where capital letters 
indicate specific amino acids, h = hydrophobic, s = small, c = charged, and x = any amino 
acid).  Additional residues involved in FAD-binding in RebC are starred (*) below in 
green.  Above the aligned residues, the domain identification for RebC is indicated, with 
domain I in red, domain II in blue, and domain III in green.  
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Figure II.4 
  DOMAIN I--------------------------------------------- 
RebC    1  MNAPI-ETDVLILGGGPVGMALALDLAHR-QVGHLVVEQTD-GTITHPRVGTI   50 
MHBH   30   ----PSQVDVLIVGCGPAGLTLAAQLAA----RTCIVEQKEGPM----QADGI   77         
PHHY    7   ------YCDVLIVGAGPAGLMAARVLS-E-YV-VRIIDKRS-T-----QADGL   56 
PHBH    1 ----M-KTQVAIIGAGPSGLLLGQLLHKA-GIDNVILERQT-PD---IRAGVL   48 
       VhhhGsGhhGhhhs    **         * 
  
                                                               
  DOMAIN I---------------DOMAIN II---------------------  
RebC   51 GPRSMELFRRWGVA-KQIR-TAGWPGDHPLDAAWVTRVGGHEVYRIPLGTADT  101 
MHBH   78   ACRTMEMFEAFEFADS-IL----------------------------------   95 
PHHY   57   QCRTLESLKNLGLADK-ILSE--------------------------------   76 
PHBH   49 EQGMVDLLREAGVD-RRMA-R--------------------------------   67 
     
 
            --DOMAIN I------------------------------------------- 
RebC  102 RATPEHTPEPDAICPQHWLAPLLAEAVGERLRTRSR-LDSFEQR-DDH-VRAT  151 
MHBH  131   -----SE-FPHVILNQ-------------EPHYARR-VLDVKVD-----VTVT  183                 
PHHY  108   -----SR-YHQVVLHQ-GR----------KVERPLI-PEKMEI---AYPVTMT  165 
PHBH   97 ----------VTVYGQTEVTRDLMEARE-TTVYQAAEV-RLHD--GER-PYVT  140 
 
                       
            DOMAIN I-------------------------------------DOMAIN II 
RebC  152 ITDLR--TG-ATRAVHARYLVACDGASSPTRKAL-G--I-DAPPRHRTQ--VF  195 
MHBH  184 LERCDAAHAGQIETVQARYVVGCDGARSNVRRAI-G-R--QLVG---------  223                 
PHHY  166  LRYMS---G-EIETVHCKYVIGCDGGHSWVRRTL-G--F-EMIG---------  241 
PHBH  141   FER-------ERLRLDCDYIAGCDGFHGISRQSIPAERLK-VFE--RVYPFGW  185 
         chhhssDGxcSxhR 
                     
            DOMAIN II-------------------------------------------- 
RebC  196   RNILFRAPELRSLLGER-AALFFFLM-LSSSLRFPLR-ALDGRGLYRLTV-GV  244 
MHBH        -----------------------------------------------------   
PHHY  260   ----------------PDIR------------GSI------------------  276 
PHBH  186   LGLL-A--------------------------FALCS-QRSAT-RSRYYVQVP  226 
                       *     
       
            DOMAIN II--------------------------DOMAIN I --------- 
RebC  245   DDASKSTMDSFEL-VRRAV-AFDTEIEVLSDSEWHLTHRVADSFSAG-RVFLT  294 
MHBH 315   -------------------------------SVYELGQRICAKYDD—-RVFIA  347        
PHHY 336   ---------------------------------YHIGQRVTEKFSKDERVFIA  355 
PHBH  258   -------------------------GPSLEKSIAPLRSFVVEPMQHG-RLFLA  284 
          *      G xhhLh       
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            DOMAIN I--------------------------------------------- 
RebC  295   GDAAHTLSPS-GGFGMNTGIGSAADLGWKLAATLRGWAGPGLLATYEEERRPV  346 
MHBH  348   GDACHTHSPKAG-QGMNFSMQDSFNLGWKLAAVLRKQCAPELLHTYSSERQVV  399 
PHHY 356   GDACHTHSPK-AGQGMNTSMMDTYNLGWKLGLVLTGRAKRDILKTYEEERQPF  407 
PHBH  285   GDAAHIVPPT-GAKGLNLAASDVSTLYRLLLKA-YG-R-E-LLERYSAICLRR  335 
       GDAAHxxxP 
 
 
            ---------DOMAIN II ---------------------------------- 
RebC  347   AITSL-EEANVNLRRT-MDRELPPGLHDDGPRGERIRAAVAEKLERSGARREF  396    
MHBH 400   AQQLIDF----------------------------------------------  406 
PHHY 408   AQALI-DFDHQFSRLFSG-----------------------------------  424   
PHBH  336   IWKAE-RFSWWMTSVL-H-----------------------------------  350  
 
 
            --DOMAIN III----------------------------------------- 
RebC  397   DAPGIHFGHTYR-SSI-VCGEPETEVATG----GWRPSARPGARAPHAWL-TP  443 
MHBH 444   -----GVGTHYAPSLL-TGQAK---------------GFTVGMRFHSAPV---  478 
PHHY 454   -----GTAINYD-ENLVTDK------------------CVVGTRFKSQ-----  487 
 
 
            DOMAIN III------------------------------------------- 
RebC  444   TTSTLD-LFGR-GFVLLSFG-TT-DGVEAVTRAF-ADRH-VPLETVTCH-APE 490 
MHBH  487   -VQLGH-CG-G-RWRLYAFA-GLLALC-------------------------- 521 
PHHY  499   --HFGDRL-TDGRFRIIVFA-------------------- RIDVITIH---- 562                  
 
 
            DOMAIN III--------------------------------- 
RebC  491   IHALYERAHVLVRPDGHVAWRGDH-LP-AELGGLV-DKVRGAA           529    
MHBH 607   -------ALVVVRPDQYVAQVLPLGD----S-AYF-ES-F              636 
PHHY  601   -------AVVVVRPDGYTSLVT-D------D-RYFSG                 642                  
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Figure II.5.  Reactions catalyzed by structural homologues of RebC.   
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Figure II.6.  Mobile flavins.  A.  Phenol hydroxylase (PDB code 1PN0)27 has a mobile 
flavin, as seen from the superimposed structures of the FAD, which is found in both the 
OUT (light blue carbons) and IN (green carbons) conformations.  The substrate phenol is 
also shown.  B.  Two positions of FAD in RebC, manually superimposed from structures 
of substrate-free (light blue carbons, OUT) and chromopyrrolic acid-soaked structures 
(green carbons, IN), are shown.  7-carboxy-K252c, which was refined into the 
chromopyrrolic acid-soaked structure, is shown with green carbons.  C.  Cut-away view 
of FAD (light blue carbons) with a 2Fo-Fc omit map at 1σ shows that the flavin in the 
substrate-free structure is OUT, with a hydrogen bond between the isoalloxazine ring and 
Arg239.  The isoalloxazine ring is stacked between Arg46 and Trp276. Because FAD is 
thought to be reduced by NAD(P)H in the OUT conformation via a reaction at the re face 
of the isoalloxazine ring,39 Trp276 would have to move aside for reduction to occur, just as 
proposed for the structurally homologous residue, Tyr317 in meta-hydroxybenzoate 
hydroxylase, which also stacks on the re face of its isoalloxazine ring.29  D.  Cut-away 
view of FAD (green carbons) in the chrompyrrolic acid-soaked structure shows that the 
isoalloxazine ring in the IN conformation no longer stacks between Trp276 and Arg46, and 
the interaction with Arg239 is lost.  Arg46 now interacts with FAD phosphate oxygens, and 
Arg239 interacts with bound 7-carboxy-K252c (green carbons). The 2Fo-Fc omit map is 
contoured at 1 σ.  
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Figure II.7. Binding of the adenosine diphosphate portion of FAD.  The adenosine 
diphosphate portion of FAD (blue carbons) from the substrate-free structure of RebC is 
shown in a composite omit map at 1.0 σ.  The adenosine of FAD is bound by domain I 
(red).  Three previously characterized sequence motifs are visible.  The GxGxxG motif41 
(orange carbons) cradles one side of the adenosine diphosphate.  The GD motif42 (yellow 
carbons) includes Asp296, which hydrogen bonds with the second hydroxyl of the ribityl 
chain.  The DG motif43 (purple carbons) is also positioned near the adenosine.  The DG 
motif is thought to be involved in NADPH binding in para-hydroxybenzoate 
hydroxylase;43 whether it plays the same role in RebC is unknown, as RebC lacks a 
partially conserved charged residue two amino acids after the DG motif.  Additionally, 
two residues that are not part of conserved sequence motifs are also involved in binding 
the adenosyl-diphosphate portion of the flavin, and these are partially conserved between 
RebC and the three structurally conserved flavin aromatic hydroxylases: Glu36 (gray 
carbons) has hydrogen bonds with the hydroxyls of the ribose, and Gln37 (gray carbons) 
interacts with one face of the adenine ring.  All depicted interactions are also preserved in 
both the chromopyrrolic acid-soaked and K252c-soaked structures.   
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Figure II.8. Bound molecules in chromopyrrolic acid-soaked structure.  A.  Fo-Fc omit 
density of the chromopyrrolic acid-soaked crystal, contoured at 3.0 σ, shows the planarity 
of the density.  B.  As in (a), tilted 90° towards the viewer.  C.  Fully protonated 
chromopyrrolic acid was minimized in the program Gaussian, using a gas-phase 
minimization by DFT with the B3LYP functional and 6-31G+(d,p) basis set.24  The 
preferred conformation of chromopyrrolic acid has the two indole rings twisted out from 
planarity, to relieve an energetically unfavorable van der Waals clash.  The resulting 
structure is shown without hydrogens.  Positioning this molecule (without refinement) 
into omit density demonstrates its poor fit.  D.  As in C, tilted 90° toward the viewer.  E.  
Refinement of compound 9 is shown with an Fo-Fc map contoured in red at -3.5 σ and in 
green at +3.5 σ.  A large negative density peak is seen at the C-5 carboxylate.  A small 
negative density peak is seen at the pyrrole nitrogen.  F.  Refinement of arcyriaflavin A is 
shown with an Fo-Fc map contoured in red at -3.5 σ and in green at +3.5 σ.  Positive 
density peaks are seen on either side of the C-7 carbonyl, near where out-of-plane 
carboxylate oxygens would be situated.  A small negative density peak is seen at the 
pyrrole nitrogen.  G.  Refinement of 7-carboxy-K252c is shown with an Fo-Fc map 
contoured in red at -3.5 σ and in green at +3.5 σ.  A small negative density peak is seen 
at the pyrrole nitrogen, which likely indicates some noise in the data.   
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Figure II.9.  HPLC analysis of chromopyrrolic acid.  HPLC traces (280 nm) of authentic 
samples of arcyriaflavin A 5, K252c 7, and 7-hydroxy-K252c 6, as well as samples of 
chromopyrrolic acid 4 (CPA) stored at -20°C or left at room temperature for one week.  
In the sample of chromopyrrolic acid left at room temperature for one week, multiple low 
intensity peaks appear, three of which co-elute with the authentic samples arcyriaflavin 
A, K252c, and 7-hydroxy-K252c.   
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Figure II.9 
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Figure II.10.  Substrate binding site.  A.  7-carboxy-K252c, which was refined in the 
chromopyrrolic acid-soaked structure, is bound at the interface of domain I (red) and II 
(blue), surrounded by a number of hydrophobic side chains, including Phe227, which 
shifts conformation.  Leu358 is found on the helix that is disordered in the substrate-free 
structure.  A loop (red, residues 303-306) from domain I interacts with one face of 7-
carboxy-K252c.  Hydrogen bonding interactions with 7-carboxy-K252c include Glu396, 
Arg230, and Arg239.  An Fo-Fc omit map is contoured at 3.0 σ.  B.  Binding site of the 
K252c-soaked structure shows the isoalloxazine ring of flavin (green) locked in an OUT 
conformation.  Trp276 stacks on the re face of the isoalloxazine ring, Phe227 is not shifted, 
and Arg230 is too far to interact with K252c.  Charged residue Glu396 hydrogen bonds with 
the indole nitrogens, and Arg239 hydrogen bonds with the FAD, and it does not interact 
with the substrate.  K252c is contoured with an Fo-Fc omit map at 3.0 σ.  C.  The 
substrate-free structure of RebC shows the exposure of the substrate-binding pocket to 
solvent with the absence of the ‘melting’ helix.  Additionally, Glu396 is disordered, Phe227 
is not shifted, and Phe216 assumes two alternate conformations.  FAD (green), as in the 
K252c-soaked structure, is positioned in the OUT conformation.  D.  Cut-away view of 
7-carboxy-K252c and FAD binding site in shows that one ring carbon of 7-carboxy-
K252c is 5.1 Å from the C4a carbon of FAD.  One oxygen of the carboxylate of 7-
carboxy-K252c additionally has hydrogen bonds to both Arg230 and Arg239.   
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Figure II.11. Omit map density for chromopyrrolic acid- and K252c-soaked structures.   
A.  Fo-Fc omit density contoured at +3.0 σ around the 7-carboxy-K252c, which is 
modeled into the chromopyrrolic acid-soaked structure.  B.  Fo-Fc omit density from 
K252c-soaked crystal, contoured at +3.0 σ.  K252c is shown, as modeled into the final 
structure.  Note that while density is poor compared to density from the chromopyrrolic 
acid-soaked crystal, it is clear the carbonyl should be positioned as shown.  Refinement 
of K252c results in high B-factors for this molecule (Table II.2).   
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Figure II.12. Water molecule modeled near C4a carbon of FAD.  During the refinement 
process, a water molecule was refined in the active site to account for density observed 
between the flavin-C4a carbon and one carboxylate oxygen of 7-carboxy-K252c.  Given 
its position relative to the flavin-C4a carbon and the likely site of hydroxylation on the 
substrate, we suggest that this water molecule represents the likely binding site for 
dioxygen during the catalytic cycle of RebC.  NAD(P)H, which would be required to 
reduce the flavin before it could react with dioxygen to form the reactive peroxy-flavin, is 
absent from all our crystallographic conditions, so actual turnover cannot occur.  Hence, 
under these non-catalytic conditions, it seems that the oxygen-binding site may be 
reserved by a water molecule.  The FAD, 7-carboxy-K252c, and water molecule are each 
contoured with a 2Fo-Fc composite omit map at 1.0 σ. 
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Chapter III: 
The FAD cofactor of RebC shifts to an IN conformation upon flavin reduction 
 
III.A.  Summary 
 RebC is a putative flavin hydroxylase functioning together with RebP to carry out 
a key step in the biosynthesis of rebeccamycin.  To probe the mechanism of flavin-based 
chemistry in RebC, we solved the structure of RebC with bound FADH2.  Dramatically, 
upon flavin reduction, the RebC crystal undergoes a change in its unit cell dimension 
concurrent with a 5 Å movement of the isoalloxazine ring, positioning the flavin ring 
adjacent to the substrate binding pocket.  Additionally, a disordered helix becomes 
ordered upon flavin reduction, closing off one side of the substrate binding pocket.  This 
FADH2-RebC structure, along with previously reported structures, increases our 
understanding of the RebC enzyme mechanism, indicating that either the reduction of the 
flavin itself or binding of substrate is sufficient to drive major conformational changes in 
RebC to generate a closed active site. Along with kinetic data presented here, these 
structures suggest that the first cycle of catalysis in RebC may resemble that of para-
hydroxybenzoate hydroxylase, with substrate binding promoting flavin reduction.   
 
Note:  RebC protein was prepared by Dr. Annaleise R. Howard-Jones in the laboratory of Prof. Christopher 
T. Walsh at Harvard Medical School.  Rate constants were determined with the guidance of Prof. David P. 
Ballou and with technical assistance from Sumita Chakraborty at the University of Michigan.   
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III.B.  Introduction  
 Rebeccamycin, a human DNA-topoisomerase I inhibitor, is a natural product 
generated in the bacterium Lechevalieria aerocolonigenes by the action of eight 
enzymes:  RebF, RebH, RebO, RebD, RebP, RebC, RebG, and RebM.1-3  While some 
Reb enzymes function alone to catalyze discrete steps in the biosynthetic pathway, others 
function in pairs.  Although a complex has not yet been detected experimentally between 
the two proteins, RebC is required together with RebP, a cytochrome P450 enzyme, to 
generate the rebeccamycin aglycone from chlorinated chromopyrrolic acid3 (a net 8-
electron oxidation).   Because two proteins are required for this conversion, it was 
unclear from initial studies if RebC played a catalytic role in this process or simply 
served to modify the activity of RebP.  The puzzle arose from the observation that small 
amounts of product are produced in the absence of RebC when a close RebP homologue 
(StaP) is used,4 suggesting that StaP and its homologues are capable of performing all the 
necessary chemistry for aglycone formation.  In contrast, the addition of RebC to a 
reaction mixture eliminates the production of side products and promotes the production 
of the desired product (Fig. III.1),4 suggesting a role as an modifying factor.  However, 
recent work suggests that StaP does not produce product directly but rather produces a 
reactive intermediate that spontaneously forms some product over time.5  When RebC is 
present, this reactive intermediate is sequestered in the RebC active site, preventing its 
decomposition, and is then converted enzymatically to the rebeccamycin aglycone.5,6  
Specifically, RebC is thought to be a flavin-dependent hydroxylase that reacts with 
putative substrates, aryl-aryl coupled chromopyrrolic acid 2 and/or 7-carboxy-K252c 3, 
produced by the RebP homologue StaP.5-7  Given the reactivity of both molecules, 
however, the ability of either to act as a RebC substrate is difficult to test directly.5     
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 Due to the instability of the putative substrate molecule(s), we have chosen a 
largely crystallographic approach to study RebC, publishing three crystal structures prior 
to this work.6  These RebC structures include a substrate-free form, a structure with a 
tautomer of 7-carboxy-K252c 3 bound in the active site, and a structure with K252c 4 
bound in the active site (Table III.1).  These structures show that RebC is highly 
homologous to members of the flavin-dependent hydroxylase family8-11 such as the well-
studied para-hydroxybenzoate hydroxylase (pHBH).12  A comparison of substrate-free 
and bound structures of RebC shows that the binding of molecules into the active site 
elicits a change in residues 354-363.  These residues, which are adjacent to the substrate 
binding pocket, are disordered in the substrate-free structure, and become ordered as part 
of a helix in the two structures with bound indolocarbazoles (Table III.1).  This helix, 
including residues 354-363, is termed the ‘melting helix,’ reflecting its ability to change 
states (ordered or disordered) depending on the conditions.  The melting of this helix is 
thought provide the route by which substrates enter and products depart the active site.6  
The presence of a ‘melting helix’ contrasts with its structural homologue, para-
hydroxybenzoate hydroxylase, which uses a third conformation of the flavin, an OPEN 
conformation, to enable entry to the active site.13      
 Structural comparisons also show that the FAD can adopt two conformations in 
RebC: an OUT conformation in which the isoalloxazine of FAD is more solvent 
accessible, and an IN conformation where the isoalloxazine is more secluded from 
solvent and positioned to interact with bound substrate-like molecules.  pHBH also 
utilizes a 'mobile flavin' in its reaction mechanism.8  Interestingly, not all substrate-like 
molecules elicit a change in FAD conformation from OUT to IN in RebC.  The 
isoalloxazine of FAD is IN in the structure with 7-carboxy-K252c 3 bound, but is OUT 
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when K252c 4 is bound. This difference in observed FAD conformation may reflect the 
fact that 7-carboxy-K252c 3 is, or more closely resembles, the true substrate of RebC.  
While K252c 4 is known not to be a substrate,4 7-carboxy-K252c 3 is too reactive to be 
tested conveniently as a possible substrate.5  We were only able to obtain the structure of 
7-carboxy-K252c 3 bound RebC by soaking crystals in a mixture of chromopyrrolic acid 
1 degradation products for a week.  Over this time period, 7-carboxy-K252c 3 selectively 
accumulates in the active site of crystallized RebC, allowing for its structural 
characterization.  This selectivity of RebC for 7-carboxy-K252c 3 over a mixture of 
chromopyrrolic acid degradation products is consistent with the idea that 7-carboxy-
K252c 3 may closely resemble or be the RebC substrate.   
 Like the FAD in RebC, the isoalloxazine in pHBH shifts to an IN conformation 
when substrate is bound.  Substrate binding to pHBH also dramatically affects the rate of 
reduction of the FAD by NADPH.  When NADPH binds to a pHBH–pOHB complex, 
spectral shifts indicate that the FAD moves from IN to OUT, positioned for the N5 of the 
isoalloxazine to accept a hydride from NADPH.  Upon FAD reduction, crystallographic 
data tell us that the FADH2 of pHBH moves back to an IN conformation where it can 
react with molecular oxygen and substrate.  To examine the structural effect of FAD 
reduction in RebC, we have determined the structure of the FADH2-RebC complex.  We 
find FADH2 in an IN conformation, with the ‘melting helix’ ordered.  This structure is 
very similar to the structure of RebC with a bound tautomer of putative substrate 7-
carboxy-K252c 3, suggesting that either reduction of the flavin to FADH2 or appropriate 
positioning of a carboxylate-containing substrate such as the tautomer of 7-carboxy-
K252c 3 is sufficient to trigger the movement of the isoalloxazine to the IN position and 
to cause the ‘melting helix’ to form, sealing off the substrate binding pocket.   We have 
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also examined the rate of reduction of FAD in RebC by NADH in the absence of 
substrate and find that like pHBH in the absence of substrate the rate is slow.  These new 
findings, along with the previous structural work on RebC, allow for a detailed 
comparison of putative flavin hydroxylase RebC with pHBH, one of the better studied 
family members.  
 
III.C.  Materials and Methods 
Sample preparation   
 RebC protein was prepared and crystallized as described earlier.4,6  Reduced 
RebC was generated by incubating a RebC crystal in a cryogenic solution (19% PEG-
8000, 0.1 M HEPES pH 7.4, 20% glycerol) and adding an amount of solid sodium 
dithionite that is in slight excess of the point at which the crystal became completely 
clear, indicating that all FAD was reduced to FADH2.  The crystal was then flash-frozen 
in liquid nitrogen.   
 
Data collection and processing and structure determination   
 Data were collected at beamline 9-2 at the Stanford Synchrotron Radiation 
Laboratory, integrated in HKL2000, and scaled in Scalepack14 without sigma cutoff.  The 
unit cell volume of FADH2-RebC is 602,000 Å3, almost twice the volume of substrate-
free RebC (Table III.1).  Data collection statistics are shown in Table III.2.  The structure 
of FADH2-RebC was solved in CNS,15 using rigid-body refinement and the coordinates 
from PDB ID 2R0G, with reflections flagged as ‘free’ identically to the structure factor 
file used in refinement of PDB ID 2R0G.  Only coordinates for protein atoms were used 
in rigid-body refinement, with coordinates for water molecules and FADH2 molecules 
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added later in refinement.  Following rigid-body refinement, multiple rounds of 
refinement were carried out in CNS with alternate rounds of manual adjustment carried 
out in COOT.16  The topology and parameter files for FADH2 were generated from the 
PrnA structure (PDB ID 2ARD)17 using XPLO2D.18  A composite omit map was used to 
verify the overall structure, with omit maps also generated for the flavin cofactor and the 
‘melting helix.’  There are two protein chains in the asymmetric unit, each containing 529 
residues from RebC with 20 amino acids in an N-terminal tag.  RebC residues 3-529 from 
chain A and 2-529 from chain B are included in the final model, with residues 246-250 
disordered in chain A and residues 246-251 and 418-425 disordered in chain B.  There is 
also one molecule of FADH2 in each active site.   
 The ratio of Rfree to Rcryst is higher than desired (1.35), but the ratio of these values 
is often large with lower-resolution structures.19  Additionally, more residues are outside 
of the ‘most favored’ region of a Ramachandran plot than has been observed for other 
RebC structures;6 this is likely another reflection of the lower resolution of this data 
relative to other RebC structures (Table III.1).  Refinement statistics for FADH2-RebC 
are shown in Table III.2.      
  
Analysis of surface accessibility of substrate binding pocket   
 CAVER20 was used to determine if any pathways connected the substrate binding 
pocket of RebC to external solvent, with subsequent examination of results in PYMOL 
(http://pymol.sourceforge.net).  Based on the representation of this pathway as spheres 
with varying radii, the widest pathway identified that leads to solvent in the FADH2-
RebC is too narrow for a putative RebC substrate to traverse.   
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Determination of rate constant for reduction of FAD in absence of substrate under single 
turnover conditions   
 RebC was diluted in 150 mM NaCl, 10% glycerol, 25 mM HEPES pH 7.5 in a 
glass tonometer and made anaerobic by ~15 alternate cycles of incubation with argon gas 
and purging by vacuum.  3,4-Dihydroxybenzoate and protocatechuate 3,4-dioxygenase 
were included to scavenge any residual oxygen.21  A stock solution of 13 mM NADH 
was prepared in unneutralized Tris base, and dilutions were made into the RebC buffer 
(150 mM NaCl, 10% glycerol, 25 mM HEPES pH 7.5).  All NADH solutions were 
bubbled with argon for >15 min prior to use.  A Hi-Tech DX-2 stopped-flow 
spectrophotometer (Bradford on Avon, United Kingdom) was incubated with an 
anaerobic solution of 3,4-dihydroxybenzoate and protocatechuate 3,4-dioxygenase 
overnight prior to use.  The tonometer containing the enzyme was connected to one 
syringe and the buffer or NADH solution was connected to the second syringe of the 
stopped-flow spectrophotometer. Detection was with a photomultiplier, and spectra were 
recorded at approximately 5 min intervals.  Data were analyzed using KinetAsyst 3.16. 
 
III.D.  Results 
Unit cell dimensions change  
 RebC crystals grown from recombinantly expressed and purified protein have unit 
cell dimensions of a = 63.2 Å, b = 77.6 Å, c = 64.7 Å, and β = 108.0° (space group P21) 
with one monomer per asymmetric unit (PDB ID 2R0C).6  Dramatically, however, upon 
incubation of these crystals with dithionite, the crystals assume alternate unit cell 
dimensions of a = 63.3 Å, b = 78.2 Å, c = 123.1 Å, β = 98.7° (space group P21) with two 
monomers per asymmetric unit.  The unit cell dimensions of the sodium dithionite-
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reduced crystals are similar to the unit cell dimensions observed from RebC with a bound 
tautomer of 7-carboxy-K252c 3 (PDB ID 2R0G), which also changes cell dimensions 
relative to the substrate-free structure, and has unit cell dimensions of a = 64.9 Å, b = 
78.4 Å, c = 123.6 Å, and β = 99.6° (space group P21).6  Unlike the RebC crystals with a 
bound tautomer of 7-carboxy-K252c 3, however, which diffracted to 2.4 Å resolution,6 
sodium dithionite soaked RebC crystals generally gave poorer quality data, with the best 
data obtained reported here (3.2 Å resolution).  The dramatic change in unit cell 
dimensions must occur over a short period of time (less than a few min) in the case of 
sodium dithionite soaking of RebC, whereas the accumulation of the tautomer of 7-
carboxy-K252c 3 in the active site of RebC takes much longer (an entire week).6  It is 
possible that the rapid change in unit cell dimensions caused by soaking in the presence 
of sodium dithionite resulted in the lower quality data achieved for the FADH2-RebC 
structure compared to the structure of RebC with a bound tautomer of 7-carboxy-K252c 3 
(Table III.1).   
  
The FAD cofactor moves IN upon reduction   
 The similarities of the FADH2-RebC structure to that of FAD-RebC with a bound 
tautomer of 7-carboxy-K252c 3 extend to the positioning of the isoalloxazine in the 
active site.  In the structure of FAD-RebC with a bound tautomer of 7-carboxy-K252c 3, 
the FAD is observed in the IN conformation, adjacent to the bound molecule in the 
substrate binding pocket.  Likewise, the FADH2 in the FADH2-RebC structure is also 
observed in the IN conformation.  The positioning of the cofactor in the FADH2-RebC 
structure and in the structure of FAD-RebC in complex with a tautomer of 7-carboxy-
K252c 3 is different from the substrate-free and K252c 4-soaked structures, where the 
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FAD is observed in the OUT conformation (Table III.1).  Hence, after reduction by 
dithionite, the reduced isoalloxazine of the FADH2 cofactor moves approximately 5 Å on 
a pivot of the lowest phosphate from the OUT to the IN position (Fig. III.2A).     
  
The overall structure is highly similar to the structure of RebC with a bound tautomer of 
7-carboxy-K252c 
 The root mean squared deviation (RMSD) distance between the FADH2-RebC 
and structure of RebC with a bound tautomer of 7-carboxy-K252c 3 is 0.66 Å for 514 
Cα-carbon atoms.  By comparison, the RMSD variations in distances between the 
FADH2-RebC and FAD-RebC with bound K252c 4 structure is 0.82 Å for 504 Cα-carbon 
atoms, and RMSD between the FADH2-RebC and the FAD-RebC substrate-free structure 
is 1.02 Å for 494 Cα-carbon atoms.  The active sites themselves of the FADH2-RebC 
structure and structure of FAD-RebC with a bound tautomer of 7-carboxy-K252c 3 also 
are nearly superimposable, with one key exception: no substrate molecule is bound in the 
FADH2-RebC structure (Fig. III.2C and D).  Interestingly, even the ‘melting helix,’ a 
helix that is disordered in the substrate-free structure, which becomes ordered in the 
structures of RebC with bound K252c 4 and with the bound tautomer of 7-carboxy-
K252c 3 (Fig. III.2F), also becomes ordered in FADH2-RebC, despite the lack of a 
substrate-like molecule in the substrate-binding pocket (Fig. III.2B and E, Fig. III.3). 
  
The substrate binding pocket is inaccessible to substrate upon flavin reduction 
 To determine if an indolocarbazole-like substrate could enter the binding pocket 
of the FADH2-RebC structure, the program CAVER was used20 to identify the favored 
path by which a probe beginning in the active site would escape to the solvent.  The four 
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available structures of RebC (2R0C, 2R0G, 2R0P, and the FADH2-RebC structure 
presented here) were analyzed, with bound molecules in the active site removed for 
2R0G and 2R0P.  The substrate-free RebC structure (2R0C) showed the most solvent 
accessible pathway, with a probe placed in the active site moving immediately to the 
solvent, via the disordered, ‘melted helix,’ between residues 354-363 (Fig. III.4A and B).  
By contrast, for the other three structures, each of which contain a formed helix between 
residues 354-363 (Fig. III.4C and D), the pathway from the substrate binding site to 
external solvent is via another side of the active site (Fig. III.5A).  However, based on 
examination of the results in PYMOL, this pathway is unlikely to be wide enough near 
the active site for an indolocarbazole-like molecule to traverse to the surface of the 
enzyme (Fig. III.5B).  This pathway is also the widest route to the substrate binding site 
from the surface of the protein in the FADH2-RebC structure.  We suggest that an 
indolocarbazole-sized molecule would require an opening with a radius of at least 4.5 Å; 
however, the pathway out of the FADH2-RebC structure from where a substrate would be 
positioned does not become 4.5 Å wide until just before the surface of the enzyme.     
  
Reduction of RebC is slow in the absence of substrate 
 Previous studies have shown that NADH is the preferred reductant for RebC in 
the two-enzyme conversion of chromopyrrolic acid 1 to arcyriaflavin A 6.4  To 
investigate the rate constant of reduction of the FAD in RebC by NADH, we used a 
stopped-flow spectrophotometer, and analyzed the reduction of FAD to FADH2 (by 
monitoring A450).  Reduction was extremely slow, and, in retrospect, the use of a 
stopped-flow spectrophotometer to determine the rate constant was unnecessary.  
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However, using an extremely high concentration of NADH (1 mM), the rate constant for 
reduction was determined as 0.0023 sec-1 (Table III.3), an extremely slow rate.   
 
III.E.  Discussion 
 Our structure of FADH2-RebC provides insight into the catalytic cycle of RebC.  
The structure of FADH2-RebC contains flavin in an IN conformation and contains an 
ordered helix adjacent to the substrate binding pocket.  Substrate-free RebC, by contrast, 
which was used to generate the FADH2-RebC by dithionite soaking, has flavin in an 
OUT conformation and a disordered, ‘melting helix.’  Thus, reduction of the cofactor 
causes the isoalloxazine to move IN and the ‘melting helix’ to become ordered.  Together 
with another structure of RebC, that of RebC with a bound tautomer of 7-carboxy-K252c 
3, where flavin is IN and the ‘melting helix’ is ordered, we now have several 
crystallographic ‘snapshots’ of this interesting enzyme (Table III.1). 
 However, RebC remains a mysterious enzyme, largely because its putative 
substrates are too reactive for convenient enzymatic study.  Hypothetical reaction 
schemes of RebC with putative substrates 7-carboxy-K252c 3 or aryl-aryl coupled 
chromopyrrolic acid 2 suggest that RebC may have to carry out multiple rounds of 
oxidative chemistry to generate the rebeccamycin aglycone, but few wild-type flavin 
hydroxylases are capable of doing multiple rounds of flavin-based catalytic chemistry on 
a single substrate molecule.  One interesting enzyme to compare with RebC might be 
salicylate hydroxylase, which catalyzes both hydroxylation and decarboxylation reactions 
of its substrate,7,22 however, many mechanistic details are lacking for this enzyme.  In any 
case, the possibility that RebC, like other flavin hydroxylases, carries out only one round 
of catalysis on its substrate is still a reasonable hypothesis if the remainder of the 
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chemistry is spontaneous in aerobic conditions and results in only the desired final 
product.  Because of the many unknowns in the catalytic cycle of RebC, it makes sense to 
think about a single round of catalysis in comparison to the best-studied flavin 
hydroxylase enzyme, para-hydroxybenzoate hydroxylase.   
 Para-hydroxybenzoate hydroxylase, the canonical flavin-dependent hydroxylase, 
is thought to carry out a flavin-based hydroxylation of its substrate through at least 7 
states (Fig. III.6). The details of these states have been elucidated using a combination of 
stopped-flow spectroscopy and X-ray crystallography (Table III.4).  In brief, pHBH, 
initially existing with oxidized flavin in a dynamic equilibrium between the OPEN and 
IN positions (state 1), captures a molecule of para-hydroxybenzoate (pOHB) while in the 
OPEN conformation, an additional conformation of the flavin that enables entry of 
substrate and departure of product in pHBH.23  Substrate binding then shifts the 
equilibrium of the isoalloxazine towards the IN conformation (state 2), a state that is 
represented by one of the original structures of pHBH, where pOHB was bound to 
pHBH.24  When NADPH binds the enzyme containing bound pOHB, the flavin is 
triggered to move to the OUT conformation (state 3) where the N5 of the isoalloxazine is 
positioned optimally to receive a hydride from NADPH; this transition only occurs when 
substrate is bound.  Upon reduction of the FAD by NADPH (state 4), NADP+ is released. 
The resultant FADH– anion shifts to the IN position due to the positive electrostatic field 
near the IN position (state 5); the structure of pHBH with FADH2 and bound substrate 
(obtained using anoxygenic solutions) represents this state.25  Next, flavin reacts with 
oxygen and hydroxylates the bound pOHB, while in the IN conformation (state 6 and 7).  
Finally, the resulting product, 2,3-dihydroxybenzoate, is released via the OPEN 
conformation, and loss of H2O returns the cofactor to its FAD form and pHBH to the 
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initial state (state 1), which is a dynamic equilibrium between the OPEN and IN 
positions.12  Table III.4 describes the experimental support for each step of this scheme, 
including those states which have been observed crystallographically.   
 Our crystallographic observations have collectively captured three states of RebC. 
Using the known reaction mechanism for pHBH, we can begin to piece together a likely 
reaction cycle for one round of flavin-based hydroxylation in RebC (Table III.5).  The 
first state we have captured is state 1, prior to substrate binding.  In this stage, the flavin 
is OUT and the ‘melting helix’ is disordered.  In contrast to pHBH, where a third 
conformation of the flavin, the OPEN conformation, is thought to enable entry of 
substrate and departure of product, in RebC, we believe the ‘melting helix’ is instead the 
route for substrate entry and product departure.  Unlike para-hydroxybenzoate, the 
putative RebC substrate is too large to enter the active site through a flavin OPEN 
conformation.  Additionally, in contrast to the flavin in pHBH, the RebC flavin is OUT 
prior to substrate binding.  The second state we have captured is a state 2 conformation, 
where substrate is bound.  In this state, the flavin is IN (as is true in pHBH) and the 
‘melting helix’ is ordered.  The third state we have captured is likely off-pathway, having 
bound FADH2 but no bound substrate, but this structure is suggestive of a state 5-like 
conformation, where flavin is reduced and substrate is bound.  Although there is no 
substrate bound in this structure, the ‘melting helix’ is ordered, and substrate would be 
unable to enter.  Therefore, although no actual substrate molecule is present in this 
structure, RebC appears to assume a conformation as though a substrate molecule were 
bound, i.e., this FADH2-RebC structure seems to represent a stage in the catalytic cycle 
where substrate is bound adjacent to reduced flavin.  Overall, our structural investigation 
of RebC has revealed two major similarities with the para-hydroxybenzoate hydroxylase 
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catalytic cycle:  there is a mobile flavin, and the flavin moves IN upon reduction.  There 
are also two key differences from the para-hydroxybenzoate hydroxylase catalytic cycle, 
based on our crystallographic observations:    1) the ‘melting helix’ appears to be the 
route for substrate entry and departure, rather than an OPEN conformation of the flavin, 
likely because of the larger size of RebC’s substrate(s), and 2) prior to substrate binding, 
the FAD in RebC exists in an OUT conformation, in contrast to the OPEN structure for 
pHBH.24 
 The most intriguing aspect of our reduced flavin structure is the sealing of the 
‘melting helix’ without the presence of a bound substrate-like molecule.  While the 
ordering of the helix in the presence of bound hydrophobic molecules can be explained 
by hydrophobic interactions between the bound-molecules and protein residues, such as 
leucine-358 (Fig. III.2F), there is no apparent structural rationale for ordering of the helix 
upon change in the redox state of the cofactor and its movement to the IN conformation 
(Fig. III.2E).  While the molecular explanation for this conformation change remains 
elusive, the fact that the helix is formed after flavin reduction is certainly suggestive of a 
key detail in the RebC catalytic cycle: substrate apparently cannot enter (or exit) once the 
helix is formed.  The ordering of the helix suggests that substrate binding will normally 
occur before flavin reduction.  Substrate binding occurring prior to flavin reduction is 
also consistent with the para-hydroxybenzoate hydroxylase catalytic cycle, where 
substrate binding causes a 100,000-fold increase in the rate of NADPH oxidation.12  
Although the instability of the proposed RebC substrates has so far prevented us from 
obtaining the analogous data for RebC, we can compare the rate of FAD reduction 
without substrate to the rate of overall turnover for the coupled enzyme (StaP/RebC) 
system in the presence of substrate. The kcat of the coupled enzyme system using 
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chromopyrrolic acid 1 is 0.068 ± 0.01 sec-1.4  This experiment was carried out using a 
mixture including StaP (1 μM), RebC (5 μM), NADH (5 mM), spinach ferredoxin (20 
μM), flavodoxin NADP+-reductase (1 μM), and FAD (1.7 μM). This turnover rate, which 
includes reduction and hydroxylation steps, is substantially greater than the rate for FAD 
reduction of RebC by 1 mM NADH in the absence of substrate (0.0023 sec-1) (Table 
III.3). This comparison suggests that substrate binding to RebC must accelerate the rate 
of flavin reduction by its preferred reductant, NADH, by an order of magnitude.  
Together with the structural data, this kinetic result suggests that reduction of FAD in the 
absence of substrate resulting in the ordering of the ‘melting helix’ is unlikely to be 
physiological relevant, and points to a mechanism in which substrate binding to RebC 
occurs first, ordering the ‘melting helix,’ and promoting flavin reduction by NADH.  
 If the mechanism of RebC includes two hydroxylation steps, one could imagine 
that the first hydroxylated intermediate that is formed is held in place in the active site by 
an ordered ‘melting helix,’ while the newly re-oxidized FAD could swing OUT for re-
reduction by a second molecule of NADH.  Only after the completion of the full reaction 
would product be released.  Regardless of the number of hydroxylation events, the 
observation that one product is formed when RebC is added to a StaP reaction mixture 
indicates that accessibility of the active site of RebC must be tightly controlled, and our 
structural studies suggest that the ‘melting helix’ is critical to that control.  While our 
structural and kinetic studies show many similarities between RebC and pHBH, we do 
find that RebC adaptations, such as the ‘melting helix,’ make it ideally suited to partner 
with a P450 enzyme, perhaps through a transient interaction during catalysis, accepting 
and sequestering RebP’s reactive product for the exclusive production of the 
rebeccamycin aglycone.  
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III.H.  Tables and Figures 
 
Table III.1.  Available structures of RebC. 
 
Structure name Substrate-
free 
Bound K252c Bound tautomer of 7-
carboxy-K252c 
FADH2 
PDB ID 2R0C 2R0P 2R0G (TBD) 
Resolution 1.8 Å 2.1 Å 2.4 Å 3.2 Å 
Bound cofactor 
 
FAD FAD FAD FADH2 
Unit cell 
dimensions (Å3) 
302,000 299,000 620,000 602,000 
Bound 
indolocarbazole 
- K252c 
 
 
N
H
N
H
H
N O
 
tautomer of 7-carboxy-
K252c 
 
N
H
N
H
H
N OH
O
-O
 
 
- 
Flavin position OUT OUT IN IN 
Helix ordering disordered ordered ordered ordered 
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Table III.2  Data collection and refinement statistics for FADH2-RebC structure. 
 
Data collection  
Beamline SSRL, 9-2 
Wavelength (Å) 0.9797 
Space group P21 
Unit cell  a = 63.3  Å, 
b = 78.2 Å, 
c = 123.1 Å, 
β = 98.7° 
Resolution (Å)a 40.0 – 3.2  
(3.31 – 3.20) 
Completeness (%)a 92.3 (80.4) 
I / σa 11.6 (4.9) 
Redundancya 3.5 (3.2) 
Rsyma,b 0.118 (0.203) 
Refinement  
Resolution range (Å) 40.0 – 3.2 
Rcryst (%)c 22.8 
Rfree (%)c 30.9 
No. non-hydrogen atoms  
     Protein 7826 
     FADH2 106 
     Water 30 
Average B-factors (Å2)  
     Protein 41.2 
     FADH2 50.1 
     Water 17.4 
r.m.s.d.d bond length (Å) 0.007 
r.m.s.d.d bond angle (°) 1.57 
Ramachandran plot (% 
residues) 
 
     Most favored 73.7 
     Additionally allowed 24.9 
     Generously allowed 1.2 
     Disallowed 0.2 
 
aValues in parentheses indicate highest resolution bin 
bRsym = ( ∑i∑hkl ǀ Ii(hkl) - <I(hkl)> ǀ ) / ∑hkl <I(hkl)>, where Ii(hkl) is the intensity of the ith measured 
reflection, and <I(hkl)> is the mean intensity for the reflection with the miller index (hkl). 
cRcryst  = ( ∑hkl ǀǀFobs(hkl) ǀ - ǀFcalc(hkl) ǀǀ ) / ∑hkl ǀFobs(hkl)ǀ ; Rfree is calculated identically, using 5% of 
reflections omitted from refinement. 
droot mean squared deviation 
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Table III.3.  The reductive half-reaction of RebC was investigated using anaerobic 
stopped-flow spectroscopy.  Stopped-flow experiments were done in anaerobic 
conditions using only FAD bound to RebC.  The concentration of FAD bound to RebC 
was ~2.5 μM (after mixing).  Initial tests with 13 μM NADH (after mixing) showed 
extremely slow reduction; therefore the NADH concentration was increased to 325 μM 
and then to 1 mM for subsequent trials.  Because of the saturation of the signal from 
NADH at 343 nm, rates were determined instead from the loss of absorbance at 450 nm 
as FAD was reduced.  Reduction of FAD by NADH in the absence of substrate is 
extremely slow, with a rate of only 0.0023 sec-1 even with the high, non-physiological 
concentration of 1 mM of NADH (after mixing). 
Concentration of NADH (μM, 
after mixing) 
Rate of  
reduction (sec-1) 
Standard error (sec-1) 
13 0.0007 0.0001 
325a 0.0017 0.0001 
325b 0.0015 0.0001 
1000 0.0023 0.0005 
 
aTrial 1 
bTrial 2 
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Table III.4.  Experimental evidence for states of para-hydroxybenzoate hydroxylase 
catalytic cycle.   
 
Stat
e 
Description 
of state 
Position of 
flavin 
Crystallographicall
y  
observed 
PDB ID Biochemical evidence 
1 Substrate-
free 
OPEN-IN 
equilibrium 
Yes, but as R220Q 
mutant 
1K0L 13 Slow substrate binding but 
otherwise unchanged catalysis of 
E49N mutant suggests two 
interconverting states 26; R220Q 
mutant more stable in OPEN than 
IN state 23; single molecule studies 
on substrate free pHBH 27 
2 Substrate-
bound 
IN Yes 1PBE 24 - 
3 Substrate-
bound, 
NADPH-
bound 
transition 
to OUT 
No, but R220Q 
mutant observed with 
NADPH (no 
substrate) and wild-
type with alternate 
substrate observed in 
OUT conformation 
1K0J 13 
 
1DOD 8,28 
Spectral shifts on flavin 
movement to the OUT position; 
R220K mutant stabilized in OUT 
conformation 29 
4 Substrate-
bound, 
FADH-, 
NADP+-
bound 
OUT No, but R220Q 
mutant observed with 
NADPH (no 
substrate) 
1K0J 13 
 
- 
5 Substrate-
bound, 
FADH- 
IN Yes Not 
deposited 25 
Movement of FADH2 to IN 
conformation driven by positive 
electrostatic field as shown by 
K297M mutant 30 
6 Substrate-
bound, 
Flavin-C4a-
O-OH 
IN No - Observed spectroscopically 31 
7 Product 
bound, 
Flavin-C4a-
OH 
transition 
to OPEN 
Yes, but with product 
bound, FAD-
complex 
1PHH 32 Observed spectroscopically 31 
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Table III.5.   Proposed states of the RebC catalytic cycle.   
 
State in 
RebC 
catalytic 
cycle 
Description of state Position of 
flavin 
State of the 
‘melting’ 
helix 
Crystallographically 
observed 
PDB ID 
1 Substrate-free OUT Disordered Yes 2R0C 
2 Substrate-bound IN Ordered Yes 2R0G 
3 Substrate-bound, NADH-
bound, 
Unknown Unknown No - 
4 Substrate-bound, FADH-, 
NAD+-bound 
Unknown Unknown No - 
5 Substrate-bound, FADH- IN Ordered No, but substrate-free 
FADH2-RebC 
structure is 
suggestive of IN 
conformation 
(TBD) 
6 Substrate-bound, flavin-
C4a-O-OH 
Unknown Unknown No - 
7 Product-bound, flavin-
C4a-OH 
Unknown Unknown No - 
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Figure III.1.  Reaction scheme for StaP- (a close homologue of RebP) and RebC-
mediated production of the des-chloro rebeccamycin aglycone, arcyriaflavin A 6, from 
chromopyrrolic acid 1.  StaP alone generates a mixture of products (K252c 4, 7-OH-
K252c 5, and arcyriaflavin A 6).  By contrast, a single product, arcyriaflavin A 6, is 
produced from chromopyrrolic acid 1 by the action of StaP and RebC together.  Aryl-aryl 
coupled chromopyrrolic acid 2 or 7-carboxy-K252c 3 are proposed products of StaP 5,6.   
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Figure III.1 
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Figure III.2.  Structural comparisons between FADH2-RebC and other RebC structures.  
A.  FADH2 from the FADH2-RebC structure (this work) is shown with magenta carbons, 
FAD from the substrate-free structure (PDB ID 2R0C) is shown with blue carbons, and 
FAD from the structure of RebC with a bound tautomer of 7-carboxy-K252c 3 (PDB ID 
2R0G) is shown with green carbons.  Top:  Structure with FADH2 superimposed with 
FAD from the substrate-free structure.  Bottom:  Structure with FADH2 superimposed 
with FAD from RebC structure with a bound tautomer of 7-carboxy-K252c 3.  B.  
Structure of FADH2-RebC colored red (Domain I, cofactor-binding domain), blue 
(Domain II, base of substrate-binding pocket), and green (Domain III, thioredoxin-like 
domain).  Blue composite omit density is contoured at 1.4 σ around the FADH2 molecule.  
Arrows indicate the boundaries of the ‘melting helix,’ which is ordered in this structure.  
C.  Active site of FADH2-RebC structure, with dashes indicating hydrogen-bonding 
interactions.  D.  Active site of RebC with a bound tautomer of 7-carboxy-K252c 3 (PDB 
ID 2R0G) with dashes indicating hydrogen-bonding interactions.  E.  The ‘melting helix’ 
from the FADH2-RebC structure is shown with side-chain atoms as sticks, with leucine-
358 labeled.  F.  The ‘melting helix’ from the RebC structure with a bound tautomer of 7-
carboxy-K252c 3 (PDB ID 2R0G) is shown with side chain-atoms as sticks.  Leucine-
358 is less than 4 Å from the bound tautomer of 7-carboxy-K252c 3. 
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Figure III.2 
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Figure III.3.  Omit density for ‘melting’ helix.  An omit map was generated by removing 
residues 354-363 from chain A of FADH2-RebC, carrying out simulated annealing CNS, 
and generating an Fo-Fc map from the resulting PDB file.  Residues 345-369 from chain 
A are shown, with the ‘melting helix’ shown with lines and with residues outside the 
‘melting helix’ shown with lines and cartoons depicting secondary structure.  Omit map 
density at 2.5 σ is shown around the ‘melting helix,’ residues 354-363, in blue. 
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Figure III.3 
 
 
 148
Figure III.4. ‘Melting helix’ of RebC.  A.  In the substrate-free structure of RebC, 
residues 354-363 are disordered.  The boundaries of this region are shown in red.  FAD is 
shown with blue sticks.  B.  Surface representation of the structure in A.  Part of the FAD 
molecule (blue sticks) can be seen inside the structure.  C.  An identical view of the 
FADH2-RebC structure with the ‘melting helix’ in red.    D.  Surface representation of the 
FADH2-RebC structure shown in B.   
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Figure III.5.  Access of the substrate binding pocket to external solvent in structures 
with a formed ‘melting helix.’  A.  A pathway traced to external solvent from the active 
site of FADH2-RebC.  Protein is in gray with the surface traced.  Flavin is depicted in 
thick blue sticks, and the pathway is shown with red spheres.  B.  The same pathway can 
be traced from the active site of the structure of RebC with a bound tautomer of 7-
carboxy-K252c 3.  The protein surface is shown in pale green, with the tautomer of 7-
carboxy-K252c 3 shown in red.  This entryway to the substrate binding site is likely too 
narrow for a substrate-like molecule to traverse. 
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Figure III.5 
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Figure III.6.  A general reaction cycle for flavin-based hydroxylases, based on previous 
reports describing the reaction cycle for pHBH 12,33,34 and data on RebC presented here 
and previously 6.  States 1-7 are labeled, which correspond to the states described in 
Tables III.4 and III.5.   The conformation of the flavin cofactor in pHBH is shown in the 
top box and, when known, the likely state of the flavin in RebC is shown in the lower box 
(in bold and italicized text).  Note that NADPH is the favored reductant for pHBH, 
whereas the favored reductant for RebC is NADH. 
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Chapter IV: 
Redesign of the flavin binding site of the staurosporine biosynthetic enzyme StaC 
 
IV.A.  Summary 
 The staurosporine biosynthetic enzyme StaC is predicted to contain a binding site 
for flavin adenine dinucleotide (FAD) from bioinformatic analysis.  Yet StaC fails to co-
purify with FAD.  StaC’s failure to co-purify with FAD is in contrast to its close 
homologue RebC, which binds FAD and catalyzes a distinct reaction from StaC.  Here 
we show that among StaC and its three closest, characterized homologues RebC, AtmC, 
and InkE, there is a correlation between the affinity for FAD and the oxidative state of 
the product produced, with a stronger affinity for FAD associated with production of a 
more oxidized product.  Using a structure-based site-directed mutagenesis approach, we 
install a higher affinity binding site for FAD in StaC, generating a protein with ten amino 
acid substitutions, which we call StaC-10x.  Interestingly, StaC-10x possesses a redox 
potential that is near-identical to that of RebC.  Additionally, StaC-10x is partially 
converted to a RebC-like protein, as shown by its increased affinity for FAD and its 
increased production of the RebC product in activity assays.  These results suggest that, 
at least in part, the functional differences seen between StaC and RebC are determined by 
their affinities for the cofactor FAD.  Further, these affinities for FAD are dictated in part 
by residues that are outside of previously characterized flavin binding motif regions. 
 
Note:  Michael J. Hamill determined the redox potential of the StaC mutant in the laboratory of Prof. Sean 
J. Elliott at Boston University.  Dr. Annaleise R. Howard Jones prepared StaC protein, and RebC, StaC, 
and InkE expression vectors, and Carl J. Balibar prepared Actinomadura melliaura genomic DNA, all in 
the laboratory of Prof. Christopher T. Walsh at Harvard Medical School.  Activity assays were carried out 
using equipment in the laboratory of Prof. Christopher T. Walsh.   
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IV.B.  Introduction 
 Staurosporine (Fig. IV.1), a natural product frequently isolated from Streptomyces 
and other soil-dwelling actinomycete bacteria,1 is a potent protein kinase inhibitor.2  Its 
role in chemical ecology is unknown.  An analog of staurosporine (7-hydroxy-
staurosporine, also known as UNC-01) has been in clinical trials as an anti-cancer  
agent.3-5  A key step of staurosporine biosynthesis is the conversion of chromopyrrolic 
acid (CPA) to the staurosporine aglycone K252c, a reaction that involves two enzymes 
and is a net four-electron oxidation (Fig. IV.2).  The first enzyme StaP, a cytochrome 
P450 enzyme, is thought to catalyze an aryl-aryl coupling reaction to generate a reactive 
intermediate from CPA,6-9  and the second enzyme, StaC, is thought to intercept this 
intermediate and enable its conversion to the staurosporine aglycone, which is an 
asymmetric molecule with a carbonyl at the C-5 position and a fully reduced C-7 carbon 
(numbering in Fig. IV.1).  The exact identity of the StaC substrate is unknown.   
 Substitution of StaC in a reaction mixture by RebC, an enzyme from the 
rebeccamycin biosynthetic pathway with 65% sequence identity to StaC (Table IV.1, Fig. 
IV.3), results in production of an alternate product, arcyriaflavin A, through a net eight-
electron oxidation reaction.  Arcyriaflavin A is a symmetric molecule with a carbonyl at 
both the C-5 and C-7 positions (Fig. IV.1 and IV.2).6  Surprisingly, although both RebC 
and StaC contain three motifs typical of flavin hydroxylase proteins,6,10,11 only RebC co-
purifies with FAD.  Upon purification, StaC does not contain FAD.  Nonetheless, StaC is 
capable of converting FAD to FADH2 using NAD(P)H.6   
 Beyond RebC, StaC has two other close sequence homologues, InkE and AtmC, 
each of which are involved in separate indolocarbazole biosynthetic pathways (Table 
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IV.1, Fig. IV.3).  InkE is involved in the biosynthesis of K252a (Fig. IV.1), a molecule 
that has a carbonyl at the C-5 carbon but a fully reduced C-7 carbon.  The aglycone of 
K252c is likely generated through a largely similar pathway as the staurosporine 
aglycone, with InkE (like StaC) mediating a net four-electron oxidation of 
chromopyrrolic acid (Fig. IV.2).  By contrast, AtmC is involved in the biosynthesis of 
AT2433-A1 (Fig. IV.1), a molecule that has a carbonyl at the both the C-5 and C-7 
carbons.  The aglycone of AT2433-A1 is likely generated through a highly similar 
pathway as the rebeccamycin aglycone, with AtmC (like RebC) mediating a net eight 
electron oxidation of chromopyrrolic acid (Fig. IV.2).   
 Here we investigate the role (or lack thereof) of FAD in the reaction catalyzed by 
StaC.  Our approach is three-fold:  first, we use isothermal titration calorimetry (ITC) to 
identify the binding constant of StaC for FAD, as well as the binding constants for FAD 
of StaC homologues RebC, AtmC, and InkE.  Second, we use the structure of RebC11 in 
combination with sequence analysis of the StaC homologues to generate a StaC protein 
with ten amino acid substitutions, called StaC-10x, capable of binding FAD.  Finally, we 
determine the reduction potential, activity, and binding constant for FAD of StaC-10x.  
We find that StaC-10x possesses a reduction potential nearly identical to that of RebC.  
Further, StaC-10x is weakly active as RebC-like enzyme in enzymatic assays and has a 
binding constant for FAD between that of StaC and RebC, suggesting that introduction of 
a higher affinity FAD binding site in StaC has made it catalytically more ‘RebC-like.’   
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IV.C.  Materials and Methods 
Generation of expression vectors for wild-type proteins  
 RebC was cloned into pET28a and StaC into pET22b as previously described.6  
InkE was amplified via PCR from Nonomuraea longicatena12 genomic DNA using 
primers 5'-ggagagCATATGACTCGCAGCGAAGAGACCGAC-3' and 5'-
ccgAAGCTTTCACCCCGCCCCTCGCACGAGATC-3' (where italicized text indicates 
an overhang and bold text indicates a restriction digest site).  The PCR product was gel 
purified, cut with NdeI and HindIII, gel purified, and ligated into similarly cut pET28a 
(Annaleise R. Howard-Jones, personal communication).   
 AtmC was amplified from Actinomadura melliaura genomic DNA (a kind gift of 
Carl Balibar) via PCR.  A reaction mixture with 2.5 U of Pfu Turbo (Stratagene), 1x 
cloned Pfu buffer (Stratagene, 20 mM Tris-HCl pH 8.8, 2 mM MgSO4, 10 mM KCl, 10 
mM (NH4)2SO4, 0.1% Triton X-100, 100 μg/mL bovin serum albumin), 5% DMSO, 300 
μM dNTPs (an equimolar mixture dATP, dCTP, dGTP, and dTTP), 1 μL of purified 
genomic DNA, and 1.25 ng of each primer (5'-
caagttaCATATGACCACGGCTTACGAGACCGA-3' and 5'-
caagttaGAATTCCCATGAAGACCAGCCAGTTCTCCA-3', purchased from Integrated 
DNA Technologies) in a 50 μL reaction mixture was subjected to the following PCR 
cycle:  2 minutes at 95°C; 30 cycles of 30 seconds at 95°C, 30 seconds at 57°C, and 3 
minutes at 72°C; 10 minutes at 72°C; and cooling to 4°C.  The PCR fragment was gel 
purified using the QIAquick Gel Extraction Kit (Qiagen) and digested with NdeI and 
EcoRI (New England Biolabs) in NEBuffer EcoRI (New England Biolabs, 50 mM NaCl, 
100 mM Tris-HCl, 10 mM MgCl2, 0.025% Triton X-100, pH 7.5).  Purified pET28a 
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(Novagen) was identically digested with NdeI and EcoRI (New England Biolabs).  Both 
digested PCR product and pET28a were again gel purified.  Various ratios of insert to 
vector were ligated in a 10 μL reaction volume using 1x T4 DNA ligase buffer (New 
England Biolabs, 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM 
ATP, 25 μg/mL bovine serum albumin) and 400 U of T4 DNA ligase (New England 
Biolabs), with incubation at room temperature for 50 minutes.  Ligation reactions were 
transformed into DH5α cells and plated onto LB-agar-kanamycin plates.  Resulting 
colonies were amplified in LB with 30 mg/L kanamycin, and the plasmid was purified 
(QIAprep Spin Miniprep Kit) and assayed via restriction digestion for incorporation of 
the insert.  The integrity of the sequence was assayed with sequencing reactions spanning 
the length of the insert.  Sequencing was carried out at the MIT Biopolymers Laboratory.  
 
Generation of the StaC-10x expression vector 
 Twenty eight overlapping primers encoding the first part of the StaC protein with 
ten amino acid substitutions were designed using DNAWorks 2.4 
(http://mcl1.ncifcrf.gov/dnaworks/dnaworks2.html) and synthesized by Integrated DNA 
Technologies (Table IV.2).  Primers were designed with each codon for a modified 
amino acid in a non-overlapping portion of a primer, such that each primer encoding a 
modified amino acid could be singularly ‘swapped’ with a primer encoding the wild-type 
amino acid (Fig. IV.4).  This primer design scheme enables facile production of modified 
StaC proteins with fewer unwanted mutations. 
 To generate the StaC-10x expression vector, a first PCR was carried out using 1x 
cloned Pfu buffer (Stratagene, 20 mM Tris-HCl pH 8.8, 2 mM MgSO4, 10 mM KCl, 10 
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mM (NH4)2SO4, 0.1% Triton X-100, 100 μg/mL bovin serum albumin), 2.5 U of Pfu 
Turbo (Stratagene), 250 μM of dNTPs (an equimolar mixture dATP, dCTP, dGTP, and 
dTTP), and 125 nM of each of the 28 primers, with a temperature cycle of 94°C (2 min); 
45 cycles of 94°C (30 s), 58°C (30 s), and 72°C (1 min); and 72°C (2 min).  A second 
PCR was then carried out using 1x cloned Pfu buffer, 2.5 U of Pfu Turbo, 250 μM 
dNTPs, 300 nM of each primer 1 and 28, and 1 μL of the first PCR, in a total volume of 
50 μL.  The product of the second PCR was gel purified using a gel extraction kit 
(Qiagen).  Gel purified DNA from the second PCR was then incubated with 20 U of NdeI 
(New England Biolabs) in Buffer 3 (New England Biolabs, 50 mM Tris-HCl, 10 mM 
MgCl2, 100 mM NaCl, 1 mM DTT, pH 7.9) at 37°C for 2 h; then, after addition of 15 U 
of BclI (New England Biolabs), the reaction was incubated at 50°C for 2 h.   
 Separately, pET28a-StaC6 was transformed into dam-/dcm- E. coli competent cells 
(New England Biolabs) and purified using a minprep kit (Qiagen).  Purified plasmid was 
incubated with 20 U of HindIII (New England Biolabs) in NEBuffer 2 (New England 
Biolabs, 10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1mM DTT, pH 7.9) at 37°C for 
two h; then, after adjustment of the buffer to 50 mM Tris-HCl and 100 mM NaCl and 
addition of 15 U of BclI, incubated at 50°C for 2 h.  Additionally, purified plasmid was 
separately incubated with 20 U of NdeI and 20 U of HindIII in NEBuffer 2 (New England 
Biolabs) at 37°C for 2 h, followed by heat inactivation of the restriction enzymes at 65°C 
for 20 min.  2.5 U of calf alkaline phosphatase (New England Biolabs) was then added to 
this final reaction mixture, which was incubated at 37°C for 2 h.   
 All restriction digests were gel purified.  Ligation reactions were set up with 20 
ng of the purified NdeI/HindIII digest reaction, 8 ng of the purified HindIII/BclI reaction, 
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8 ng of the purified NdeI/BclI digest reaction, 1x T4 DNA ligase buffer (New England 
Biolabs, 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, 25 
μg/mL bovine serum albumin), and 200 U of T4 DNA ligase (New England Biolabs) and 
incubated at 16°C for 24 h.  Ligation reactions were transformed into DH5α cells and 
plated on LB-agar-kanamycin plates.  Plasmid was purified from overnight cultures of 
single colonies, analyzed for the presence of the PCR insert via a diagnostic PCR 
reaction, and sequenced at the MIT Biopolymers Laboratory using three different primers 
to gather data from the entire length of StaC-10x gene.   
 
Protein purification   
 Apo-CHis6-StaC was purified as described earlier.6  Protein frozen at -80°C was 
thawed on ice and loaded onto a Superdex-200 column (Amersham) pre-equilibrated with 
150 mM NaCl, 25 mM HEPES, 10% glycerol, pH 7.5.  3 mL fractions were collected, 
and the fraction with the most StaC present (based on A280) used in further studies, 
described below.  All other protein expression vectors were transformed into Rosetta 2 
pLysS (DE3) cells (Novagen).  Single colonies were used to inoculate LB media 
containing 30 mg/L kanamycin and 34 mg/L chloramphenicol.  Cultures were grown at 
37°C to an OD600 of ~0.45, at which point the temperature was lowered to 21°C.  At an 
OD600 of ~0.65, cultures were induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) and grown for ~20 hours at 250 rpm.  Cells were pelleted by centrifugation, 
suspended in 300 mM NaCl, 25 mM Tris-HCl, 5 mM imidazole, pH 8.0, sonicated, and 
centrifuged at 25,000 rpm to pellet insoluble material.  The supernatant was incubated 
with nickel (II) loaded chelating sepharose fast flow (GE Biosciences) for 40 min at 4°C.  
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Unbound material was removed, and then the column was washed with 25 column 
volumes of 300 mM NaCl, 25 mM Tris-HCl, 20 mM imidazole, pH 8.0 and then, for 
AtmC and RebC, washed with 2 M KBr, 2 M urea, 300 mM NaCl, 25 mM Tris-HCl, 20 
mM imidazole, pH 8.0 to remove bound flavin, and then re-washed with 300 mM NaCl, 
25 mM Tris-HCl, 20 mM imidazole, pH 8.0.  Protein was then eluted with 300 mM 
NaCl, 25 mM Tris-HCl, 200 mM imidazole, pH 8.0.  Eluted protein was loaded onto a 
Superdex-200 column pre-equilibrated with 150 mM NaCl, 25 mM HEPES, 10% 
glycerol, pH 7.5, and 3 mL fractions were collected.  Fractions containing purified 
protein were pooled and used directly in isothermal titration calorimetry experiments.  
Protein concentration was assayed using absorbance in the linear range at A280, using 
theoretical extinction coefficients calculated for each protein by ProtParam.13  For StaC-
10x, protein concentration was calculated instead using the BSA assay (BioRad). 
 
Isothermal titration calorimetry (ITC) experiments with StaC, RebC, InkE, AtmC, and 
StaC-10x   
 All experiments were carried out using a MicroCal Isothermal Titration 
Calorimeter in the MIT Biophysical Instrumentation Laboratory.  Protein was taken from 
the peak fractions of a gel filtration run and diluted in gel filtration buffer to the desired 
concentration.  Protein concentrations used in ITC experiments were:  29.6 μM (RebC), 
30 μM (AtmC), 27 μM  (StaC), 132 μM (InkE), and 30 μM (StaC-10x).  FAD was 
dissolved in the identical gel filtration buffer, and its concentration was calculated using 
A450 using ε450 = 11,300 cm-1 M-1.  FAD concentrations used in ITC experiments were:  
300 μM (RebC experiment), 300 μM (AtmC experiment), 405 μM (StaC experiment), 
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1.05 mM (InkE experiment), and 300 μM (StaC-10x experiment).  The ratio of 
FAD:protein was varied depending on the heat change upon FAD injections in initial 
experiments, as well as to determine a most optimal binding curve for each protein.  ITC 
experiments were carried out with protein in the cell and FAD in the syringe with the 
following parameters:  30 injections (one of 0.5 μL, 29 of 10 μL; with a duration time of 
1 sec for the first injection and 20 sec for the remaining 29 injections), 240 sec spacing, 2 
sec filter, 25°C, reference power of 15 μCal/sec, initial delay of 60 sec, stirring speed of 
310, feedback set at high, ITC equilibrium set at fast and auto.  For the InkE experiment, 
all conditions for ITC were identical, except that 60 injections were used (one of 0.5 μL, 
59 of 5 μL; with a duration time of 1 sec for the first injection and 10 sec for the 
remaining 59 injections).  Equilibrium constants of binding (Kb’s) were determined using 
the Origin Software and were converted to equilibrium constants of dissociation (Kd’s).  
The single binding site model was used in determining Kb’s.   
  
Activity assays of StaC, RebC, and StaC-10x   
 All enzyme assays were carried out as described earlier6 in the presence of 75 mM 
HEPES pH 7.5, 1 mg/mL BSA, 5 mM NADH, 20 μM ferredoxin, and 1 μM flavodoxin 
NADP+ reductase.  RebC, StaC, or StaC-10x was added at 5 μM.  All reactions were 
initiated with the addition of 1 μM StaP and incubated at room temperature for 30 min, 
which has previously been shown to be in the linear range for production of products.  
Reactions were then quenched with two volumes of methanol and incubated on ice for at 
least five min prior to centrifuging to remove precipitated protein.  Reactions were 
assayed using a Beckman System Gold reverse-phase HPLC with a Higgins analytical 
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C18 column (50 x 4.6 mm).  Two buffers (A is 0.1% trifluoroacetic acid in distilled, 
filtered water, and B is 0.1% trifluoroacetic acid in acetonitrile) were used in the 
following program of linear gradients at a 3 mL/min flow rate:  0% B for three min, 0 to 
30% B over two min, 30% B for eight min, 35 to 50% B over 5 min, 50% B over 1 min, 
50 to 0% B over 30 s, and 0% B for 3.5 min.  Authentic samples of indolocarbazoles 
eluted at 11.6 min  (289 nm, K252c), 8.7 min (299 nm, 7-hydroxy-K252c), and 17.1 min 
(315 nm, arcyriaflavin A) at 289 nm, 299 nm, and 315 nm, respectively.  Peaks appearing 
at these times from experimental samples were integrated at the appropriate wavelength.  
Because reactions are linear at 30 min, integrated peak areas were converted to turnover 
rates using previously described methods.6  All assays were carried out in triplicate.   
 
IV.D.  Results  
Correlation of FAD binding affinity with the reaction catalyzed 
 StaC and its three closest characterized homologues RebC, AtmC, and InkE were 
purified recombinantly without addition of riboflavin to the media.  As reported earlier, 
StaC purifies without bound FAD, whereas RebC purifies with bound FAD.6  We found 
that InkE (like StaC) purifies without bound FAD.  We also found that AtmC (like RebC) 
purifies with bound FAD.   
 Apo proteins were purified for isothermal titration calorimetry experiments.  The 
removal of the FAD cofactor was either unnecessary, as in the case of StaC and InkE, as 
each of these proteins purifies without bound FAD, or (for RebC and AtmC) was 
accomplished by washing the protein bound to the metal affinity column with a buffer 
containing 2 M KBr and 2 M urea.14  Purified apo proteins were used in isothermal 
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titration calorimetry experiments to determine binding constants for FAD (Fig. IV.5A-D).  
While RebC and AtmC, both of which facilitate net 8-electron oxidations of 
chromopyrrolic acid,6,15 have binding affinities for FAD in the low nanomolar range 
(Table IV.4), StaC and InkE, both of which facilitate net 4-electron oxidations of 
chromopyrrolic acid,6,12 have binding affinities in the low micromolar range (Table IV.4).  
There is a difference of approximately three orders of magnitudes in binding affinities 
between, first, RebC and AtmC, and second, StaC and InkE.  This initial result suggests 
that, among this group of enzymes, there is a correlation between, on one hand, tight 
binding of FAD and mediation of a net 8-electron oxidation of CPA and, on the other 
hand, between substantially weaker binding of FAD and mediation of a net 4-electron 
oxidation of CPA.   
 
StaC-10x has a higher affinity for FAD than StaC 
 Because of the close sequence similarity of RebC, StaC, AtmC, and InkE and 
because the structure of RebC was solved, we were able to determine which residues 
were likely to mediate the differences in affinity for FAD between the two groups of 
enzymes (Table IV.5, Fig. IV.3, Fig. IV.6).  We targeted ten residues that might play a 
role in differentiating the two groups, and we generated StaC-10x, a StaC protein with ten 
amino acid substitutions that make it ‘RebC-like’ at those positions (Table IV.5).  Like 
RebC and AtmC, StaC-10x co-purifies with FAD.  Unlike RebC and AtmC, however, it 
was challenging to produce apo-StaC-10x.  After passing a buffer containing 2M urea 
and 2M KBr over a metal affinity column with bound StaC-10x to remove FAD, protein 
could not be eluted from the column using any tested elution buffer (protein presumably 
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aggregated or cross-linked to the column after loss of the FAD).  Therefore protein, 
which is co-purified with less than full occupancy of the flavin cofactor (33% 
constituency of FAD), was used ‘as-purified’ in an ITC experiment and the Origin 
Software was modified to account for the non-zero starting concentration of FAD in the 
cell to calculate the Kd.   
 StaC-10x has a binding constant of approximately 470 nM for FAD (Figure 
IV.5E, Table IV.4).  By targeting ten amino acids that may be involved in binding FAD, 
we have increased StaC’s affinity for FAD ~36-fold, suggesting that we have identified 
many of the residues important for high affinity binding of FAD.    
 
StaC-10x has a near-identical redox potential to RebC 
 We were eager to investigate if the reduction potential of StaC-10x resembled the 
reduction potential of RebC, a value which we reported earlier.  Using the xanthine 
oxidase reduction assay16,17, we found that the reduction potential of the modified StaC 
enzyme was -178 mV (Michael Hamill and Sean Elliott, personal communication), 
almost exactly the reduction potential of RebC of -179 mV.11  While it is impossible to 
measure the reduction potential of wild-type StaC using the xanthine oxidase reduction 
method (due to StaC’s failure to co-purify with FAD), this result shows that conversion 
of StaC to StaC-10x has created a similar environment surrounding the flavin cofactor to 
that found in RebC, leading to a similar redox potential as that of RebC.   
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StaC-10x is a weak RebC catalyst 
 To investigate the activity of the StaC mutant, we carried out activity assays using 
a previously described method.6  Because the substrate(s) of StaC and RebC is unknown, 
this assay uses the upstream enzyme StaP and its known substrate CPA together with an 
electron source provided by spinach ferredoxin, flavodoxin NADP+ reductase, and 
NADH.  The 4-, 6-, and 8-electron oxidation products (K252c, 7-hydroxy-K252c, and 
arcyriaflavin A) are then analyzed via HPLC.  In the presence of StaP alone, products are 
K252c, 7-hydroxy-K252c (major product), and arcyriaflavin A.  In a StaP/RebC system, 
the major product is arcyriaflavin A.  In a StaP/StaC system, the major product is K252c.   
 StaC-10x behaved like RebC to the extent that it produced arcyriaflavin A as its 
major product.  However, the rate of arcyriaflavin A production (based on authentic 
samples and standard curves) was ~6-fold lower than that of wild-type RebC (Table 
IV.6), although the rate was increased >2-fold relative to a reaction containing wild-type 
StaC.  Additionally, the mutant did not promote formation of the normal StaC product 
K252c (Table IV.7).  Collectively, these results show that StaC-10x is an active RebC-
like catalyst, albeit as a less efficient catalyst than wild-type RebC.  Given that StaC-10x 
does not promote K252c production, it is no longer active as a StaC-like catalyst.   
 
IV.E.  Discussion 
 When StaC was first purified,6 it was a complete surprise that the protein was 
purified without FAD.  After all, StaC has intact all three FAD binding motifs typical of 
flavin-dependent hydroxylases.  These are the Rossmann fold (containing a GXGXXG 
sequence), involved in binding the ADP moiety of FAD;18 the DG motif, involved in 
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binding the O3' of the ribose;19 and the more recently reported GD motif;10 no other 
sequences motifs have been reported for flavin-dependent hydroxylases.  Further, 
although it was possible that heterologous expression of this Streptomyces protein in the 
E. coli overexpression strain BL21(DE3) had affected the ability of StaC to bind FAD, 
this explanation seemed unlikely.  After all, RebC, a protein with 65% identity to StaC 
(including every amino acid in designated motif regions) and also isolated from an 
actinomycete bacteria (Lechevalieria aerocolonigenes), was successfully purified with 
FAD from BL21(DE3) cells using an identical protocol.  It thus appears that the 
difference in StaC and RebC’s abilities to co-purify with FAD is related to the identities 
of amino acids outside of designated flavin binding motif regions, which differ between 
StaC and RebC.   
 We used isothermal titration calorimetry methods to establish the magnitude 
difference in affinity between StaC and RebC for FAD.  We found that the affinity of 
StaC for FAD was 17 μM, whereas that of RebC was 25 nM.  Further, we investigated 
whether this trend held true across other homologues, InkE and AtmC.  Based on the 
oxidative state at the C-7 carbon in the products they produce, InkE should be ‘StaC-like’ 
and AtmC should be ‘RebC-like’ (Fig. IV.1, Fig. IV.2).  Our ITC results verify the 
hypothesis that the binding affinity for FAD is correlated with the product produced, with 
InkE having a binding affinity of 90 μM (compared to 17 μM for StaC) and AtmC having 
a binding affinity of 77 nM (compared to 25 nM for RebC).  We thus propose that there 
is a correlation between a strong affinity for FAD and mediation of a net 8-electron 
oxidation of CPA and between a substantially weaker affinity for FAD and mediation of 
a net 4-electron oxidation reaction of CPA. 
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 We further tested the idea that there is correlation between FAD binding affinity 
and the activity of the enzyme by generating StaC-10x.  We identified amino acids to 
alter in StaC based on two types of analysis.  First, we used the structure of RebC to 
identify amino acid residues that appear to play a role in mediating the binding FAD or 
were near the putative active site (Fig. IV.3, Fig. IV.6).  Second, we used an analysis of 
the sequence alignment of all four homologues to identify residues that have one identity 
in RebC and AtmC and have another identity in StaC and InkE (Table IV.5).  Using these 
criteria, we chose ten amino acids in StaC to alter to the corresponding residues in RebC.  
The resulting StaC-10x has a substantially increased affinity for FAD (from 17 μM to 
470 nM).  Further, this protein now promotes the production of the RebC product over all 
other products, albeit at a significantly reduced rate versus RebC itself.  It appears that 
this mutant is ‘on its way’ to becoming a RebC protein.  If we could identify the residues 
needed to make StaC bind FAD with 25 nM affinity, possibly altering those residues  
would also increase catalytic activity to the rate seen in RebC.   
 However, it is unclear which additional residues might need to be targeted in StaC 
to enable full conversion to RebC.  Some residues that were not targeted, that had one 
identity in RebC and AtmC and another identity in StaC and InkE were Asp100 (Ala), 
Pro105 (Phe), Ala121 (Asn), Leu123 (Val), Phe286 (Tyr), Glu416 (Asp), and Pro437 (Ala) 
(amino acid outside parenthesis from RebC/AtmC with numbering from RebC, and 
amino acid in parenthesis from StaC/InkE), however, based on the structure of RebC, 
none of these residues appear to influence either FAD-binding or the conformation of the 
active site (Table IV.5).  However, another approach is targeting residues that differ 
between RebC and StaC but have no specific identities in InkE and AtmC.  Although 
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RebC and StaC share 65% sequence identity, there are still 208 amino acids that StaC 
does not share with RebC (Table IV.8).  Many of these residue differences are extremely 
conservative (i.e. isoleucine to leucine) and others are situated on the surface of the 
protein or are situated in the third, thioredoxin-like domain of the proteins, distant from 
the active site.  Ignoring these exceptions still leaves possible targets for future site-
directed mutagenesis experiments, however, none are obviously involved in FAD binding 
or molding of the active site cavity (Table IV.8).  We should also note that we have 
partially taken this approach already.  We ignored the sequence of AtmC in choosing to 
mutate residues 38 and 39 in StaC; AtmC in fact shares the amino acid alanine with StaC 
in the first position and has a completely distinct amino acid from either RebC or StaC at 
the second position (Table IV.5).  But because these residues are near the FAD and are 
surrounded by a completely conserved set of residues between RebC and StaC (Fig. 
IV.3), we ignored the information from AtmC and nonetheless mutated these two 
residues.   
 Introduction of an improved FAD binding site into StaC also enabled us to 
measure the redox potential of this StaC mutant.  Interestingly, the redox potential of this 
StaC mutant (-178 mV) is near identical to that of RebC (-179 mV).  The key question 
regarding this result is whether StaC began with an identical redox potential to RebC or if 
StaC began with a distinct redox potential from RebC, which has now been successfully 
‘converted’ to that of RebC.  Unfortunately, these questions are extremely difficult to 
answer using the xanthine oxidase reduction method of measuring redox potentials, as we 
cannot measure the redox potential of StaC itself, given StaC’s failure to stably bind to 
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FAD.  Nonetheless, our result certainly shows that introduction of an FAD binding site 
into StaC has ‘re-constituted’ the redox potential of RebC. 
 Collectively, our work has investigated the role of the FAD cofactor in StaC.  We 
have explored the binding affinities of StaC and its homologues for FAD, and we have 
used a structure-based site-directed mutagenesis approach to create higher affinity FAD 
binding site in StaC.  Introduction of this binding site in StaC has re-constituted the RebC 
redox potential, has increased StaC’s affinity for FAD, and has resulted in a protein able 
to produce more arcyriaflavin A than the wild-type StaC protein.  These results suggest to 
us that StaC’s failure to bind tightly to FAD may be a key feature of its catalytic function, 
and RebC’s ability to bind tightly to FAD may be a key feature of its catalytic function.  
The fact that the enzymes RebC and AtmC, which do bind FAD tightly, mediate 
production of a more oxidized product, and the fact that StaC and InkE, which do not 
bind FAD tightly, mediate production of a less oxidized product, implies that while tight 
binding of a cofactor is needed to produce the more oxidized product, only weak binding 
of the cofactor is needed to produce the less oxidized product.   
 We earlier proposed that RebC has a dual role in sequestering a reactive 
intermediate and in carrying out flavin-based chemistry.11  We suggested this idea 
because our structure of CPA-soaked RebC led to the ‘crystallographic trapping’ of a 
CPA degradation product (a putative RebC substrate).  Subsequent synthetic work 
showed that the trapped molecule decomposed in solution,8 implying a unique role of 
RebC in stabilizing this molecule.  Given the close sequence similarity between RebC 
and StaC and the facile installation of RebC-like activity in StaC with only ten amino 
acid substitutions, we now hypothesize that StaC may share with RebC the ability to 
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stabilize the same reactive intermediate.  The differences in catalytic outcome between 
RebC and StaC instead appear to be mediated by the differences in affinity of StaC and 
RebC for FAD.  While RebC binds FAD tightly and is likely to generate product via 
flavin-based hydroxylation chemistry, StaC’s relationship with FAD may be quite 
distinct.  Although StaC does bind FAD, its affinity for FAD is three orders of magnitude 
weaker than that of RebC.  Instead of using FAD in flavin-based hydroxylation chemistry 
per se, StaC may use FAD instead to stabilize the conformation of its active site or may 
use FAD instead only as an electron sink for an otherwise spontaneous oxidation of a 
reactive intermediate to K252c.  It appears that the modulation of product outcome is 
mediated by the affinity for FAD, with a high affinity for FAD resulting in higher rates of 
production of the eight-electron oxidation product, and a lower affinity for FAD resulting 
instead in higher rates of production of the four-electron oxidation product.   
 The ubiquity of staurosporine as a natural product1 suggests that the oxidation 
state of the C7 carbon, which StaC controls, is an essential part of the chemical ecology 
of Streptomyces and other bacterial strains.  In turn, the evolutionary pressure for the 
staurosporine molecule – whatever those pressures are – may have provided the driving 
force to create an enzyme distinct from RebC in its activity.  This evolutionary pressure 
may have enabled conversion of RebC into a StaC enzyme, a process which may have 
involved, quite simply, decreasing the enzyme’s affinity for FAD sufficiently that the 
new enzyme binds FAD weakly.  Loss in affinity for FAD may in turn have converted 
the activity of StaC, enabling StaC to mediate production of K252c rather than 
acyriaflavin A, with a distinct oxidation state at the C7 carbon.  Future studies on these 
interesting ‘cousin’ enzymes StaC and RebC should enable us to investigate further the 
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role of the affinity for FAD in production of indolocarbazole natural products such as 
staurosporine. 
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IV.H.  Tables and Figures 
Table IV.1.  Percent identity of each homologue pair based on sequence alignment in 
Figure IV.3.   
 
Enzyme Pair % identity 
RebC-StaC 65 
RebC-AtmC 64 
StaC-InkE 63 
RebC-InkE 59 
StaC-AtmC 62 
InkE-AtmC 44 
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Table IV.2.  Primers used in construction of StaC mutant gene.  Bold text within 
oligonucleotide sequences indicates restriction digest sites, italicized text indicates 
modified overhangs, and underlined text indicates the modified codon.  Note that even 
numbered primers are reverse primers.   
 
Primer Number Sequence 
1 5'-ggagagCATATGACCCACTCTGGCGAACGTACGGATGTT-3' 
2 5'-TACCGACTGGACCACCACCAACGATTAAAACATCCGTACGTTCGC-3' 
3 5'-GGTGGTCCAGTCGGTATGGCACTGGCGTTAGACTTACGCTACCGC-3' 
4 5'-GACAACTAAACAATCAATGCCGCGGTAGCGTAAGTCTAACGCCAG-3' 
5 5'-TGATTGTTTAGTTGTCGAACAGACGGATGGCACGGTCCGTCATCC-3' 
6 5'-ATAGAACGCGGACCAATGGTGCCAACACGTGGATGACGGACCGTG-3' 
7 5'-ATTGGTCCGCGTTCTATGGAGCTGTTCCGCCGTTGGGGTGCAGCA-3' 
8 5'-CCGCTGGCCAACCGGCGTTACGGATTGCGTCTGCTGCACCCCAAC-3' 
9 5'-GGTTGGCCAGCGGATCACCCATTAGATATTGCGTGGGTGACCAAG-3' 
10 5'-ACGATAACGATAGATCTCATGACCGCCGACCTTGGTCACCCACGC-3' 
11 5'-TCATGAGATCTATCGTTATCGTCGCGGTACGGCAGCGAATCGTCC-3' 
12 5'-TGGTCTGGTTCCGGGGTGTGGACAAACGCTGGACGATTCGCTGCC-3' 
13 5'-CCCGGAACCAGACCAAATCTGTCCGCAACACTGGTTAAACCCAGT-3' 
14 5'-CTGGGTGCACGCCCACCGCCTCAATCAGCACTGGGTTTAACCAGT-3' 
15 5'-GTGGGCGTGCACCCAGACGGCCCACTGTTATTATCTACGACCGTT-3' 
16 5'-TCGTCGGTTTGGACGACGCCGTCAACGGTCGTAGATAATAACAGT-3' 
17 5'-CGTCCAAACCGACGACCATGTCGAGGCGACGCTGACCGATCACGC-3' 
18 5'-CGGGCACGCACGGTGCCGGTGGTACCGGTGGCGTGATCGGTCAGC-3' 
19 5'-CGTGCGTGCCCGCTTTCTGGTTGCCTGCGACGGCGCAAGCTCTCC-3' 
20 5'-TGGGGCTTCAATACCACAGGCACGACGAACCGGAGAGCTTGCGCC-3' 
21 5'-GTGGTATTGAAGCCCCAGCACGCCATCGCACGCAGGTCTTCCGTA-3' 
22 5'-TTTTAACTCCGGGGCACGGAATAAGATATTACGGAAGACCTGCGT-3' 
23 5'-GTGCCCCGGAGTTAAAAGATCGCCTGGGTGAACGTGCGGCGCTG -3' 
24 5'-AGCGTAACGTGCTGCTTAACATTAAGAAATGAAACAGCGCCGCAC-3' 
25 5'-GCAGCACGTTACGCTTTCCATTACGCGCATTAAATGGTAGCGATT-3' 
26 5'-ATCATCTGCACCAACCGTCAGACGGTATAAATCGCTACCATTTAA-3' 
27 5'-GTTGGTGCAGATGATGATACGGGTGCCCGTCCGGATGCATTAGCA-3' 
28 5'-cgtcctTGATCAGTGCTAATGCATCCGGACGG-3' 
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Table IV.3.  Molecular weights and ε280 for enzymes under investigation.   
 
Protein Molecular weight Extinction coefficient
RebC-NHis 59,834.6 g/mol 64,190 cm-1M-1 
StaC-CHis 61,021.6 g/mol 74,160 cm-1M-1 
AtmC-NHis 60,703.8 g/mol 70,275 cm-1M-1 
InkE-NHis 59,069.7 g/mol 77,140 cm-1M-1 
StaC-10x-NHis 61,911.5 g/mol 74,160 cm-1M-1 
 
 
 
 
Table IV.4.  Binding constants for FAD of StaC and its homologues, as determined by 
isothermal titration calorimetry. 
 
Protein Binding Constant for FAD
StaC 17,300 ± 1,200 nM 
InkE 90,000 ± 14,000 nM 
RebC 25 ± 11 nM 
AtmC 77 ± 9 nM 
StaC-10x 470 ± 30 nM 
 
 178
Table IV.5.  List of all amino acid targeted in constructing StaC-10x and residues that 
have one identity in RebC and AtmC, but have a different identity (in the same position 
in the alignment) in StaC and InkE.   
Position  
in 
RebC 
Position 
in StaC 
Amino  
acid in 
RebC/ 
AtmC 
Amino 
acid in 
StaC/ 
InkE 
Possible functions for amino 
acid in RebC based on crystal 
structure 
Altered in 
generating 
StaC-10x? 
36 37 Glu Asp Binding to ribose hydroxyls of 
FAD 
Yes 
37 38 Gln/Ala  Ala Stacks against adenine ring Yes 
38 39 Thr/Ser Gly Near FAD Yes 
46 47 Arg Lys Stacks against isoalloxazine ring 
in one conformation; interaction 
with phosphate oxygens in 
second conformation 
Yes 
48 49 Gly Ser On loop near FAD Yes 
100 101 Asp Ala Surface residue distant from 
active site 
No 
105 106 Pro Phe On loop distant from active site No 
117 118 Gln Ala Conserved Gln in flavin 
hydroxylases; hydrogen-bond 
network through water to 
phosphate on FAD 
Yes 
121 122 Ala Asn On helix distant from FAD No 
123 124 Leu Val On helix distant from FAD No 
216 221 Phe Val Hydrophobic residue in active 
site adjacent to 7-carboxy-K252c 
Yes 
231 236 Ala Ser Last residue in β-strand at outer 
edge of 7-carboxy-K252c 
binding site 
Yes 
239 244 Arg Asn Hydrogen bonding to 
isoalloxazine ring in one 
conformation; interaction with 
carboxylate oxygen of 7-
carboxy-K252c in other 
conformation 
Yes 
241 246 Thr Val In active site; role unknown Yes 
286 291 Phe Tyr Far from FAD or 7-carboxy-
K252c binding site 
No 
416 421 Glu Asp In third domain distant from 
active site 
No 
437 446 Pro Ala In third domain distant from 
active site 
No 
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Table IV.6.  Relative rates of arcyriaflavin A production.   
 
 
Proteins assayed Rate relative to 
StaP alone 
StaP / StaC 0.68 ± 0.01 
StaP / RebC 10.4 ± 0.7 
StaP / StaC-10x 1.68  ± 0.05 
 
 
 
Table IV.7.  Relative rates of K252c production. 
 
 
Proteins assayed Rate relative to 
StaP alone 
StaP / StaC 1.67  ± 0.03 
StaP / RebC 0.9  ± 0.1 
StaP / StaC-10x 1.04  ± 0.09 
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Table IV.8.  Pair-wise sequence alignment of StaC to RebC, with comments indicating 
the possible relevance of the amino acid in differentiating StaC from RebC.   
 
Position 
in 
RebC 
Amino 
acid in 
RebC 
Amino 
acid in 
StaC 
 
Position 
in StaC 
 
Possible Relevance based on RebC 
structure? 
1 M T 2 not in density 
2 N H 3 not in density 
3 A S 4 unlikely; near disordered N-terminus 
4 P G 5 unlikely; near disordered N-terminus 
5 I E 6 unlikely; far from active site 
6 E R 7 unlikely; surface residue 
26 A R 27 unlikely; on α-helix far from FAD 
binding site 
27 H Y 28 unlikely; on surface 
29 Q G 30 unlikely; on surface 
30 V I 31 unlikely; highly conservative change 
31 G D 32 possibly; in controlling 2° structure 
32 H C 33 possibly; some H-bond interactions 
36 E D 37 yes; targeted 
37 Q A 38 yes; targeted 
38 T G 39 yes; targeted 
42 I V 43 unlikely; extremely conservative 
change 
43 T R 44 unlikely; surface residue 
46 R K 47 yes; targeted 
48 G S 49 yes; targeted 
63 V A 64 possibly; in hydrophobic patch far 
from active site 
65 K D 66 unlikely; surface residue 
66 Q A 67 possibly; H-bond ineractions via side 
chain 
69 T N 70 unlikely; surface residue 
74 G A 75 possibly; in controlling 2° structure 
80 A I 81 possibly; in hydrophobic patch in 2nd 
sphere from substrate binding pocket 
85 R K 86 unlikely; surface residue 
91 V I 92 no; conservative change 
94 I Y 95 possibly; in hydrophobic patch in 
2nd/3rd sphere from substrate binding 
pocket 
95 P R 96 possibly; in controlling 2° structure 
96 L R 97 possibly; large change in identity and 
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not at surface 
100 D A 101 possibly; surface residue but no 
charge on alanine 
101 T N 102 unlikely; surface residue 
103 A P 104 possibly; in controlling 2° structure 
104 T A 105 possibly; at surface but alanine is 
non-polar 
105 P F 106 possibly; in controlling 2° structure 
106 E V 107 possibly; on surface but valine is 
uncharged 
113 A Q 114 possibly; in 2nd/3rd sphere from 
substrate but new side-chain might 
interact with other residues 
117 Q A 118 yes; targeted 
121 A N 122 possibly; outside of active site but 
new side-chain might interact with 
other residues 
123 L V 124 no; conservative change 
125 A I 126 unlikely; on α-helix far from FAD 
binding site 
130 E V 131 possibly; on surface but change to 
non-charged side-chain 
131 R H 132 unlikely; on surface 
  P 133 unlikely; likely to be a loop region 
  D 134 unlikely; likely to be a loop region 
  G 135 unlikely; likely to be a loop region 
  P 136 unlikely; likely to be a loop region 
133 R L 138 possibly; on surface but change to 
non-charged side-chain 
134 T L 139 possibly; not far from FAD 
135 R S 140 possibly; on surface but not far from 
FAD 
136 S T 141 possibly; not far from FAD 
137 R T 142 possibly; on surface but not far from 
FAD 
138 L V 143 possibly; conservative change but 
close to FAD 
140 S G 145 possibly; might control 2° structure 
141 F V 146 unlikely; in hydrophobic patch not 
near active site 
142 E V 147 possibly; on surface but change to 
non-charged side-chain 
144 R T 149 possibly; on surface but change to 
non-charged side-chain 
149 R E 154 unlikely; on surface and both are 
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charged side-chains 
152 I L 157 no; conservative change 
155 L H 160 possibly; near surface but not far 
from FAD 
156 R A 161 possibly; on surface but change to 
non-charged side-chain 
159 A T 164 unlikely; on surface and far from 
FAD 
161 R G 166 possibly; in controlling 2° structure 
162 A T 167 unlikely; near surface 
164 H R 169 unlikely; near surface 
167 Y F 172 unclear; near surface but also close to 
hydrophobic patch 
178 T V 183 unlikely; in hydrophobic patch far 
from FAD 
180 K R 185 unlikely; near surface 
182 L C 187 perhaps; in hydrophobic patch with a 
change to a polar side-chain 
185 D E 190 unlikely; near surface 
188 P A 193 possibly; in controlling 2° structure 
206 R K 211 unlikely; near surface 
207 S D 212 unlikely; near surface 
208 L R 213 possibly; near surface but change to a 
charged side-chain 
216 F V 221 yes; targeted 
217 F H 222 possibly; pointed away from active 
site but in a hydrophobic patch 
224 S T 229 unlikely; near surface 
231 A S 236 yes; targeted 
236 G D 241 possibly; in controlling 2° structure 
239 R N 244 yes; targeted 
241 T V 246 yes; targeted 
244 V A 249 unlikely; far from active site 
247 A D 252 (not in density) 
248 S T 253 (not in density) 
249 K G 254 (not in density) 
250 S A 255 (not in density) 
251 T R 256 unclear; near disordered loop 
252 M P 257 unclear; near disordered loop 
254 S A 259 unlikely; far from active site 
255 F L 260 unlikely; far from active site 
256 E A 261 unclear; on surface but change to 
non-charged side-chain 
258 V I 263 no; conservative change 
259 R K 264 unlikely; on surface 
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260 R D 265 unlikely; on surface 
262 V L 267 no; conservative change 
264 F L 269 unlikely; far from active site 
267 E P 272 possibly; on surface but drastic 
change in side-chain 
268 I V 273 no; conservative change 
270 V L 275 no; conservative change 
272 S G 277 possibly; in controlling 2° structure 
275 E A 280 possibly; near surface but change to 
non-charged side-chain 
277 H R 282 unlikely; on surface 
285 S R 290 unlikely; on surface 
286 F Y 291 possibly; change in side chain 
identity may foster H-bond formation 
287 S R 292 unclear; far from active side but large 
change in side-chain identity 
291 V I 296 no; conservative change 
294 T A 299 unclear; not far from active site 
309 M L 314 possibly; close to bound FAD  
315 S D 320 possibly; internal residue and large 
side-chain change but far from active 
site 
328 R D 333 unlikely; surface residue 
333 P R 338 possibly; in controlling 2° structure 
334 G H 339 possibly; in controlling 2° structure 
337 A D 342 unlikely; near surface  
340 E D 345 unlikely; near surface 
341 E S 346 unlikely; near surface though change 
to non-charged residue 
346 V I 351 no; conservative change 
348 I E 353 possibly; near surface but change to a 
charged side-chain 
349 T E 354 possibly; near surface but change to a 
charged side-chain 
352 E N 357 possibly; near surface but change to a 
non-charged side-chain 
355 N H 360 possibly; on ‘melting’ helix 
356 V D 361 possibly; on ‘melting’ helix 
363 D K 368 unlikely; on surface of ‘melting’ 
helix but conservative change 
366 L V 371 no; conservative change 
369 G E 374 possibly; in controlling 2° structure 
370 L I 375 no; conservative change 
372 D L 377 possibly; on surface but change to 
non-charged side-chain 
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376 R E 381 unlikely; on surface 
380 I A 385 unlikely; distant from active site 
384 V M 389 unlikely; distant from active site 
386 E R 391 unlikely; on surface 
387 K R 392 unlikely; on surface 
390 R N 395 unlikely; on surface 
401 G Q 406 unlikely; in third domain 
406 H L 411 unlikely; in third domain 
407 T R 412 unlikely; in third domain 
412 I A 417 unlikely; in third domain 
413 V I 418 unlikely; in third domain 
414 C V 419 unlikely; in third domain 
415 G D 420 unlikely; in third domain 
416 E D 421 unlikely; in third domain 
418 E D 423 unlikely; in third domain 
419 T V 424 unlikely; in third domain 
420 E P 425 unlikely; in third domain 
422 A R 427 unlikely; in third domain 
423 T Q 428 unlikely; in third domain 
  Q 430 unlikely; in third domain 
  P 431 unlikely; in third domain 
  D 432 unlikely; in third domain 
  A 433 unlikely; in third domain 
429 S G 438 unlikely; in third domain 
430 A S 439 unlikely; in third domain 
431 R E 440 unlikely; in third domain 
434 A Y 443 unlikely; in third domain 
437 P A 446 unlikely; in third domain 
441 L W 450 unlikely; in third domain 
442 T D 451 unlikely; in third domain 
443 P S 452 unlikely; in third domain 
459 S R 468 unlikely; in third domain 
461 G A 470 unlikely; in third domain 
462 T D 471 unlikely; in third domain 
463 T H 472 unlikely; in third domain 
466 V L 475 unlikely; in third domain 
467 E P 476 unlikely; in third domain 
469 V I 478 unlikely; in third domain 
470 T E 479 unlikely; in third domain 
475 D E 484 unlikely; in third domain 
477 H G 486 unlikely; in third domain 
481 E T 490 unlikely; in third domain 
482 T V 491 unlikely; in third domain 
483 V H 492 unlikely; in third domain 
484 T Q 493 unlikely; in third domain 
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485 C G 494 unlikely; in third domain 
487 A D 496 unlikely; in third domain 
488 P T 497 unlikely; in third domain 
491 H A 500 unlikely; in third domain 
492 A K 501 unlikely; in third domain 
495 E A 504 unlikely; in third domain 
497 A S 506 unlikely; in third domain 
498 H F 507 unlikely; in third domain 
513 H D 522 unlikely; in third domain 
516 A G 525 unlikely; in third domain 
517 E D 526 unlikely; in third domain 
518 L P 527 unlikely; in third domain 
519 G T 528 unlikely; in third domain 
520 G A 529 unlikely; in third domain 
524 K T 533 unlikely; in third domain 
528 A E 537 unlikely; in third domain 
  A 539 unlikely; in third domain 
  P 540 unlikely; in third domain 
  R 541 unlikely; in third domain 
  E 542 unlikely; in third domain 
  P 543 unlikely; in third domain 
  R 544 unlikely; in third domain 
  G 545 unlikely; in third domain 
  K 546 unlikely; in third domain 
  L 547 unlikely; in third domain 
  A 548 unlikely; in third domain 
  A 549 unlikely; in third domain 
  A 550 unlikely; in third domain 
  L 551 unlikely; in third domain 
  E 552 unlikely; in third domain 
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Figure IV.1.  Natural products rebeccamycin, AT2433-A1, staurosporine, and K252a 
with standard numbering. 
 
H
N
NN
H
OO
ClCl
O
OH
OCH3
HO
OH
OHN
HO
N
NN
H
OO
ClO
H3CO
OH
CH3
O
HO
H
N
NN
O
O
NHCH3
H3C
H3CO
NN
H
N O
O
H3C
H3C
O OCH3
7
7
7
7
6
6
6
6
5
5
5
5
4
4
4
4
3
3
3
3
2 2
2
2
1
1 113 13
13
1312
12
1211
1010
10
10
9
8
11 12
8
8
8
9
9
9
11
11
1
Rebeccamycin
AT2433-A1
Staurosporine
K252a
 
 187
Figure IV.2.  Reaction scheme for StaP/StaC mediated production of K252c from 
chromopyrrolic acid, and reaction scheme for StaP/RebC mediated production of 
arcyriaflavin A from chromopyrrolic acid.   
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Figure IV.3.  A sequence alignment between the highly homologous enzymes AtmC, 
RebC, StaC, and InkE was carried out using ClustalW.  High conservation is seen across 
all four proteins.  A star (*) represents residues conserved across all four proteins, and 
double dots or single dots represents similar (not identical) residues across all four 
proteins, according to the conventions of ClustalW.  To identify amino acids that may be 
responsible for the functional differences seen between the two pairs of enzymes (AtmC 
and RebC; StaC and InkE), the crystal structure of RebC in complex with FAD and 7-
carboxy-K252c (PDB ID 2R0G) was analyzed.  Residues where any atom is within 4 Å 
of FAD are highlighted in pink, residues where any atom is within 4 Å of 7-carboxy-
K252c are highlighted in turquoise, and residues where any atom is within 4 Å of both 
FAD and 7-carboxy-K252c are highlighted in yellow.  Green arrows indicate amino acids 
where the aligned residues are identical between StaC and InkE but distinct from the 
identical residues of RebC and AtmC.  Note that some of these residues are not within 4 
Å of either FAD or 7-carboxy-K252c. 
 
         ↓         ↓ ↓ 
AtmC            -MTTAYETDVLVIGGGPVGMALVLDLKYRGVGCQLIEASDGSVSHPRVGSIGPRSMELFR 59 
RebC            -MNAPIETDVLILGGGPVGMALALDLAHRQVGHLVVEQTDGTITHPRVGTIGPRSMELFR 59 
StaC            MTHSGERTDVLIVGGGPVGMALALDLRYRGIDCLVVDAGDGTVRHPKVSTIGPRSMELFR 60 
InkE            -MTRSEETDVLIVGGGPVGLALSLDLTHRGVRHIVIDAGDGVVRHPKVSTVGPRSMEHFR 59 
                      .****::******:** *** :* :   :::  ** : **:*.::****** ** 
 
             ↓     ↓       ↓ 
AtmC            RWGIADRIRAAGWPGDHSLDTAWVTQVGGHEIHRLRVGTADTRPLPPYTPEPEQVCPQHW 119 
RebC            RWGVAKQIRTAGWPGDHPLDAAWVTRVGGHEVYRIPLGTADTRATPEHTPEPDAICPQHW 119 
StaC            RWGAADAIRNAGWPADHPLDIAWVTKVGGHEIYRYRRGTAANRPAFVHTPEPDQICPAHW 120 
InkE            RWGVAGRVRDAGWPPGHPLDIAWVTRVGEYEIHRFERGTAAARPVFRHTPEPDQVCPAHL 119 
                *** *  :* **** .*.** ****:** :*::*   ***  *.   :****: :** *  
 
                 ↓ ↓ 
AtmC            LAPLLLEEARTHPGGVVRTRCRLDGFTQHDDHVEATVTDLAEGRELRIRARYMVAVDGAS 179 
RebC            LAPLLAEAVGER----LRTRSRLDSFEQRDDHVRATITDLRTGATRAVHARYLVACDGAS 175 
StaC            LNPVLIEAVGVHPDGPLLLSTTVDGVVQTDDHVEATLTDHATGTTGTVRARFLVACDGAS 180 
InkE            LNPVLAGAVGRP----LRYLHRLEHFEQDAGCVRATIS--SNGEESVVWARYLVACDGSS 173 
                * *:*   .       :     :: . *  . *.**::    *    : **::** **:* 
 
                                                           ↓              ↓ 
AtmC            SPVRKACGIPSSARYDVMTFRNILFRAPELRARLGQR---EAMFYFLMLSNQLRFPVRAL 236 
RebC            SPTRKALGIDAPPRHRTQVFRNILFRAPELRSLLGER---AALFFFLMLSSSLRFPLRAL 232 
StaC            SPVRRACGIEAPARHRTQVFRNILFRAPELKDRLGER---AALVHFLMLSSTLRFPLRSL 237 
InkE            SVVRKALGIDSPARHEAQVFRNVLFRAPGLPARLAERGHRSALVYYLMHSWSLRYPMRSL 233 
                * .*:* ** :..*: . .***:***** *   *.:*    *:..:** *  **:*:*:* 
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     ↓ ↓                ↓                           ↓                
AtmC            DGRSLYRLTVSGTDA-----DARDLVTMALAFETPVEILSDAVWHLTHRVAERFRQDRIF 291 
RebC            DGRGLYRLTVGVDDASKSTMDSFELVRRAVAFDTEIEVLSDSEWHLTHRVADSFSAGRVF 292 
StaC            NGSDLYNLVVGADDDTGARPDALALIKDALALDTPVELLGDSAWRLTHRVADRYRAGRIF 297 
InkE            DGRGLYNMVVDGRSDQ----GALELIRSAIAFDVPVELVADGLWHLTHRVADRYRAGRVF 289 
                :* .**.:.*.  .      .:  *:  *:*::. :*::.*. *:******: :  .*:* 
 
                   
AtmC            LLGDAAHTLSPSGGFGMNTGICAAADLGWKLAAELDGWAGRGLLDTYEEERRPVAVESLE 351 
RebC            LTGDAAHTLSPSGGFGMNTGIGSAADLGWKLAATLRGWAGPGLLATYEEERRPVAITSLE 352 
StaC            LAGDAAHTLSPSGGFGLNTGIGDAADLGWKLAATLDGWAGRHLLDTYDSERRPIAEESLN 357 
InkE            LAGDAAHTLSPSGGFGMNTGIGDAADLGWKLAAAVAGWAGDGLLGTYETERRPVAIAGLD 349 
                * **************:****  ********** : ****  ** **: ****:*  .*: 
 
 
AtmC            EANLNLRRTMGRPVPPELHLDTPAGAEARARMARQLALSDVAREFDAPGIHFGFTYRSSL 411 
RebC            EANVNLRRTMDRELPPGLHDDGPRGERIRAAVAEKLERSGARREFDAPGIHFGHTYRSSI 412 
StaC            EAHDNLRRTMKREVPPEIHLDGPEGERARAVMARRLENSGARREFDAPQIHFGLRYRSSA 417 
InkE            AAEANLRRTVDRDLPAELAASTEKGARLRAEMAERLVNSGAREEFDAPRVHFGFHYRSPI 409 
                 *. *****: * :*. :  .   * . ** :*.:*  *.. .***** :***  ***.  
 
  
                   ↓                 ↓       ↓ 
AtmC            IVAEPEQAPVDPRK----WQQSATPGARAPHAWLSPGASTLDLFGRGFTLLTFAEGAVGL 467 
RebC            VCGEPE-TEVATGG----WRPSARPGARAPHAWLTPTTSTLDLFGRGFVLLSFGT----T 463 
StaC            IVDDPD-VPVRQGQPDADWRPGSEPGYRAAHAWWDSTTSTLDLFGRGFVLLRFAD----H 472 
InkE            VVSDGP---AEQGP---RWRPGSDPGCRAAHAWVRPGVSTLDLFGDGFTLLRFAD----S 459 
                :  :     .        *: .: ** **.***  . .******* **.** *.       
 
 
AtmC            EGVAGLERAFAERGVPLTTVRCDDRAVADLYEHPFVLVRPDGHVAWRAEAPPDDPGALAD 527 
RebC            DGVEAVTRAFADRHVPLETVTCHAPEIHALYERAHVLVRPDGHVAWRGDHLPAELGGLVD 523 
StaC            DGLPAIERAFAERGVPLTVHQGHDTEIAKLYARSFVLVRPDGHVAWRGDDLPGDPTALVD 532 
InkE            PALSAFVTAFTERGVPFRSVLVGDPDTAALYGHRFVLVRPDGHVAWRGDDLEAAPANLAD 519 
                 .: ..  **::* **:            ** : .************.:        *.* 
 
 
AtmC            LVRGGRR------ 534 
RebC            KVRGAA------- 529 
StaC            TVRGEAAPREPRG 545 
InkE            LVRGAG------- 525 
                 ***          
         
 
 190
Figure IV.4.  Construction of the StaC-10x gene.  A.  Primer-based construction of the 
N-terminus of the StaC mutant.  Encoded amino acids are listed below the DNA 
sequence, with altered amino acids and their corresponding codons highlighted in yellow.  
DNA sequences in bold represent restriction digestion sites, and DNA sequences in 
italics represent overhangs.  B.  PCR gives rise to a fragment encoding ten modified 
amino acids.  C.  A three-part ligation incorporates the fragment into the pET28a-StaC 
vector, replacing the region encoding the N-terminus of the StaC protein.   
 
A. 
 
1 --->                                             3 --->            
ggagagCATATGACCCACTCTGGCGAACGTACGGATGTT            ggtggtccagtcggtatg 
                  CGCTTGCATGCCTACAAAATTAGCAACCACCACCAGGTCAGCCAT   
                                                        <---  2   
          M  T  H  S  G  E  R  T  D  V  L  I  V  G  G  G  P  V  G  M  
  
 
  
                                5 --->                      
gcactggcgttagacttacgctaccgc     TGATTGTTTAGTTGTCGAACAGACGGAT 
   gaccgcaatctgaatgcgatggcgccgtaactaacaaatcaacag       
                                         <---  4       
A  L  A  L  D  L  R  Y  R  G  I  D  C  L  V  V  E  Q  T  D  
  
 
  
                              7 --->                        
GGCACGGTCCGTCATCC             attggtccgcgttctatggagctgttccgc 
  GTGCCAGGCAGTAGGTGCACAACCGTGGTAACCAGGCGCAAGATA              
                                        <---  6              
 G  T  V  R  H  P  R  V  G  T  I  G  P  R  S  M  E  L  F  R  
  
 
  
                                  9 --->                      
 cgttggggtgcagca                  GGTTGGCCAGCGGATCACCCATTAGAT 
  caaccccacgtcgtctgcgttaggcattgcggccaaccggtcgcc               
                                        <---  8               
  R  W  G  A  A  D  A  I  R  N  A  G  W  P  A  D  H  P  L  D  
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                          11 --->                            
 ATTGCGTGGGTGACCAAG        tcatgagatctatcgttatcgtcgcggtacggca 
    CGCACCCACTGGTTCCAGCCGCCAGTACTCTAGATAGCAATAGCA        ccgt 
                                          <--- 10             
  I  A  W  V  T  K  V  G  G  H  E  I  Y  R  Y  R  R  G  T  A  
  
  
  
                          13 --->                            
gcgaatcgtcc               CCCGGAACCAGACCAAATCTGTCCGCAACACTGG 
cgcttagcaggtcgcaaacaggtgtggggccttggtctggt              TGACC 
                                  <--- 12                    
 A  N  R  P  A  F  V  H  T  P  E  P  D  Q  I  C  P  Q  H  W  
  
 
  
                        15 --->                              
TTAAACCCAGT             gtgggcgtgcacccagacggcccactgttattatct 
AATTTGGGTCACGACTAACTCCGCCACCCGCACGTGGGTC       tgacaataataga 
                                 <--- 14                        
 L  N  P  V  L  I  E  A  V  G  V  H  P  D  G  P  L  L  L  S  
  
    
  
                 17 --->                                     
acgaccgtt        CGTCCAAACCGACGACCATGTCGAGGCGACGCTGACCGATCAC 
tgctggcaactgccgcagcaggtttggctgct               CGACTGGCTAGTG 
                         <--- 16                             
 T  T  V  D  G  V  V  Q  T  D  D  H  V  E  A  T  L  T  D  H  
  
 
  
                    19 --->                                  
GC                  cgtgcgtgcccgctttctggttgcctgcgacggcgcaagc 
CGGTGGCCATGGTGGCCGTGGCACGCACGGGC                   ccgcgttcg 
                         <--- 18                             
 A  T  G  T  T  G  T  V  R  A  R  F  L  V  A  C  D  G  A  S  
  
 
  
                   21 --->                                   
tctcc              GTGGTATTGAAGCCCCAGCACGCCATCGCACGCAGGTCTTC 
agaggccaagcagcacggacaccataacttcggggt            TGCGTCCAGAAG 
                             <--- 20                         
 S  P  V  R  R  A  C  G  I  E  A  P  A  R  H  R  T  Q  V  F  
  
 
  
                23 --->                                      
CGTA            gtgccccggagttaaaagatcgcctgggtgaacgtgcggcgctg 
GCATTATAGAATAAGGCACGGGGCCTCAATTTT                cacgccgcgac 
                          <--- 22                            
 R  N  I  L  F  R  A  P  E  L  K  D  R  L  G  E  R  A  A  L  
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    25 --->                                   
                   GCAGCACGTTACGCTTTCCATTACGCGCATTAAATGGTAGC 
aaagtaaagaattacaattcgtcgtgcaatgcga              AATTTACCATCG 
                           <--- 24                           
 F  H  F  L  M  L  S  S  T  L  R  F  P  L  R  A  L  N  G  S  
  
 
  
                  27 --->                                        
GATT              gttggtgcagatgatgatacgggtgcccgtccggatgcatta 
CTAAATATGGCAGACTGCCAACCACGTCTACTA           ggcaggcctacgtaat 
                          <--- 26                           <--- 
 D  L  Y  R  L  T  V  G  A  D  D  D  T  G  A  R  P  D  A  L  
  
     |        |         |         |         |         |         | 
  
         
gca    
cgtgACTAGTtcctgc 
        < --- 28 
 A  
 
 
 
B.   
 
PCR
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Figure IV.5.  Isothermal titration calorimetry data for FAD binding to StaC and 
homologues.  A.  ITC trace for StaC.  B.  ITC trace for RebC.  C.  ITC trace for InkE.  D. 
ITC trace for AtmC.  E.  ITC trace for StaC-10x. 
 
 
A. 
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Figure IV.6.  Residues from RebC installed in StaC-10x.  A.  A stretch of three 
residues from RebC – Glu36, Gln37, and Thr38 – were installed in StaC-10x, 
replacing the StaC residues Asp37, Ala38, and Gly39.  These residues may 
modulate binding of the adenosine portion of FAD.  These residues are shown in 
the substrate-free structure of RebC, with their orientation unchanged in the 
structure with bound 7-carboxy-K252c.  B.  Gln117 in RebC may interact with a 
phosphate on the FAD via a water molecule.  This residue was installed in StaC-
10x, replacing Ala118.  Shown is Gln117 in the substrate-free structure of RebC; the 
orientation of both water and Gln117 is unchanged in the structure of RebC with 
bound 7-carboxy-K252c.  C.  Arg46 in RebC binds on the si face of the FAD in 
the substrate-free structure.  Two residues away is Gly48 (shown in pink).  The 
corresponding residues in StaC are Lys47 and Ser49, which were replaced by Arg 
and Gly, respectively, in StaC-10x.  Also shown is Trp276, which is unchanged in 
StaC, but is shown because it stacks on the re face of the FAD.  D.  As in C, but 
in the structure of RebC with a bound tautomer of 7-carboxy-K252c.  Arg46 now 
hydrogen bonds with a phosphate on the FAD.  E.  Residues Phe216, Ala231, 
Arg239, and Thr241 in RebC line the active site pocket, however, only Arg239 
directly interacts with FAD, via a hydrogen bond with a carbonyl oxygen on the 
isoalloxazine ring.  These residues were installed in StaC-10x, replacing Val221, 
Ser236, Asn244, and Val246, respectively.  Shown are the orientations of the RebC 
residues in the substrate-free structure, with Ala231 shown in pink.  F.  As in E, but 
in the structure of RebC with a bound tautomer of 7-carboxy-K252c.  Arg239 now 
hydrogen bonds with the bound molecule in the active site.   
 199
Figure IV.6 
 
 
R46 
R46 
G48 
G48 
W276 W276 
FAD FAD 
7-COOH- 
K252c 
R239 R239 
T241 
T241 
A231 A231 F216 F216 
7-COOH- 
K252c 
FAD FAD 
C               D 
E             F 
Q37 
E36 T38 
Q117 
A              B 
 200
  
 
 201
Chapter V:   
The violacein biosynthetic enzyme VioE shares a fold with lipoprotein transporter 
proteins 
 
V.A.  Summary 
 VioE, an unusual enzyme with no characterized homologues, plays a key role in 
the biosynthesis of violacein, a purple pigment with antibacterial and cytotoxic 
properties.  Without bound cofactors or metals, VioE, from the bacterium 
Chromobacterium violaceum, mediates a 1,2 shift of an indole ring and oxidative 
chemistry to generate prodeoxyviolacein, a precursor to violacein.  Our 1.21 Å resolution 
structure of VioE shows that the enzyme shares a core fold previously described for 
lipoprotein transporter proteins LolA and LolB.  For both LolB and VioE, a bound 
polyethylene glycol molecule suggests the location of the protein’s binding and/or active 
site.  Mutations of residues near the bound polyethylene glycol molecule in VioE have 
identified the active site and five residues important for binding or catalysis.  This 
structural and mutagenesis study suggests that VioE acts as a catalytic chaperone, using a 
fold previously associated with lipoprotein transporters to catalyze the production of its 
prodeoxyviolacein product.   
 
Note:  This chapter was previously published as:  Ryan K.S., Balibar C.J., Turo K.E., Walsh C.T., Drennan 
C.L. The violacein biosynthetic enzyme VioE shares a fold with lipoprotein transporter proteins. J. Biol. 
Chem. 283: 6467-6475 (2008).1  Mutant proteins were prepared and assayed by Carl J. Balibar in the 
laboratory of Prof. Christopher T. Walsh at Harvard Medical School, and Kaitlyn Turo performed circular 
dichroism experiments on these mutants under my supervision.   
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V.B.  Introduction 
 Violacein 5 (Fig. V.1) is a purple pigment that gives tropical bacterium 
Chromobacterium violaceum its characteristic coloring.2-6  Violacein 5 has potential 
medical applications as an anti-bacterial,7-9 anti-tryptanocidal,9-11 anti-ulcerogenic,12 and 
anti-cancer drug.9,13-18  The molecule, synthesized from L-tryptophan and molecular 
oxygen,19-22 was originally thought to be synthesized by the action of just four enzymes 
VioABCD,23,24 but an additional open reading frame,25 also in the operon, was shown to 
encode the enzyme VioE.26,27  A 22-kDa protein with few homologues based on sequence 
analysis, VioE is required for formation of prodeoxyviolacein 3, a precursor to violacein 
5.26-28  Without the presence of VioE, a shunt product, chromopyrrolic acid 4, is 
produced, rather than 3.26-28  VioE is therefore required for the 1,2 shift of the indole ring 
and subsequent chemistry that gives violacein 5 its distinctive architecture.  Surprisingly, 
despite carrying out this chemistry, VioE lacks any bound cofactors or metal ions.27   
 Using genetic and biochemical analysis, an enzymatic pathway for violacein 5 
production has been determined (Fig. V.1) and intermediates have been identified,27 with 
the major exception that the substrate of VioE (product of VioB) is still unknown.  It has, 
however, been established that the product of VioB is the substrate for VioE:  when VioA 
and VioB are incubated in a reaction mixture with the VioA substrate L-tryptophan for 10 
min, passed through a 10 kDa filter (removing VioA and VioB), and then incubated with 
VioE, prodeoxyviolacein 3 is produced.27  By contrast, in the absence of VioE, no 
prodeoxyviolacein 3 is made.27  This result reveals three things: first, the VioB product is 
a small molecule that can pass through a 10 kDa filter; second, no interaction between 
VioB and VioE is necessary for product formation; and third, VioE is a catalyst.  The 
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small molecule passed through the filter has not yet been isolated and is known to convert 
spontaneously to chromopyrrolic acid 4 when VioE is not present; chromopyrrolic acid 4 
itself is not a substrate for VioE.26,27  Homologues of VioB are RebD (36% identity), 
StaD (38% identity), InkD (34% identity), and AtmD (38% identity) from the 
rebeccamycin, staurosporine, K252a, and AT2433-A1 biosynthetic pathways, 
respectively.29-32  Each of these homologues produce chromopyrrolic acid 4 scaffolds as 
on-pathway products to generate indolocarbazole natural products and each lacks a VioE 
homologue in its biosynthetic cluster.29-32  Yet, in vitro tests of RebD from the 
rebeccamycin biosynthetic pathway show that co-incubation of a reaction mixture of 
RebD and IPA imine 1 with VioE results in the production of prodeoxyviolacein 3, rather 
than chromopyrrolic acid 4.27  Thus, the presence of the enzyme VioE re-routes toward a 
violacein biosynthetic pathway and away from the related indolocarbazole biosynthetic 
pathways.   
 To characterize VioE, we solved its crystal structure to 1.21 Å resolution.  The 
structure, which confirms that VioE lacks bound cofactors or metals, reveals VioE’s 
similarity to the core structure of the lipoprotein carrier proteins LolA and LolB.33  
Further, VioE resembles LolB in its binding of a PEG molecule in what appears to be the 
active site.  To investigate whether the PEG molecule indeed identified the active site of 
VioE, we carried out site-directed mutagenesis on each of nine residues near the bound 
PEG molecule and further along the putative active site.  Five of the altered proteins 
show significantly reduced production of prodeoxyviolacein 3 compared to wild-type 
VioE.  This work suggests that the fold of a lipoprotein carrier protein has been co-opted 
to a catalytic function, enabling VioE to bind a chiefly hydrophobic molecule in a 
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hydrophobic cavity and to catalyze a 1,2 shift reaction and oxidative chemistry, 
producing prodeoxyviolacein 3, rather than the unshifted shunt product chromopyrrolic 
acid 4.   
 
V.C.  Materials and Methods 
Protein preparation and crystallization   
 Eight L of LB medium containing 30 mg/L of kanamycin and 34 mg/L of 
chloramphenicol were inoculated with a starting culture of RosettaTM 2(DE3)pLysS 
(Novagen) transformed with pET24b-VioE.27  Cultures were grown at 21°C to an A600 of 
0.6 and then induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and 
grown for an additional 17 h at 21°C at 250 rpm.  Cell pellets (40g) were frozen at -20°C 
overnight, then sonicated with lysozyme in 300 mM NaCl, 25 mM Tris-HCl, 5 mM 
imidazole, pH 8.0, and then centrifuged at 50,000 x g to pellet insoluble material.  The 
supernatant was incubated with nickel (II) loaded Chelating SepharaseTM Fast Flow (GE 
Biosciences) for 40 min at 4°C.  Unbound material was removed, and then the column 
was washed with 25 column volumes of 300 mM NaCl, 25 mM Tris-HCl, 20 mM 
imidazole, pH 8.0.  Bound protein was then eluted with 300 mM NaCl, 25 mM Tris-HCl, 
200 mM imidazole, pH 8.0.  This sample was then loaded onto a HiLoad SuperdexTM 75 
prep grade column (Amersham) pre-equilibrated with 50 mM NaCl, 20 mM Tris-HCl pH 
8.0.  Fractions containing VioE were pooled and concentrated to 17 mg/mL in 10% 
glycerol, 50 mM NaCl, 20 mM Tris-HCl pH 8.0.  Protein was then frozen in liquid 
nitrogen and stored at -80°C.  VioE was crystallized at room temperature from this 
sample using the hanging drop vapor diffusion method by incubating 1.5 μL of protein 
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with 1.5 μL of a precipitant solution (composed of 25% (v/v) PEG-400, 20% (w/v) PEG-
3350, 0.1 M MgCl2, and 0.1 M Tris-HCl pH 8.5) over a 0.5 mL precipitant well solution.  
Crystals appeared overnight and grew larger over subsequent days.  Native crystals were 
flash frozen in liquid nitrogen, without additional cryoprotection, for X-ray data 
collection. 
 Selenomethione protein was prepared by inoculating minimal media (6 g/L 
Na2HPO4, 3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl, 1 mM MgSO4, 0.4% (w/v) 
glucose, 30 mg/L kanamycin, 34 mg/L chloramphenicol) with a starting culture of 
RosettaTM 2(DE3)pLysS transformed with pET24b-VioE and growing cultures at 37°C.  
At an A600 of 0.6, the cultures were supplemented with 100 mg/L of each L-lysine, L-
threonine, and L-phenylalanine and 50 mg/L of each L-isoleucine, L-leucine, L-valine, 
and L-selenomethionine34 and grown for an additional 20 min.  Protein expression was 
then induced with 0.1 mM IPTG, and cultures were grown for an additional 20 h at 21°C 
at 250 rpm.  Selenomethionine protein was purified identically to native protein, except 
that all buffers, excluding the final storage buffer, were supplemented with 5 mM β-
mercaptoethanol.  A purified sample of the selenomethionine protein was assayed for 
incorporation of selenium using LCMS, and strong peaks were found from a 23,028 amu 
species, corresponding to the incorporation of four seleniums, with weak peaks found 
from a 23,104 amu species, corresponding to the incorporation of four oxidized 
seleniums.  A small number of crystals with defects were produced in the same condition 
as the native protein, and these were used in streak seeding experiments to obtain crystals 
appropriate for X-ray data collection.  Single selenomethionine-VioE crystals were flash 
frozen directly into liquid nitrogen for X-ray data collection. 
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Data collection and processing   
 Data were collected at the Advanced Photon Source (Argonne, IL), beamline NE-
CAT 24ID-C, with the Quantum 315 detector in a cryostream of 141.6 K.  For the native 
crystal, data were collected in two sweeps, one of 180° and one of 360°.  A 180° sweep 
was first carried out in 1° oscillation steps to obtain data to 1.8 Å resolution.  Next, a 
360° sweep was carried out in 0.5° oscillation steps to full resolution.  A small 
selenomethionine VioE crystal was used for a fluorescence scan, to obtain the appropriate 
wavelengths for anomalous dispersion data collection.  A larger selenomethionine VioE 
crystal was then used to carry out a single-wavelength anomalous dispersion data 
collection at the selenium peak wavelength of 0.9792 Å, with a 360° sweep in 0.5° 
oscillation steps.  All data were indexed and integrated in DENZO and scaled in 
SCALEPACK.35  Data processing statistics are shown in Table V.1.  Data to 1.21 Å 
resolution for the native and to 1.86 Å resolution for the selenomethionine derivative 
were used, despite the low completeness in the highest resolution bins (54.3% and 58.7%, 
respectively).  The values of other statistics in these highest resolution bins (including 
Rsym, I/σ, and redundancy) suggest that the data are of high quality to these resolutions.   
      
Structure building and refinement   
 Six selenium sites were found using SHARP;36 these include three 
selenomethionines from each of the two protein molecules in the asymmetric unit and do 
not include the N-terminal methionines, which are disordered.  The overall figure of 
merit (acentric) of data to 1.87 Å was calculated by SHARP to be 0.438.  The native and 
selenomethionine data were scaled in SHARP to generate a single file used for all initial 
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building and refinement.  2.0 Å resolution experimental maps from the SHARP output, 
solvent flattened with SOLOMON,37 were used to build manually the entire main-chain 
of the protein, with placement of most side-chains.  This model was then used in iterative 
rounds of CNS38 refinement and manual adjustment of the model in COOT39 to the full 
1.21 Å resolution of the native data, to generate a near-complete structure with placement 
of a first set of water molecules.  Iterative rounds of refinement were then continued in 
Refmac40 with manual adjustment of the model in COOT, using only native data (with 
identically flagged reflections).  Alternate conformations of side-chains, additional water 
molecules, and PEG molecules were incorporated at this stage.  Refinement was then 
carried out with incorporation of anisotropic B-factors, and, in final rounds of refinement, 
with incorporation and refinement of hydrogen atoms.  Crystallized VioE contains 199 
residues, including the C-terminal (His)6 tail with two linking residues.  In both chains A 
and B of VioE, residues 1-4 are disordered; in chain A, residues 190-199 are additionally 
disordered, and in chain B, residues 195-199 are absent.  Refinement statistics are listed 
in Table V.1. 
  
Calculation of buried surface area   
 The program AREAIMOL, from the CCP4i suite of programs,41 was used to 
calculate the accessible surface area for chain A alone, chain B alone, and the dimer, 
using a 1.4 Å probe radius.  The buried surface area was taken as the sum of the 
accessible area for chain A and chain B, minus the accessible area for the dimer.  The 
accessible area of chain A is 10,300 Å2, chain B is 10,700 Å2, and the dimer is 17,400 Å2.   
 
 208
Sedimentation velocity experiments  
 Sedimentation velocity experiments were carried out in a Beckman Coulter 
Optima XL-I analytical ultracentrifuge using a Beckman An60Ti rotor and a Beckman 
XL-A Monochrometer in the MIT Biophysical Instrumentation Facility.  Absorbance 
data were collected during a velocity sedimentation run at 20.0°C at 42,000 rpm.  Protein 
samples were prepared as for crystallization, except that VioE eluting from a nickel (II) 
loaded Chelating SepharoseTM Fast Flow (GE Biosciences) column was loaded onto a 
HiLoad SuperdexTM 75 prep grade column (Amersham) pre-equilibrated with 200 mM 
NaCl, 25 mM Tris-HCl, pH 8.0.  VioE from the peak gel filtration fraction was then 
diluted in the identical buffer to concentrations of 8.6 μM and 2.3 μM, and the samples 
were loaded into one side of a sample cell, with buffer (200 mM NaCl, 25 mM Tris-HCl, 
pH 8.0) loaded into the other side of each sample cell.  Sednterp42 was used to derive 
values based on the experimental conditions and protein sequence for the density, partial 
specific volume, and mass extinction coefficient at 280 nm.  These values were used to 
analyze the absorbance data from the sedimentation velocity experiments using 
SEDANAL.43   
 
Gel Filtration  
 The oligomeric state of purified VioE was additionally assayed via gel filtration 
using a HiLoad SuperdexTM 75 prep grade column (Amersham) pre-equilibrated with 200 
mM NaCl, 25 mM Tris-HCl, pH 8.0.  Gel filtration standards (BioRad) were used to 
calibrate this column. 
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Mutagenesis and mutant protein preparation   
 All VioE mutants were generated using splicing by overlap extension method 
(SOE)44 with the primers listed in Table V.2.  Two overlapping fragments (‘a’ and ‘b’) 
were generated from two initial PCRs, using 1 μL of miniprepped pET24b-VioE as a 
template, with 4 μM of each primer, 5% DMSO, and 2x Phusion HF master mix 
(Invitrogen).  After PCR purification using a GFX kit (GE Healthcare), the ‘a’ and ‘b’ 
fragments were mixed together and further amplified using the 5’-forward first primer 
from the ‘a’ fragment reaction and the 3’-reverse second primer from the ‘b’ fragment; all 
other components in the PCR were identical to those used in the first round of 
amplification.  All PCRs were carried out using the following cycle parameters: 98°C for 
2 min, followed by 30 cycles of 98°C for 15 s, 57°C for 30 s, and 72°C for 1.5 min, 
followed by cooling to 4°C.  The PCR products were once again purified using the GFX 
kit and then subjected to digestion with NdeI/XhoI for 3 h.  The resulting DNA was 
purified and ligated into a similarly digested pET24b vector using Quick Ligase (New 
England Biolabs).  The ligation reactions were then transformed into chemically 
competent TOP10 cells plated on LB-agar-kanamycin plates.  Resulting colonies were 
used to purify plasmid DNA, and plasmids were sequenced at the Molecular Biology 
Core Facilities of the Dana Farber Cancer Institute.  Plasmids were transformed into 
BL21(DE3) cells and protein was prepared as described previously,27 using dialysis 
rather than gel filtration to transfer protein into the final storage buffer. 
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Activity assays  
 Activity assays were carried out, as described previously,27 by incubation of L-
tryptophan (500 μM) with VioA (5 μM), VioB (5 μM), VioE (5 μM), and 50 U of 
catalase in 75 mM glycine pH 9.25.  Reactions were quenched after one h with 20% (v/v) 
DMSO and 200% (v/v) methanol, and, after removal of precipitated protein, samples 
were analyzed via HPLC, as described previously.27  Prodeoxyviolacein 3 peaks at 590 
nm were integrated with 32 Karat Software, Version 5.0, Build 1021, Beckman Coulter, 
Inc.  All activity assays were run in triplicate and compared to authentic standards of 
prodeoxyviolacein 3.  
 
Circular dichroism  
 Circular dichroism spectra of native and mutant proteins were collected on an 
Aviv Model 202 CD Spectrometer (software by Aviv, v. 3.00C) at the MIT Biophysical 
Instrumentation Facility from 190 – 250 nm with a 1 nm wavelength step, an averaging 
time of 3 s, and a settling time of 0.333 s.  Samples were processed in a 0.1 cm path 
length rectangular quartz cuvette.  All proteins, which were stored in a buffer solution 
composed of 50 mM NaCl, 20 mM Tris-HCl pH 8.4, and 10% glycerol, were diluted in 
degassed, double distilled water to 17 μM in 400 μL samples.  A buffer solution, also 
diluted in degassed, double distilled water, with a final composition of 0.2% glycerol, 1 
mM NaCl, and 0.4 mM Tris-HCl pH 8.4, was analyzed between each sample, and the 
average values over 10 buffer samples were used for background subtraction before 
generation of a final graph.      
 
 211
V.D.  Results 
Structure of VioE      
 VioE crystallizes as a dimer, with each concave side of the curved β-sheet facing 
away from the interface (Fig. V.2A) and with an average of 1800 Å2 of buried surface 
area per monomer.  The large dimeric interface of the two chains is chiefly hydrophobic 
(63% of interacting residues) with water largely excluded (only 28 ordered molecules of 
water in the interface) and with 17 hydrogen bonds that pair polar atoms with one another 
across the interface.  To investigate VioE’s oligomeric state in solution, a sedimentation 
velocity experiment was carried out at each of two concentrations (8.6 μM and 2.3 μM).  
The results of the sedimentation velocity experiment are consistent with a dimer in 
solution (Fig. V.3).  The sedimentation velocity experiments are in contrast to the result 
from preparative-scale gel filtration, which suggested that VioE eluted as a monomer, 
based on the gel filtration standards (Fig. V.4).  However, given the results of 
sedimentation velocity analysis, the large size of the dimeric interface, the predominance 
of hydrophobic residues, the general exclusion of water, and the presence of specific 
interactions distributed across much of the interface, the dimer appears to be the preferred 
oligomeric state of purified VioE.   
 In each monomer, strand 1 begins in the center of the protein, and initiates an 
anti-parallel β-sheet, building from β1 to β6 one half of the structure (Fig. V.2B).  
Between β3 and β4 is an intervening loop, which contains a four-amino acid α-helical 
turn, and β6 is composed of two short β-strands, termed 6a and 6b, which are connected 
by a loop region.  From β6, a loop extends to a four-amino acid α-helical turn, which then 
extends via another loop to β7 on the opposite side of the protein.  β7 to β11 then build 
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up, via anti-parallel β-strands, the second half of the sheet, with β11 and β1 hydrogen-
bonding to each other, bringing the two halves of the structure together.  A loop 
continues from the C-terminus of β11 into a loop including a 310 α-helical turn, which 
terminates the ordered portion of the molecule (Fig. V.2, A and B).  The long C-terminal 
structure is stabilized mainly with intrachain contacts, although there are also a small 
number of hydrophobic interactions between the two chains at their C-termini, involving 
residues Ala180, Pro183, and Ala185.   
 Based on primary sequence, there are three putative homologues of 
Chromobacterium violaceum VioE from related species (Fig. V.5), all of which are 
uncharacterized proteins.  The only partially characterized enzyme with any kind of 
sequence identity is the enzyme RifG26,45 (Fig. V.6).  RifG, a homologue of a 
dehydroquinoate synthase from Amycolatopsis mediterranei S699,45 is proposed to 
function together with other enzymes from the Rif operon in the formation in 3-amino-5-
hydroxybenzoic acid,45 specifically in the cyclization of 3,4-dideoxy-4-amino-D-arabino-
heptulosonic acid 7-phosphate.46  However, the similarity of RifG to VioE is quite poor 
(E value = 0.055, with 31 identical residues, 8 clustered in the region between β6 and β7 
of VioE), and the sizes of the proteins differ dramatically (191 residues for VioE, and 351 
residues for RifG).  Hence, the relevance of RifG’s similarity to VioE is unclear.   
 
Relationship of VioE to LolA and LolB 
 The story is different when one considers three-dimensional structure; VioE does 
have close structural homologues.  VioE is structurally homologous to the unclosed β-
barrel, core structure of both LolA (root mean squared deviation of 1.73 Å over 124 
 213
residues) and LolB (root mean squared deviation of 1.67 Å over 98 residues) (Fig. V.2C-
I, Fig. V.7).33  Unlike VioE, LolA and LolB are not enzymes.  They are well-
characterized periplasmic lipoprotein transporters in E. coli.  LolA binds lipoproteins 
released in an ATP-dependent manner by the ABC transporter LolCDE from the 
periplasmic side of the inner membrane and shuttles these lipoproteins through the 
periplasmic space, depositing them with LolB, a membrane-anchored protein, which 
incorporates them into the outer membrane.47   
 LolA and LolB have ‘lid’ regions, composed of α-helices.33,48  While the lid of 
LolB is thought to always be open,33 in LolA, these helices are thought to act as gates, 
controlling the access of hydrophobic cargo, the acyl chains of lipoproteins, to the 
unclosed β-barrel, where they are thought to be sequestered during lipoprotein 
transport.33,48,49  These LolA α-helices are thought to open and close, as lipoproteins enter 
and depart the hydrophobic core.33,48,49  In LolA, Arg43, positioned between β2 and β3, 
makes hydrogen bonding contacts with backbone carbonyls on the α1 (Leu10) and α2 
(Ile93 and Ala94) helices (Fig. V.8A);33 Arg43 is thus thought to play a key role in 
stabilizing the closed form of LolA.  Mutation of Arg43 to Leu leads to the accumulation 
of LolA-lipoprotein complexes and eliminates transfer of lipoproteins from LolA to 
LolB,50 suggesting that the closing of the lid via formation of hydrogen bonds to Arg43 
may drive the energy-independent transfer of lipoproteins from LolA to LolB.33,48,49  
LolB, which has a higher affinity for lipoproteins than LolA,51 lacks a residue playing 
this role; LolB is thought to be more stable in the ‘open’ conformation, where its 
hydrophobic core is more accessible to lipoproteins.33  
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 VioE lacks the three longer α-helices of LolA and LolB, having only two short α-
helices and one 310 α-helical turn, but it also may have similar ‘lid’ region.  Amino acids 
5 through 10 traverse a similar space in the VioE structure as the α1 helix of LolA.  
Further, amino acids 105-121 of VioE, a loop region extending from β6 to β7 and 
containing the second α-helix of VioE, traverse across similar space to that of the α2 and 
α3 helices of LolA and the α3 helix of LolB.  Finally, the structurally superimposed 
residue to Arg43 of LolA is Tyr39 of VioE.  Tyr39, which is also positioned between β2 
and β3 of VioE (like Arg43 of LolA), is in position to hydrogen bond with the indole 
nitrogen of Trp13 (positioned on β1) and with the backbone carbonyl of Leu110 (Fig. 
V.8B).  Although there are fewer hydrogen bonds to Tyr39 in VioE than to Arg43 in LolA, 
VioE, like LolA, appears to at least partially seclude its hydrophobic core from exposure 
to solvent, suggesting that VioE, like LolA, may have a dynamic lid region, involving 
Tyr39.   
 
Identification of the VioE active site  
 The 90-some liporoteins that are targeted for transfer by LolA and LolB are all 
thought to be recognized by a common feature: their acyl chains.  A structure of LolB 
reported with a bound PEG MME molecule was used to identify the likely site of acyl 
chain binding in LolB,33 and, by extension, in LolA.49  Strikingly, a tube-like molecule 
corresponding to PEG was refined into each monomer in the VioE structure (Fig. V.2A, 
Fig. V.8C).  This PEG molecule is located in the same area as the PEG MME molecule 
identified in the LolB structure (PDB code 1IWN).33  In VioE, the PEG molecule is 
bound at the base of the bowl-like curve of the β-sheet and is partially exposed to solvent.  
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Specifically, one orientation of a tri(ethylene)glycol molecule was fit to one monomer 
and one orientation of a tetra(ethylene)glycol molecule was fit to the other monomer.  
Unlike the rest of the VioE structure, however, where the B-factors of the protein atoms 
are quite low, averaging 15.0 Å2, the average B-factors of the atoms of the PEG 
molecules are significantly higher, averaging 44.2 Å2 (Table V.1).  Further, the maps 
show diffuse electron density, indicating flexibility in the binding of the PEG molecules 
(Fig. V.8C), in contrast to the sharp quality of electron density throughout most of the 
structure (Fig. V.9).  Despite the fact that the PEG is not well-ordered in the structure, its 
positioning is intriguing.  As was the case for LolB, it is tempting to speculate that the 
site of PEG binding also represents a binding site for a substrate, an acyl chain, in the 
case of LolB, or a substrate molecule, in the case of VioE. 
 Surrounding the PEG molecule in the VioE structure are a series of hydrophobic 
residues (Fig. V.8C): Trp13, Phe37, Ile46, Phe50, Pro52, Phe109, Leu110, Met160, and Phe174.  
Any putative substrates of VioE would be hydrophobic; both IPA 1 (the substrate of 
VioB) and prodeoxyviolacein 3 (the product of VioE) are poorly soluble in water, and it 
is unlikely that any molecules spanning the chemical space between IPA 1 or 
prodeoxyviolacein 3 would be well-soluble in water.  These hydrophobic residues 
surrounding the PEG molecule in the putative VioE active site should form an ideal 
binding pocket for the hydrophobic substrate molecule, any intermediates, and the 
prodeoxyviolacein 3 product during catalysis.   
 Within 6 Å of the bound PEG molecule are also a small number of polar and 
charged residues, Tyr17, Ser19, Thr31, Cys35, Asn51, Ser170, and Arg172, which might have 
relevance in binding the polar parts of the substrate molecule or in catalysis (Fig. V.8C).  
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Further from the bound PEG molecule, within 12 Å, are additional polar or charged 
residues, including Ser21, Cys44, Ser54, Glu66, Lys77, and Lys79 (Fig. V.8D), among others.  
To investigate the importance of particular residues to catalysis, and to investigate 
whether the PEG molecule had indeed identified the active site of VioE, a series of nine 
site-directed mutants were generated and their activities were tested (Fig. V.10).  To 
verify that each mutant was properly folded, each mutant was examined with CD 
spectrometry and compared to wild-type VioE.  We found that each mutant shows a 
similar CD spectrum to that of wild-type VioE (Fig. V.11), suggesting that all mutants 
are properly folded and that mutations reveal the importance of particular residues to 
binding or catalysis and not a general effect on the proper folding of the protein.  All 
targeted side-chains were mutated to alanine.   
 Two groups of mutants were generated.  The first group was in the immediate 
area of the PEG molecule (within 6 Å), and includes Arg172, closest to the PEG molecule 
(Fig. V.8C).  Mutation of Arg172 resulted in a significant decrease in prodeoxyviolacein 3 
production (Fig. V.10).  Similarly, mutation of either Tyr17 or Ser19, each between 3 and 5 
Å from the bound PEG molecule (Fig. V.8C) resulted in a significant decrease in 
prodeoxyviolacein 3 production (Fig. V.10).  Additionally, mutation of Asn51, between 5 
and 8 Å from the bound PEG molecule (depending on the monomer) (Fig. V.8C), 
resulted in a significant decrease in prodeoxyviolacein 3 production (Fig. V.10).  By 
contrast, mutation of Cys35, approximately 4Å from the bound PEG molecule (Fig. 
V.8C), yet on a different side of the PEG from Tyr17 and Ser19, did not result in a 
significant change in prodeoxyviolacein 3 production (Fig. V.10).  Additionally, mutation 
of Ser170, which is out further from the PEG molecule (Fig. V.8C), but positioned near 
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Ser19, did not significantly alter prodeoxyviolacein 3 production (Fig. V.10).  These 
mutations thus delineate the active site adjacent to the bound PEG molecule (Fig. V.8D). 
 The second group of amino acids mutated is further away from the PEG molecule 
(> 8 Å), but still in the general area of the concave β-sheet where substrate might bind.  
Glu66, positioned a distance of 9Å from Arg172 (Fig. V.8D), was a primary target, because 
its distance from Arg172 is within range of the size of putative substrates and products; for 
instance, the distance in prodeoxyviolacein 3 from the ketone oxygen to the furthest 
indole nitrogen is approximately 7Å.  Mutation of Glu66 resulted in a significant decrease 
in prodeoxyviolacein 3 production (Fig. V.10).  Two nearby residues, Met64 and Lys77, 
were then targeted for mutagenesis.  Although the average production of 
prodeoxyviolacein 3 was increased for both mutants relative to wild-type, based on the 
standard deviation, the increase was non-significant for both mutants (Fig. V.10).  This 
group of mutants therefore delineates a second part of the putative active site of VioE that 
includes charged residue Glu66 (Fig. V.8D).   
 
V.E.  Discussion 
 The unexpected result that VioE adapts a fold normally associated with 
lipoprotein carrier proteins to carry out an enzymatic function suggests that a crucial part 
of its function is, like a lipoprotein carrier protein, to bind a hydrophobic molecule. In the 
case of VioE, the binding of a hydrophobic substrate in a particular conformation may 
effectively chaperone the production of a desired product.  The conversion that VioE 
facilitates involves oxidative chemistry, but the most unusual aspect of the reaction, a 1,2 
shift of an indole ring, is a reaction that is not known to be catalyzed by other 
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characterized enzymes.  Other shift reactions have been characterized,52-55 and each of the 
responsible enzymes utilize iron as a cofactor (as a heme or non-heme iron), whereas 
VioE requires no cofactors or metals.  VioE’s lack of cofactors might mean that this 
indole shift reaction is mechanistically more facile than other observed, enzyme-mediated 
shift reactions.  Perhaps VioE’s main role is to stabilize its substrate in a favorable 
conformation to enable the 1,2 shift reaction to occur through classic acid-base or 
oxidative chemistry, and the fold adapted by VioE works well for this.  Other enzymes 
thought to use stabilization of an alternate, higher-energy orientation of a substrate to 
promote catalysis include the peptidyl-prolyl isomerases,56,57 although a precise 
delineation of the mechanisms of these enzymes is still under investigation.  One 
proposed substrate for VioE is the Cβ-Cβ benzylically coupled iminophenylpyruvate 
dimer 2 (Fig. V.1),27 a molecule which could collapse spontaneously to chromopyrrolic 
acid 4.27  Stabilization of this molecule (or a related intermediate) by VioE in an 
orientation suitable for promotion of a 1,2 indole shift might re-route it toward 
prodeoxyviolacein 3.     
 Our site-directed mutagenesis studies have identified a number of residues likely 
to be involved in binding polar parts of the substrate molecule or in catalysis: Tyr17, 
Ser19, Asn51, Glu66, and Arg172.  Although mutation of any of these residues does not 
completely abolish VioE activity, the significant decrease in activity by each of these 
mutants implies that they play a role in enzymatic acceleration of prodeoxyviolacein 3 
production by VioE.  Our findings do suggest that the PEG molecule co-crystallized with 
VioE has indeed identified the active site of the enzyme.  However, it appears that the 
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active site extends beyond the site of PEG binding to include the side-chain of Glu66.  An 
extended active site is not surprising given the larger size of the known product molecule.   
 In conclusion, our crystal structure of VioE has revealed that an unusual enzyme, 
a cofactorless, metal-free protein known to catalyze an unusual 1,2 shift reaction, also 
adapts an unusual fold, that of a lipoprotein carrier protein.  This finding indicates that 
the main role of VioE is to sequester a hydrophobic molecule from the milieu of the cell.  
Once bound, VioE likely uses acid-base chemistry, probably coupling transformations to 
spontaneous oxidative processes, to carry out its reaction, without the need for metals or 
cofactors.  Further studies of this intriguing enzyme, including elucidation of its yet-
unknown substrate, will help unravel how each residue identified in this study enables 
VioE to re-route an unknown intermediate away from spontaneous formation of 
chromopyrrolic acid 4 and toward production of the violacein 5 scaffold.   
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V.H. Tables and Figures 
  
Table V.1.  Data collection and refinement statistics for VioE. 
 
 Native Selenomethioninea
Wavelength  (Å) 0.9795 0.9792 
Space group P212121 P212121 
Unit cell (Å) a = 53.5, b = 82.5, 
c = 90.6 
a = 53.4, b = 82.3, 
c = 90.6 
Resolution (Å)b 50 – 1.21  
(1.25 – 1.21) 
50 – 1.86  
(1.93 – 1.86) 
Rsymb,c  0.066 (0.258) 0.060 (0.226) 
Completeness (%)b 90.6 (54.3) 95.0 (58.7) 
Unique reflections 111,465 61,353 
Redundancyb 13.9 (3.2) 6.9 (3.8) 
I/σb 35.7 (3.4) 27.8 (5.1) 
Refinement statistics 
Resolution range (Å) 50 – 1.21 
Rcryst (%)d  16.8 
Rfree (%)d 19.5 
No. non-hydrogen atoms  
   Protein 3183 
   Water 680 
   PEG 23 
Average B-factors (Å2)  
    Protein 15.0 
    Water 32.0 
    PEG 44.2 
r.m.s.d.e bond length (Å) 0.006 
r.m.s.d.e bond angle (°) 1.209 
Ramachandran plot (% 
residues) 
 
     Most favored  91.6 
     Additionally allowed 8.4 
     Generously allowed 0 
      Disallowed 0 
 
a For this dataset, Bijovet pairs were not merged during data processing   
b Values in parentheses indicate highest resolution bin 
c Rsym = ( ∑i∑hkl ǀ Ii(hkl) - <I(hkl)> ǀ ) / ∑hkl <I(hkl)>, where Ii(hkl) is the intensity of the ith measured 
reflection, and <I(hkl)> is the mean intensity for the reflection with the miller index (hkl) 
d Rcryst  = ( ∑hkl ǀǀFobs(hkl) ǀ - ǀFcalc(hkl) ǀǀ ) / ∑hkl ǀFobs(hkl)ǀ ; Rfree is calculated identically, using 5% of 
reflections omitted from refinement 
e r.m.s.d. = root mean squared deviation 
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Table V.2.  Primers used for generation of site-directed mutants.  Bold text within 
oligonucleotide sequences indicates restriction digest sites, italicized text indicates 
modified overhangs, and underlined text indicates the modified codon. 
 
 
Protein Fragment Sequence 
   
All mutants a – 5’ forward caagttacatatggttaaccgcccgtacgc 
 b – 3’ reverse caagttactcgagctcgctatctgtaatcacgtc 
   
VioE Y17A a – 3’ reverse catcggactccagtacgacaccgcggcgctgctcca 
 b – 5’ forward ccggcgcgctggagcagcgccgcggtgtcgtactgg 
   
VioE S19A a – 3’ reverse cggcagcatcggactccagtacgccacataggcgct 
 b – 5’ forward cgctggagcagcgcctatgtggcgtactggagtccg 
   
VioE C35A a – 3’ reverse gtcgcgctcgtagtcgaaccacgcgtagccggacgt 
 b – 5’ forward gaccagctgacgtccggctacgcgtggttcgactac 
   
VioE N51A a – 3’ reverse ggtgtcgcgctccgaccagggcgcgaacaggccgtc 
 b – 5’ forward tgtcggatagacggcctgttcgcgccctggtcggag 
   
VioE M64A a – 3’ reverse ggcggcgttgccgacctcggacgcccacagccggta 
 b – 5’ forward gacaccggctaccggctgtgggcgtccgaggtcggc 
   
VioE E66A a – 3’ reverse gccgctggcggcgttgccgaccgcggacatccacag 
 b – 5’ forward ggctaccggctgtggatgtccgcggtcggcaacgcc 
   
VioE K77A a – 3’ reverse gcggccataggccaccttctgcgcccaggtgcggcc 
 b – 5’ forward gccgccagcggccgcacctgggcgcagaaggtggcc 
   
VioE S170A a – 3’ reverse gacgttggggaaatcgcgcagcgccgcgcgcgacgc 
 b – 5’ forward ggggacgaggcgtcgcgcgcggcgctgcgcgatttc 
   
VioE R172A a – 3’ reverse ctcgctgacgttggggaaatccgccagcgacgcgcg 
 b – 5’ forward gaggcgtcgcgcgcgtcgctggcggatttccccaac 
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Figure V.1.  Biosynthesis of violacein and indolocarbazoles.  Indole 3-pyruvic acid 1 
(IPA, R = NH imine form, R = O ketone form) is generated biosynthetically from L-
tryptophan by the action of the enzyme VioA or a homologue, such as RebO.  In both the 
violacein and related indolocarbazole biosynthetic pathways, two molecules of IPA imine 
1 are dimerized to generate a yet-uncharacterized intermediate, which has been proposed 
to be 2.27  The presence of VioE routes this intermediate to the production of 
prodeoxyviolacein 3, whereas in the absence of VioE this intermediate converts to 
chromopyrrolic acid 4.  Prodeoxyviolacein 3 is a precursor to violacein 5, whereas 
chromopyrrolic acid 4 derivatives are precursors to indolocarbazole compounds 
rebeccamycin, staurosporine, K252a, or AT2433.31,32,58   
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Figure V.2.  Fold of VioE and structural comparisons.  A. VioE crystallizes as a dimer, 
with the β-sheets positioned back-to-back.  Chain A is shown in light blue, and chain B is 
shown in purple.  A sigmaA-weighted 2Fo-Fc omit map that surrounds the PEG was 
generated by excluding PEG from the phase calculation, running 20 rounds of maximum 
likelihood refinement in Refmac, and converting the structure factor file to a map file.  
Resulting density is shown in blue at 1.0 σ around the PEG modeled near each chain.  β 
strands of Chain B are numbered 1-11 based on their arrangement from the N- to the C-
terminus of the protein; β3 is not visible from this view.  B. One VioE monomer is 
shown, with β strands numbered 1-11 based on their arrangement from the N- to the C-
terminus of the protein and with the C-terminus labeled with ‘C-term.’  C. Structurally 
aligned portions of VioE (purple), LolA (PDB code 1UA8, green) and LolB (PDB code 
1IWM, blue) are shown, oriented identically to the VioE monomer shown in part B.  D-I.  
D and G show VioE (chain B), with arrows designating the loop region including amino 
acids 105-121 (in D) and the loop including amino acids 5-10 (in G), and with β strands 
numbered 1-11 based on their arrangement from the N- to the C-terminus of the protein 
and with the C-terminus labeled ‘C-term.’  E and H show LolA (PDB code 1UA8), and F 
and I show LolB (PDB code 1IWM).  Models in D, E, and F are identically positioned, 
and models in G, H, and I are identically positioned.  β-strands are shown in blue, α-
helices and short 310 helices are shown in red, and loop regions are shown in green.  The 
three α-helices identified as forming a ‘lid’ in LolA and LolB are labeled α1, α2, and α3.  
Figures of protein models were prepared in PYMOL (http://pymol.sourceforge.net), with 
secondary structure assignment carried out using DSSP.59 
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Figure V.2 
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Figure V.3.  Sedimentation velocity experiments.  Sedimentation velocity experiments 
were performed on VioE at observed loading concentrations of 8.6 μM and 2.3 μM.  The 
single species model fit to this data using Sedanal gives a molecular mass of 45,879 
g/mol (calculated molecular mass of C-terminally tagged VioE dimer is 45,685 g/mol).  
Determination of F-statistics gives a range of 41,200 to 51,000 g/mol for the molecular 
mass of the observed species, with a confidence level of 95%.  These data are highly 
consistent with a VioE dimer in solution and are inconsistent with a VioE monomer or 
trimer in solution.  Plots of the sedimentation distribution function normalized to loading 
concentrations are shown as a function of the sedimentation coefficient in Svedbergs, 
with the 8.6 μM sample shown in blue and the 2.3 μM sample shown in pink.  
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Figure V.4.  Gel filtration of VioE.  Protein purified from a nickel (II) loaded Chelating 
SepharoseTM Fast Flow column was loaded onto a HiLoad SuperdexTM 75 prep grade 
column.  This column was previously calibrated using gel filtration standards, with 
bovine thyroglobulin (670 kDa) eluting at 46.8 mL, bovine γ-globulin (158 kDa) eluting 
at 51.0 mL, chicken ovalbumin (44 kDa) eluting at 64.6 mL, horse myoglobin (17 kDa) 
eluting at 79.4 mL, and Vitamin B12 (1.4 kDa) eluting at 107.0 mL.  A.  A standard curve 
was generated for the column using these standards, using the logarithm (base-10) of the 
molecular weight (in kDa) as a function of elution volume (in mL), excluding the value 
for bovine thyroglobulin, which is not on the linear portion of the curve.  The linear 
regression equation and R2 value are shown.  B.  VioE elutes as one major peak at 72.5 
mL.  This corresponds, based on the standard curve, to a calculated molecular weight of 
26.3 kDa.  The molecular weight of VioE (including the C-terminal tag) is 22.8 kDa, and 
the calculated dimeric molecular weight is 45.7 kDa.  The peak corresponding to the 
calculated molecular weight of 26.3 kDa is more likely to represent monomeric VioE.   
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Figure V.5.  Homologues of VioE.  A ClustalW alignment of the closest homologues of 
VioE from Chromobacterium violaceum ATCC 12472 (indicated as ‘CV’) is shown.  The 
homologue from Janthinobacterium lividum DSM 1522 is indicated as ‘JLD,’ the 
homologue from Janothinobacterium lividum BP is indicated as ‘JLB,’ and the 
homologue from Pseudoalteromonas tunicata D2 is indicated as ‘PT.’  Identical residues 
are indicated with *, and similar residues are indicated with one or two dots, according to 
the conventions of ClustalW.   
 
JLD             ---MPTHVSPPLLPMQWSSAYVSYWTPMQADDQVTSGYCWFDYARNICRIDGLFNPWSEK 57 
JLB             ---MSIQVAPPLLPMKWSSAYISYWTPMQEDDQVTSGYCWFDYARNICRIDGLFNPWPEK 57 
CV              ---MENRE-PPLLPARWSSAYVSYWSPMLPDDQLTSGYCWFDYERDICRIDGLFNPWSER 56 
PT              MQLSKITKKPPLLPAQWSSSYISYWMPMQPDDDITSGYCWFDYTKNVCRIDGIFNPWPEI 60 
                         ***** :***:*:*** **  **::********* :::*****:****.*  
 
JLD             EHGHLLWMSEIGDARREQSRKQKVAYARQAEAAGEQLQGTALADEVTPFHELFLPQAVLL 117 
JLB             EHGHLLWMSEIGDARREQSRKQKVAYARQAGATGEQLQGTALADEVTPFHELFLPQAVLL 117 
CV              DTGYRLWMSEVGNAASGRTWKQKVAYGRERTALGEQLCERPLDDETGPFAELFLPRDVLR 116 
PT              KMGNRLWMSEIMYPNTDESFKSKVAYAREDMKSISEFSAQVLDDEIDPCHELILTQKVLI 120 
                . *  *****:  .   .: *.****.*:     .::    * **  *  **:*.: **  
 
JLD             DGGARHDGRHTVLGREADAWVVERA-GKPPSVFYLEAGGNRLLRMVTGNDPQHLSVRDFP 176 
JLB             DGSARHDGRHTVLGQEADAWVMERA-GKPPSVFYLEAGGNRLLRMVTGNDPQHLSVRDFP 176 
CV              RLGARHIGRRVVLGREADGWRYQRP-GKGPSTLYLDAASGTPLRMVTGDEASRASLRDFP 175 
PT              ECNAQYMGIETVLGHQAEKWLFQRPDNKGPATYYFINGTNHLVRMITGDPKICASVRDFP 180 
                  .*:: * ..***::*: *  :*. .* *:. *:  . .  :**:**:     *:**** 
 
JLD             NLFVSDIPDSVFTSCNT-- 193 
JLB             NLFVGDIPDSVFTSCNT-- 193 
CV              NVSEAEIPDAVFAAKR--- 191 
PT              NFNTYKIDNEIFKPEPLKK 199 
                                     *.   .* : :* .   
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Figure V.6.  Comparison of VioE to RifG.  RifG, a 351 amino acid protein from 
Amycolatopsis mediterranei, shows similarity to VioE, a 191 amino acid protein.  RifG 
aligns at its N-terminus to the central region of the VioE sequence.  Shown are only the 
residues aligned from a BLAST search.  Based on the VioE structure, the highest identity 
is in the loop that connects β6 to β7, bridging one side of the protein to the other.  RifG is 
a putative 5-amino 3-dehydroquinate synthase,45 thought to carry out a cyclization of 3,4-
dideoxy-4-amino-D-arabino-heptulosonic acid 7-phophate.46  Heterologous expression 
studies have shown that RifG is involved, together with RifJ and RifH, in the synthesis of 
3-amino-5-hydroxybenzoic acid.45  It is unclear what RifG’s similarity to VioE reveals 
about either protein.  Yellow highlighting indicates identical residues, whereas gray 
highlighting indicates similar residues.   
 
 
VioE 86  RTALGEQLCERPLDDETGPFAELFLPRDVLRRLGARHIGRRV 127 
RifG  2  RTTIPVRLAERSYDVLVGPGVRAALP-EVVRRLGAR---RAV  39 
 
VioE 128 VLGREADGWRYQRPGKGPSTLYLDAASGTPLRMVTGDE     165 
RifG  40 VVSARPADWV---PGTGVETLLLQARDGEPTKRLSTVE      74 
 
 
 
  
 
 
  
 236
Figure V.7.  Structure-based sequence alignment of VioE, LolA, and LolB.  The 
structure of VioE was individually aligned using LSQMAN60 to the structures of LolA 
and LolB,33 which, based on analysis using DALI (http://www.ebi.ac.uk/dali/), had 
significantly higher structural homology to VioE than did any other published protein 
structures.  A final structural alignment was generated where distances between Cα 
carbons were within 3.5 Å.  Structurally aligned sequences of VioE, LolA (PDB code 
1UA8), and LolB (PDB code 1IWM) are shown with secondary structure assignments 
(blue text indicates β-sheets and red text indicates α-helices and 310 helical turns).  Gray 
highlighting indicates residues disordered in the crystal structures.    
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Figure V.7 
 
 
VioE  1  ----------------------------------MENREP 6 
LolA  1  ------------------------------DAAS-----D 5     
LolB  1  ASVTTPKGPGKSPDSPQWRQHQQDVRNLNQ---------- 30            
 
                
VioE 7   PL--L--PARWSSAYVS-Y-WSPMLPDD----------Q- 29 
LolA 6   LKSRLDKVSSFHASFTQ-KVT--------DG--SGAAVQ- 33 
LolB 31  ---------YQTRGAFAY--I-------SD-QQ-----KV 46 
                     
 
VioE 30  LTSGYCWFDY-E-R-DICRIDG----LFNPWSERDTGYRL 62 
LolA 34  EGQGDLWVKR-P---NLFNWHMTQPD-------------- 55  
LolB 47  -YARFFWQQ-TGQ-DRYRLLLTN----------------- 66 
 
            
VioE 63  -----WMSEVGNAAS--GRTWKQ--KVAYGRERTALGEQL 93   
LolA 56  -----ESILVSD-GK---TLWFY--NPF------------ 72  
LolB 67  PLGST-ELELNAQ--PGNVQLV-DNK-------------- 88  
           
          
VioE 94  CERP-L--DDETGP-FA--EL------------------- 108  
LolA 73  ----VEQ---ATATWLKDAT-GNTPF--------------  90 
LolB 89  -------G-QRYTAD-D---------AEEMIGKLTGMPIP 110 
                             
 
VioE 109 F--LP-RD------VLR---R-----------LGARHI-G 124 
LolA 91  M-LIARNQ---------SSDWQQYN---------IKQ--N 109 
LolB 111 LNSLR-Q-WILGLPG-----D-----------ATDYK-L- 130  
 
 
VioE 125 RRVVLGREA-------DGWRYQRPGK-------GPS-TL- 148 
LolA 110 ---------G------DDFVLTP----KSNGNLKQF-TI- 129 
LolB 131 ----------DDQYRLSEITYS-QN-G------KNWKV-V 151 
 
 
VioE 149 YLDAA----------SG-T-PLRMVTGDEASR----ASLR 172 
LolA 130 NVG--R---------DG-T-IHQFSAV-----EQDQRSSY 152 
LolB 152 Y-----GGYDTKTQPA-MPA-NMELTDG---G----QRIK 177 
            
VioE 173 DFPNVSEA--EIPDAVFAAKR----------          191     
LolA 153 QLKSQQNG--AVDAAKFTFTPQGVTVDDQRK          182 
LolB 178 LKMDNW-IVK---------------------    186      
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Figure V.8.  The putative ‘lid’ and extended active site of VioE.  A. The proposed closed 
lid region of LolA is shown (PDB code 1UA8), with Arg43 mediating a series of 
hydrogen-bonding interactions that close off the exposed side of the LolA structure.  B. In 
VioE, the structurally superimposed residue to Arg43 is Tyr39, which is also positioned 
between β2 and β3 and also makes hydrogen bonding contacts to residues shown in blue.  
C. Side-chains within 6Å of the PEG molecule of chain B are shown.  Alternate 
conformations were refined for Ser19, Met160, and Ser170.  D. Mutated residues are shown 
within the context of surrounding residues, each of which are within 12 Å from the bound 
PEG molecule.  Residues that were not targeted for mutagenesis are shown in gray.  
Those in pink, when mutated, had no significant effect on the production of 
prodeoxyviolacein 3, whereas those in green, when mutated, had significantly reduced 
production of prodeoxyviolacein 3.  In all panels, secondary structural elements are 
labeled in red.   
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Figure V.8 
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Figure V.9.  Electron density for VioE.  Seven residues (Tyr60, bottom, to Glu66, top) are 
shown in a 1.5 σ sigmaA-weighted 2Fo-Fc map.  The high quality of the electron density 
over most of the structure, including this segment, is in contrast to the lower quality of 
density surrounding the PEG molecules.   
 241
Figure V.9 
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Figure V.10.  Activities of mutant VioE proteins.  The average percent production of 
prodeoxyviolacein 3 by each mutant relative to that of wild-type VioE is shown, with 
error bars representing the standard deviation over three trials.  Y17A, S19A, N51A, 
E66A, and R172A show significantly reduced prodeoxyviolacein 3 production relative to 
wild-type, whereas C35A, M64A, K77A, and S170A produce prodeoxyviolacein 3 at a 
level that is not significantly different from wild-type.   
 
 243
Figure V.10 
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Figure V.11.  CD spectra of mutant proteins.  Circular dichroism spectra of all mutants 
appear similar to that of wildtype VioE, suggesting that all mutants are properly folded.  
A. Native versus C35A, N51A, and S170A. B. Native versus E66A, K77A, and M64A. C. 
Native versus Y17A, R172A, and S19A.   
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Figure V.11 
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Chapter VI: 
 
Conclusions 
 
 Natural products represent some of the most complex organic molecules ever 
identified.  Major papers on the organic synthesis of low yields of natural products, such 
as giberellic acid,1,2 taxol,3-5 or epothilone,6 suggest how challenging it is to produce 
these molecules, and the fact that we still isolate many medicinally relevant molecules, 
including morphine, vancomycin, and shikimic acid (a precursor to the anti-viral drug 
oseltamivir), from natural sources further implies that the laboratory synthesis of complex 
natural products is beset by challenges.  Yet the organisms that make natural products 
lack all of the advantages chemists possess:  these organisms make compounds without 
external heat sources, without access to solvents beyond water, and without alteration of 
the carefully regulated pH of the cell.  The presence of such a cornucopia of complex 
natural products is evidence of the presence of a diversity of enyzmes catalyzing 
challenging chemical reactions with exquisite stereo- and regioselective control at 
ambient conditions.   
 Another feature of natural products molecules is their diversity.  Closely related 
species may produce distinct products, sometimes using enzymes with near-identical 
sequences (which suggests a rapid evolution of enzymes from one function to another), or 
by adding or subtracting key modifying enzymes to natural product biosynthetic 
pathways.  The astonishing plasticity of natural product biosynthetic pathways over 
evolutionary time and between related organisms belies a delicate balance obtained by 
enzymes, between doing chemistry precisely while also maintaining the capacity to 
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evolve rapidly to new functions.  It has recently been suggested that natural product 
enzymes compromise their enzymatic specificity, producing non-desired products at low 
levels, which leaves intact in enzymes the ability to evolve to produce these side products 
later on as major products.7  Evolution can take advantage of the plasticity encoded in 
these enzymes and their substrates to generate novel but related molecules.8     
 Bisindoles represent a relatively new area of study in natural product biosynthesis.  
Although it has been assumed for decades that bisindole molecules are produced from L-
tryptophan,9 which is the most frequently occurring small molecule containing an indole 
ring, only recently have the biosynthetic steps leading to bisindole construction been 
investigated.  Starting in 2005, the biosynthesis of rebeccamycin and staurosporine were 
characterized biochemically;10-13 in 2006, the steps leading to the construction of 
violacein were explored;14,15 and in 2007, the terrequionone A biosynthetic pathway was 
elucidated (Figure I.1).16  Additional information about other bisindole biosynthetic 
pathways, particularly details about K252a17 and AT2433-A118 biosynthesis (Table I.1), 
have further expanded our understanding of the pathways that lead to bisindole 
molecules.  Identification of the enzymatic players in bisindole biosynthesis has opened 
up major, and still largely unanswered, questions about the mechanisms by which 
bisindole biosynthetic enzymes carry out complicated chemical reactions to generate 
these bisindole intermediates and products.  This thesis has taken a largely structural 
approach to begin to understand these enzymes, with a specific focus on the enzymes that 
mediate the divergence points between rebeccamycin, staurosporine, and violacein.   
 Our first investigation was of the rebeccamycin biosynthetic enzyme RebC, 
which, in concert with the upstream enzyme RebP, directs molecules towards  
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arcyriaflavin A from chromopyrrolic acid, and away from the staurosporine precursor 
K252c (Fig. II.1B).12  The interest in RebC stemmed initially from complete confusion of 
how it could function.  Why did the upstream enzyme produce a small amount of product 
without RebC present?  If RebC was an enzyme, what was its true substrate?  A 
serendipitous crystal soaking experiment (with chromopyrrolic acid) led to the ‘trapping’ 
of a molecule we identified as a tautomer of 7-carboxy-K252c.  Subsequent synthetic 
work carried out by our collaborators showed that the ‘trapped’ molecule was unstable, 
decomposing in solvent in 30 min.19  Our work revealed major details about RebC:  RebC 
shared a fold with flavin-dependent hydroxylases, and RebC bound a putative, unstable 
substrate molecule in a suitable conformation to enable flavin-based hydroxylation 
chemistry to occur in an appropriate position on the C-7 carbon atom.  Collectively, we 
concluded that RebC was indeed an enzyme (not a modifying factor of the upstream 
enzyme RebP), and that RebC played a dual role in stabilizing reactive intermediates and 
in carrying out flavin-based chemistry.   
 Despite these advances, we still did not understand how exactly RebC might 
work.  One major question was whether, if RebC’s substrate was 7-carboxy-K252c, 
RebC needed to mediate two hydroxylation reactions of this molecule to bring it to the 
final product.  This type of flavin-based chemistry would be unprecedented.  All known 
wild-type flavin-based hydroxylases mediate only a single reactive cycle on a molecule.  
Yet going from 7-carboxy-K252c to arcyriaflavin A without spontaneous chemistry 
would require at two such hydroxylation reactions.  Thus, having identified a likely 
function and a likely substrate of RebC only raised for us questions of the mechanism of 
RebC.  However, because of the reactivity of putative substrate molecules, we decided to 
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continue with a crystallographic approach to understand RebC’s mechanism, and we 
pursued the structure of RebC with a reduced flavin cofactor, to attempt to begin to 
unravel the catalytic mechanism of RebC.  
 One method to generate a reduced flavin cofactor is to incubate the protein with 
sodium dithionite.  The characteristic yellow coloring of the oxidized flavin disappears as 
the reduced flavin is generated.  Using this method, we were able to solve a crystal 
structure of FADH2-RebC.  Surprisingly, incubation of the RebC crystals with dithionite 
resulted in a drastic change in the unit cell dimensions of the crystal, exactly as we had 
seen for the structure of RebC with 7-carboxy-K252c.  Further, not only did the FADH2-
RebC structure share unit cell dimensions with the structure of RebC with a bound 
tautomer of 7-carboxy-K252c, it shared other features as well:  the flavin cofactor moved 
IN and a helix adjacent to the substrate binding pocket became ordered.  The FADH2-
RebC structure assumed a conformation that would position a substrate molecule for 
catalysis, and the FADH2-RebC structure appeared to represent a stage in the catalytic 
cycle where substrate was bound and the flavin was reduced.  By comparing the details 
we have garnered from structural studies of RebC, including the FADH2-RebC structure 
and earlier structures, and comparing those details to the better studied flavin-dependent 
hydroxylase para-hydroxybenzoate hydroxylase, we were able to begin to piece together 
what may be the single reaction cycle of RebC.  Whether RebC indeed subjects a single 
substrate to two reaction cycles or carries out one reaction cycle (with spontaneous 
chemistry enabling full conversion to arcyriaflavin A) is still, however, unknown.   
 RebC is an enzyme that shuttles molecules towards the rebeccamycin precursor 
arcyriaflavin A, apparently through a flavin-dependent process.  By contrast, StaC is a 
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homologous enzyme that shuttles molecules towards the staurosporine precursor K252c.  
Besides producing a less-oxidized product, StaC also has a strange feature:  unlike RebC, 
it is not purified with the flavin cofactor.  RebC and StaC, with 65% identity, represent a 
classic example of two enzymes extremely likely to be closely related over evolutionary 
timescales, which carry out two distinct functions.   
 To investigate StaC, we took a comparative approach.  We first compared the 
binding constant of StaC and its functional homologue InkE for FAD to the binding 
constant of RebC and its functional homologue AtmC for FAD.  We found that the 
enzymes formed two groups:  StaC and InkE (which mediate net 4-electron oxidations of 
chromopyrrolic acid) had binding constants for FAD in the low μM range, whereas RebC 
and AtmC (which mediate net 8-electron oxidations of chromopyrrolic acid) had binding 
constants for FAD in the low nM range.  This result suggested that the functional 
differences between RebC and StaC might be due exclusively to their ability (or lack of 
ability) to bind FAD tightly.  We therefore took a second comparative approach to 
investigate StaC, using the structure of RebC with the sequence alignment of all four 
homologues to identify residues which might be key to differentiating RebC from StaC.  
We targeted these residues in a site-directed mutagenesis experiment, producing a StaC 
protein with 10 mutations, called StaC-10x.  StaC-10x co-purified with the cofactor FAD.  
Although we found the binding constant of StaC-10x for FAD was weaker than that of 
RebC, and its rate of arcyriaflavin A production was lower than that of RebC, it appeared 
that we had indeed partially converted StaC to RebC, by building a better binding pocket 
for FAD in the StaC protein.   
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 Examination of the connectivity in the structures of rebeccamycin and 
staurosporine reveals their similarity, which is reflected in the similarity of their 
biosynthetic enzymes.  But the structure of violacein seems quite distinct, with the two 
indole rings connected not through an indolopyrrolocarbazole structure, but via a distinct 
connectivity.  Relative to rebeccamycin and staurosporine, violacein appears to have 
undergone a 1,2 shift of its indole ring.  Yet with the identification and subsequent 
characterization of the violacein biosynthetic enzymes, VioABCDE, it was revealed that 
there was high sequence similarity and functional equivalence of VioA and VioB with 
RebO/StaO and RebD/StaD, respectively.  The first two steps of violacein biosynthesis 
(involving VioA and VioB) and the first two steps of rebeccamycin biosynthesis 
(involving RebO and RebD) are identical (Fig. V.1).  The feature that differentiates the 
two pathways is VioE, which appears to intercept a reactive intermediate produced by 
VioB, and to shuttle it toward prodeoxyviolaein.  By contrast, in the rebeccamycin and 
staurosporine pathways, an enzyme equivalent to VioE is absent, and the intermediate 
produced by RebD/StaD is thought to spontaneously collapse to chromopyrrolic acid, a 
molecule which is off-pathway in the violacein biosynthetic pathway but is on-pathway 
to both rebeccamycin and staurosporine. 
 VioE represents an extremely unique target for crystallographic investigation.  
Based on sequence analysis, VioE has no close sequence homologues.  Based on 
biochemical analysis, VioE lacks any detectable cofactors, organic or metal.  Based on 
mechanistic analysis, VioE must mediate a 1,2 shift of an indole ring, formation of a 
pyrrole-like ring, two decarboxylations, and additional oxidative chemistry.  Further, 
VioE is extremely well-behaved in crystallographic screening experiments, generating 
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high quality crystals that diffracted to 1.21 Å resolution.  Despite the lack of a known 
structural homologue of VioE, we were able to solve the structure using a 
selenomethionine derivative, and, in retrospect, could also have used sulfur phasing on 
the native protein to solve the structure. 
 Yet high resolution did not immediately reveal how VioE might work.  Attempts 
to co-crystallize with VioE putative substrate-like molecules were generally unsuccessful.  
The problem seemed to be due to a PEG molecule from the crystallization conditions that 
bound in a cleft in the VioE protein; density from soaked or co-crystallized molecules 
would overlap in density with this PEG molecule but the features of these molecules 
could not be resolved, suggesting disorder or poor occupancy.  We thus turned to the 
PEG molecule as a possible marker of the active site, and considered the surrounding 
residues as possible active site residues.  Similar logic had already been utilized in 
investigating LolA and LolB.  LolA and LolB are (surprising) close structural 
homologues of VioE and lipoprotein transporter protein proteins that function in the 
periplasm of E. coli.  The PEG molecule co-crystallized in the LolB structure suggested 
to the authors the location of the binding site of the substrate of LolA and LolB, which is 
an acyl tail of a lipoprotein.   
 Site-directed mutagenesis experiments of the residues surrounding the PEG 
residue in VioE, results which were also verified by an independent study,20 showed that 
mutation of five separate residues to alanine reduced (but did not abolish) the catalytic 
activity of VioE.   These results suggest that the PEG molecule had indeed marked the 
active site of VioE.  These studies suggest that VioE appears to make use of a fold first 
observed for lipoprotein transporter proteins to carry out what seems be an extremely 
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complicated enzymatic transformation.  VioE appears to catalyze this reaction largely 
through orientation effects, making no use of a cofactor or even a yet-identified 
catalytically essential active site side chain.   
 Our work on rebeccamycin, staurosporine, and violacein biosynthesis has 
suggested that the key divergence points, mediated by RebC, StaC, and VioE, all involve 
reactive intermediates.  In the case of RebC and StaC, we have suggested that the 
molecule at the divergence point is 7-carboxy-K252c, and in the case of VioE, we have 
suggested that the molecule at the divergence point is a reactive intermediate such as the 
Cβ-Cβ benzylically coupled iminophenylpyruvate dimer, produced by the upstream 
enzyme VioB.  RebC, StaC, and VioE share the capacity to control the reactive chemistry 
of their respective substrates.  Both RebC and StaC prevent the spontaneous production 
of the shunt product 7-hydroxy-K252c (the major product of the StaP alone reaction), and 
VioE prevents the spontaneous production of chromopyrrolic acid, which is also a shunt 
product.  Instead, these enzymes sequester these intermediates their active sites, and 
shuttle them toward desired side products.  The fact that these putative substrates are 
highly reactive has impeded traditional biochemical investigations in all three systems; 
for instance, all activity assays include upstream enzymes whose substrates are known, 
and no kcat or Km has been obtained for the individual enzymes RebC, StaC, and VioE.  
Yet the presence of reactive intermediates also presents an interesting theme in bisindole 
biosynthesis.  The divergence points between rebeccamycin and staurosporine (mediated 
by RebC and StaC) and between the indolopyrrolocarbazoles and violacein (mediated by 
VioE) appear to take advantage of the inherent reactivity of molecules positioned at the 
divergence points.  VioE, for instance, is probably more likely to be able to carry out 
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cofactor-independent chemistry without using a catalytically essential side chain because 
of the high reactivity of its putative substrate, the Cβ-Cβ benzylically coupled 
iminophenylpyruvate dimer.  RebC as well appears to take advantage of the spontaneous 
reactivity of the molecule produced by the upstream enzyme RebP, which is most likely 
to produce the aryl-aryl coupled CPA, and can use a combination of flavin and 
spontaneous chemistry to convert it to arycriaflavin A.  StaC, which may or may not use 
the flavin cofactor in flavin-based hydroxylation chemistry, may take advantage of the 
reactivity of its substrate to shuttle it toward a desired, less oxidized side product using 
orientation effects in its active site.   
 Natural product biosynthetic enzymes taking advantage of the reactivity of their 
substrate molecules is not uncommon, and may be an emerging theme in natural product 
biosynthesis.  For instance, the closely related enzymes stilbene synthase and chalcone 
synthase take advantage of the inherent reactivity of their tetraketide intermediates, which 
can spontaneously cyclize, using positioning effects to drive the reaction toward one 
product in stilbene synthase and toward another in chalcone synthase.21  Similarly, 
carbocation intermediates derivated from farnesyl diphosphate can be directed via 
different sesquiterpene cyclases to distinct final products, again through orientation 
effects in the active site.22  Even in other bisindole biosynthetic pathways, this is not 
uncommon.  In terrequinone A biosynthesis, for instance, TdiA is thought to use the 
NRPS machinery to tether two α-keto acids adjacent to one another, to enable 
spontaneous Claison-like condensation chemistry to proceed.16,23  The use of reactive 
molecules in the divergence points between rebeccamycin, staurosporine, and violacein 
biosynthesis may enable enzymes to rely more on orientation effects to promote a desired 
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product.  Using reactive substrate molecules, which can be directed toward multiple 
products, also leaves a plasticity inherent in the pathway, and this plasticity might be re-
molded over evolutionary time to give rise to new products, as the demands of the 
environment dictate.   
 This thesis has opened up entirely new areas of future investigation.  The study of 
the reaction mechanism involved in converting the Cβ-Cβ benzylically coupled 
iminophenylpyruvate dimer to prodeoxyviolacein could be a rich area of study, as could 
more intense studies of the reactivities of aryl-aryl coupled chromopyrrolic acid and 7-
carboxy-K252c.  Further study of the distinctions between RebC and StaC might fully 
clarify what role FAD plays a role in StaC catalysis, and a comparative study of RebC, 
StaC, and their many homologues to trace the pathways that led to the production of these 
distinct enzymatic functions.  Finally, this structural work has only begun to characterize 
bisindole biosynthesis.  A variety of interesting enzymes in the bisindole biosynthetic 
pathways await exploration by crystallographers.  These include, for instance, VioB (or 
the homologues RebD or StaD) which mediate the iron-dependent formation of the Cβ-
Cβ benzylically coupled iminophenylpyruvate dimer, the glycosylase StaN from 
staurosporine biosynthesis, or the intriguing prenyltransferase TdiB from the terrequinone 
A biosynthetic pathway.  Finally, one project, already underway on the violacein 
biosynthetic enzyme VioD should also be an interesting story in steric control of 
substrate choice, once a substrate can be co-crystallized with the enzyme and key 
residues in catalysis identified for site-directed mutagenesis studies.   
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